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ABSTRACT 
 
LIANA CASTEL: Longitudinal Epidemiology of Pain Severity and Interference among 
Women with Metastatic Breast Cancer 
(Under the direction of Katherine Hartmann) 
 
Knowledge is limited about risk factors for cancer pain experienced over the course of 
disease in specific tumor types. In this study, we assessed pain hazards using data originally 
collected over 51 weeks in a clinical trial among 1,124 women with metastatic breast cancer; 
pain was measured by the Brief Pain Inventory (BPI) severity and interference with daily 
living 0-10 subscales.  
Under a continuous time assumption, we conducted univariate (per-cutpoint) and 
multivariate (cutpoints 3, 4, 5, 6, and 7 on the BPI) proportional hazards analyses to estimate 
effects of baseline characteristics on pain hazards. For the severity scale, compared with 
Caucasian race, non-Caucasian race was associated with 2.29 times the hazard of reaching 
severity cutpoint 7 versus 1.38 for cutpoint 3, all other covariates held constant. For the 
interference scale, compared with active baseline Eastern Cooperative Oncology Group 
(ECOG) status, restricted baseline ECOG status was associated with 2.97 times the hazard of 
reaching interference cutpoint 7 versus 2.00 for cutpoint 3. 
Under a categorical (interval-censored) time assumption, we used piecewise exponential 
models to estimate associations of baseline and time-dependent characteristics with 
“survival” rates for not yet reaching a score of 7 or above on each subscale, per 80-day 
interval. Estimated survival rates at the first interval were 0.92 for Caucasian women versus 
0.80 for non-Caucasian women; for the interference scale, these rates were 0.80 versus 0.70, 
  iv
respectively. In subsequent intervals, rates declined similarly for Caucasian and non-
Caucasian women, but for both pain outcomes, the cumulative survival rate for Caucasians in 
the last interval was still higher than that of non-Caucasians in the first interval.  
In confirming associations of ECOG performance status (both as a baseline and time-
dependent covariate) and race with pain hazards over time in metastatic breast cancer, our 
findings inform individualized prognoses for pain outcomes according to baseline patient 
attributes. Early intervention and more aggressive pain management strategies can be tailored 
to these personalized prognoses over the course of treatment, to delay first occurrence of 
higher pain scores among those at greatest risk. Future research should specifically target 
potential sources of racial disparities in cancer pain. 
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I. INTRODUCTION 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
As studies of both cancer-specific patient-reported outcomes (PROs) and of palliative 
care have become more common over the past few decades, researchers have devoted 
increasing efforts toward understanding and management of pain. Pain is a key dimension of 
the degradation of quality of life associated with cancer,1,2 and an important element of 
suffering associated with cancer metastases, the process by which, as disease progresses, the 
spread of cancerous cells beyond the original site can lead to disruption of many bodily 
systems. Since metastasis is the most severe and common life-threatening complication 
arising from cancer, its exacerbation by suffering constitutes an important factor in both 
palliative efficiency and disease progression.3  
Several key background elements should be considered in the study of cancer pain and 
treatment outcomes. Due to ongoing and increasing recognition of the importance of pain as 
an outcome (pain is sometimes called the “fifth vital sign”), a large body of literature has 
emerged comprising cancer pain incidence and prevalence, risk factors for pain, the 
effectiveness of various analgesic interventions, and the construction and testing of 
algorithms for pain management strategies based on available evidence. These study designs 
range from observational, experimental, meta-analytic, and measurement/validation studies. 
Key reviews have advocated for studying pain using tumor-specific data collected at repeated 
assessments over time.4-6 There is evidence that analgesic therapy is often inadequate for 
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patients in general,7 but also that the burden of pain and inadequate analgesia is greater 
among Black and Hispanic patients as compared with Caucasian patients.8 In addition, 
interpretation and translation of pain research findings often rely on grading pain severity, 
using numeric cutpoints to demarcate categories of severity such as mild, moderate, or severe 
pain on a numeric rating scale. Existing methodological studies in this area cite the need for 
further study to explore cancer-specific pain severity cutpoints in detail.9-12 
The present study, conducted under approval from the University of North Carolina at 
Chapel Hill Institutional Review Board (see Appendix A), addresses the needs for tumor-
specific information about patients’ experiences and risk of pain over time, assessment of 
racial differences in experiences and risk of pain over time, and exploration of pain severity 
cutpoints on a commonly used pain rating scale. We apply methods for assessing risks over 
time, as well as the contributions of predictive baseline and time-dependent clinical and 
demographic covariates, to clinical trial data from 1,124 breast cancer patients collected over 
at least 51 weeks. The two manuscripts prepared for fulfillment of the Epidemiology doctoral 
program requirements are as follows: 
Manuscript 1: We conducted proportional hazards analyses for reaching different 
thresholds of pain on the Brief Pain Inventory (BPI) severity and interference scales over 
time, comparing which sets of clinical and demographic baseline predictors affect hazards of 
reaching different thresholds of pain as defined by cutpoints on the 0 – 10 severity and 
interference scales. Patients reaching the intensity cutpoints of 3, 4, 5, 6, and 7 or above on 
each scale were the outcomes of interest in predictive modeling to analyze each cutpoint 
separately, and then all cutpoints together, exploring interactions between covariates and 
cutpoints. Time-to-event was treated as continuous in these analyses. Our findings provide 
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descriptive epidemiologic information about pain hazards over time among patients with 
metastatic breast cancer, the effect of using different intensity cutpoints on these scales, and 
the relationship between the pain severity and interference BPI scales with regard to baseline 
covariates as risk factors. This study addresses Aims 1 and 2 of the dissertation (see Section 
IIIA). 
Manuscript 2: We fit models to accommodate interval-censored data (categorical time-
to-event), predicting time to first reaching a pain severity or interference score of 7 or above 
on the 0-10 BPI scales. We estimated the associations of both baseline and time-dependent 
clinical and demographic characteristics with hazards for the outcomes. We investigated the 
hypothesis that, as compared with their Caucasian counterparts, non-Caucasian patients 
would have higher hazards of pain severity and pain interference in daily functions.  This 
study addresses Aims 2, 3, and 4 of the dissertation (see Section IIIA). 
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II. BACKGR
CHAPTER II 
 
BACKGROUND 
 
A. Conceptual framework     
The course of a given patient’s cancer pain over the time of cancer and pain treatment 
involves factors related to disease etiology, measurement of PROs, psychology and 
characteristics of both patients and physicians, societal and systemic characteristics, and the 
effectiveness of clinical interventions. Patient preferences, medication adherence, and 
judgments/perceptions shape the experience of pain over the course of cancer. Pain treatment 
is also affected by providers’ judgments/perceptions, as well as their levels of adherence to 
relevant clinical practice guidelines. The conceptual model shown in Figure 1 explores the 
interaction of factors with the potential to influence pain. These factors exist on many levels, 
and include characteristics of: patients, providers, patient-provider communication and 
decision making, disease, health care systems, and geographic and sociocultural 
environments, traditions, and prejudices. The specific constellation of factors that affect one 
person’s experience of pain is certainly unique, but identifying predictive patterns among 
factors that affect the risk of specific pain outcomes in specific populations over time can 
enhance our knowledge and ability to manage pain successfully. 
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Figure 1. Conceptual framework: focus of care, sample trajectory 
 
Note: Curative/Palliative portion of schema (top of diagram) adapted from a World 
Health Organization (WHO) report.13 
A hypothetical trajectory, or course of pain on a 0-10 scale over time for one patient, is 
also illustrated in Figure 1 (labeled “outcome: Pain over time…”). Patient functional status, 
disease status, and demographic characteristics are the key independent variables of concern 
in the present investigation, and are shown in the shaded oval portion of Figure 1 as they fit 
into the conceptual schema of pain experienced over time. Race was of importance in the 
present investigation and in this conceptual model because of its complexity as a construct. 
In a pragmatic sense, the minority status variable is of value in predictive modeling because 
it is often a consistent predictor of worse pain outcomes. However, simply adding evidence 
that outcomes differ by race or ethnicity is only the first step. To improve outcomes, we must 
address the sources of the disparities we observe. These sources of pain disparities by 
minority status are complex, simultaneously involving many of the factors shown in the 
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conceptual model above. The model is of use in interpreting findings of differences 
according to racial/ethnic classifications. 
Also of importance in the schema is the concept of cutpoints to define categories of pain 
intensity. The shaded portion above the 7 cutpoint in the schema illustrates that a person 
may, through the course of disease, experience degrees of pain that could be dichotomously 
defined as severe or not severe, using 7 as a cutpoint for this categorization. Such 
classifications of pain outcomes are useful in studying outcomes, but should be studied 
further in the context of clinically meaningful differences, sensitivity analyses, and scale 
validation. 
As context for understanding treatment and patient and provider decision making over 
time, it is important to consider the concept of a curative-palliation shift over time. 
Depending on the type of cancer and its progression, disease may become so advanced that 
providers and perhaps patients direct their focus more toward symptom palliation and 
increasing survival than toward curing the cancer. Past research has shown that patients have 
higher expectations of survival and treatment benefits than their providers.14-17 Effective pain 
management requires that both the patient and physician share similar goals for palliative 
treatment, and both be willing to implement the appropriate palliative measures. Palliation 
can co-exist with curative treatment, and current guidelines encourage this coexistence.5,18 
Because changes in pain can be important signals of disease progression that call for 
adjustments in intervention, treatment strategies that use signs other than pain to evaluate 
disease progression are important in ensuring that pain treatment does not decrease treatment 
effectiveness. When they follow evidence-based clinical practice guidelines and use 
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information learned from epidemiologic studies, providers are taking into account patient 
characteristics found to affect pain over time on a population level. 
The conceptual framework presented is used to interpret our findings in the context of 
past research, and in forming recommendations for future practice and research, especially 
with regard to differences in pain outcomes that are found to vary according to patient 
demographic or clinical characteristics.  
B. Substantive background 
This section provides background information that synthesizes and draws upon existing 
literature, covering the following topics: incidence and mortality of breast cancer, prevalence 
of cancer pain, measurement /assessment of cancer pain, establishment of severity cutoffs for 
the Brief Pain Inventory, measurement/ assessment of cancer severity, pain associated with 
disease or therapeutic interventions, racial disparities in pain, and therapeutic interventions 
for cancer pain. Strategies for gathering, selecting, and assessing the most relevant literature 
follow in Section C: Literature search strategies. A critical evidence-based review of the 
sources judged as most comprehensive, influential, and timely follow in the subsequent 
section (Section D: Critical review of literature). 
Incidence and mortality: breast cancer 
Cancer incidence overall in the United States (source: National Cancer Institute) appears 
to have risen and is projected to rise in future years, especially among the elderly, rising in 
those aged 65 or older from incidence of approximately 1650 cases per million in 1974 to 
2100 cases per million in 1996.19 As shown in Figure 2 (age-adjusted cancer death rates in 
US females over the past 70 years), breast cancer is second only to lung cancer among the 
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tumor types with highest mortality rates as of 2001. Our focus in the present study on breast 
cancer addresses an important tumor type. 
Figure 2. Age-Adjusted Cancer Death Rates,* Females by Site, US, 1930-2001 
 
*Per 100,000, age-adjusted to the 2000 US standard population.  
Note: Due to changes in ICD coding, numerator information has changed over time. 
Rates for cancers of the liver, lung & bronchus, colon & rectum, and ovary are affected by 
these coding changes.  
Source: American Cancer Society. Facts and Figures 2005. Atlanta: American Cancer 
Society, Inc. 
 
Prevalence of cancer pain  
A common presentation of cancer pain associated with bone metastases in women with 
metastatic breast cancer includes the following characteristics: (a) pain described as dull and 
aching, and (b) pain that is well-localized to the metastatic site.18 Breast cancer related pain 
may also take the form of epidural spinal cord compression, brachial plexopathy (radiating 
shoulder pain), postherpetic neuralgia (shock-like pain associated with skin lesions), and 
other painful syndromes.18 Disease progression in the form of metastases emerges 
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consistently as a major determinant of pain, including severity and progression. The site of 
metastases and even type of bone to which the cancer metastasizes affect pain. Metastases to 
bone affect pain differently from metastases to soft tissue, especially brain. Pain associated 
with specific tumor types depends on (a) the pain definition used, (b) patterns of metastases, 
(c) different contributions of societal and cultural factors (e.g., stigma associated with 
different tumor types), and (d) tumor-specific prevalences of different types of pain (e.g., 
neuropathic, somatic). 
Epidemiologic studies of pain prevalence can be designed to examine not only levels of 
pain severity and interference with daily functions, but also frequency and recurrence of 
these outcomes. With regards to the prevalence of cancer pain in general (i.e., not tumor-
specific), studies have estimated that chronic or recurrent pain affects about 30% of all 
patients with cancer, and about 60 to 90% of patients with advanced cancer.20,21 In an Eastern 
Cooperative Oncology Group (ECOG) study of the adequacy of pain relief among over 1300 
outpatient metastatic cancer patients, 67% reported having pain or taking analgesics, and 
36% reported pain severe enough to impair their functional status. Among those who took 
analgesics (46%), nearly half of those patients reported that they were not being given 
adequate analgesic therapy.7 Both severe pain and inadequately treated pain emerge as 
problems of particular concern among patients with cancer. Pain associated with specific 
tumor types depends on (a) the pain definition used, (b) patterns of metastases, (c) different 
contributions of societal and cultural factors (e.g., stigma associated with different tumor 
types), and (d) tumor-specific prevalences of different types of pain (e.g., neuropathic, 
somatic). 
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The persistent problems of inadequate analgesic treatment and severe pain are recurrent 
themes in studies of cancer pain and its treatment. Examples of psychological, quality of life, 
and financial consequences of inadequately treated pain are well illustrated by the American 
Pain Society at: http://www.ampainsoc.org/ce/npc/tables/5.htm in patterns of clinical 
manifestations known to result from physiological stress responses to pain; for example, 
musculoskeletal pain is known to induce stress responses such as muscle spasm and impaired 
muscle mobility and function. These stress responses may clinically manifest as weakness, 
fatigue, or immobility.22,23 Inadequate analgesic treatment of cancer pain was well-
documented in a study of 1308 cancer outpatients at 54 treatment sites.7 Sixty-seven percent 
of the patients interviewed reported pain sufficient to require daily analgesics, and 36% 
reported that the pain limited their ability to function. Only 42% of those with pain reported 
receiving sufficient pain relief. Several other studies documented that pain associated with 
terminal illness was often undertreated,24-27 and that patients who desired more pain 
treatment had poorer physical functioning, more depressive symptoms, and were more likely 
to be minority.28  
Measurement/assessment of cancer pain 
The fact that pain has long been considered to be a subjective phenomenon29 has often 
provoked a reaction that its subjectivity may somehow prevent its accurate quantitative 
measurement. Given that seemingly objective phenomena such as blood pressure (or any 
measurements taken from the patient in any manner except linguistic communication) may 
(a) be influenced by such subjective states as the patient’s mood while their blood pressure is 
being measured, and (b) still be open to interpretation error, the subjectivity of patient-
reported pain should not limit its usefulness. Differential item functioning (DIF) is a potential 
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issue because patients may report scores other than their true score (over- or under-reporting 
of pain). Although assessment for DIF is beyond the scope of this analysis, implications of 
such inaccuracies are discussed in the section on potential bias, confounding, and effect 
modification. 
As is the case with measurement of all PROs including quality of life, satisfaction, or 
psychological states, a good measure of pain will possess properties of internal and external 
validity, and can thus provide accurate quantitative information for the purposes of 
comparing subgroups of patients and generalizing findings appropriately to larger 
populations. It is important when assessing pain to keep in mind the potential influences of 
bias on patient responses. Patients may underreport or overreport the pain they experience. 
Although underestimation of pain is more a problem in retrospective studies involving 
spontaneous patient reports,30 it is still possible that in the present study, patients may 
underreport pain (there is more evidence for underreporting, rather than overreporting, being 
a likely problem). Based on cultural views, some patients may believe that pain is a spiritual 
or religious test of their faith, or believe that it is wrong to take or become addicted to 
opioids. Fear of addiction has been seen in about a third of terminally ill patients.28 Patients 
may therefore refuse to report their pain or accept palliative treatment.31 Patient reluctance 
can affect both solicited and unsolicited reports of pain, leading to underestimates of pain 
incidence, prevalence, and severity in retrospective studies.30 Prospective pain assessments 
can help to reduce this bias.32  
Despite the drawbacks of pain measurement and threats to its validity, the effectiveness 
of analgesic interventions is most effectively gauged by using patient-reported pain data. We 
can compare the effectiveness of various interventions more systematically as data collection 
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and measurement instruments are used consistently and validated more extensively in clinical 
practice and research. Several scales are routinely used. 
Visual analogue scale (VAS) and numeric rating scale (NRS) measures usually assess 
pain severity on a scale from 0 to 10, with 0 being “no pain” and 10 being “worst pain I can 
imagine”. The instructions preceding the scale may say “Place a mark on the scale according 
to how you feel right now”, or “indicate the intensity of the worst pain you felt over the past 
2 weeks”. According to the American Pain Society Clinical Practice Guideline for the 
Management of Cancer Pain in Adults and Children,18 NRS measures are among the most 
common, valid, and reliable measures used to assess cancer pain intensity, and are preferred 
by patients over VAS measures. An example of a question from the Brief Pain Inventory,33 
or BPI (a classic NRS measure created by Charles Cleeland) is shown in Figure 3. A reprint 
of the relevant sections of the BPI is included as Appendix B. 
Figure 3. Excerpt from the Brief Pain Inventory (BPI) severity subscale.  
 
Copyright 1991 Charles S. Cleeland, Ph.D.; Pain Research Group; Used by permission. 
 
 
The concepts of intensity and severity are sometimes used synonymously in the field of 
pain research, but for the BPI, both severity and interference fall under the category of pain 
intensity, which is measured by the entire BPI.  The BPI has been administered and assessed 
for validity in several languages including Spanish, French, Japanese, Chinese, Italian, Hindi, 
German, Greek, and Vietnamese.34-40  
Patients with cancer may experience pain at multiple sites on the body, separately or 
concurrently, and their pain may be occurring through different or multiple mechanisms. 
 13 
13
Attempts have been made to categorize patterns of pain, such as continuous, movement-
related, acute, and spontaneous breakthrough pain.41 Breakthrough pain is defined as a brief 
flare-up of severe pain that occurs even as the patient is being treated regularly with pain 
medication; this type of pain usually comes on quickly and may last from a few minutes to an 
hour. Both numeric and non-numeric categorizations and characterizations of pain and 
changes in pain are key cues for making both disease- and pain-treatment decisions. Pain-
related considerations specific to different types of cancer, however, should also be included 
in understanding and treating pain. Some pain syndromes are tumor-specific manifestations 
of local or distant metastases, while others reflect diffuse effects (such as metastases to blood 
or lymphatic systems). Any form of pain mentioned may not be related to disease at all, but 
rather have been brought about as a secondary effect of diagnostic procedres, cancer 
treatment such as surgery, radiation, or chemotherapy, infection, or immobility. 
Tumor-specific measures of cancer pain may offer information more pertinent to patients 
with a given tumor type than information gained from other types of measures, which may be 
cancer-specific versus non-disease-specific, tumor-specific versus non-tumor-specific, and 
may measure pain alone or as a component of quality of life. For example, there is one item 
“I have pain” that is a component of the Physical Well-Being subscale of the FACT-G 
(Functional Assessment of Cancer Therapy – General, i.e., not tumor specific), but in the 
tumor-specific version of this quality of life measure (the FACT-B, a breast cancer-specific 
version of the FACT), the “I have pain” item still exists, but there is also the item “I have 
certain parts of my body where I experience significant pain” as a component of the 
Additional Concerns subscale. Tumor-specific measures structured in this way retain the 
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validity and reliability of the original “core” measure, while adding information pertinent to 
detriments experienced in specific subpopulations as a result of their disease.  
Adequacy of Analgesic treatment 
Successful pain management requires both responsive and even pre-emptive analgesic 
treatment to avoid worse pain outcomes,42 based on ongoing gathering and use of disease, 
clinical, and patient-reported information available to the clinician. In addition to defining 
severity of pain, capturing the concept of inadequate pain treatment is important in order to 
accurately measure pain as an outcome; this importance becomes clear when one considers 
the previously mentioned possible negative psychological, quality of life, and financial 
consequences of inadequately treated pain. One method of ascertaining whether inadequate 
analgesic treatment is a problem for a given patient is to ask the patient whether they feel 
they are receiving sufficient pain relief. Another method is to measure pain before and after 
analgesic administration to assess whether the analgesic was associated with pain reduction.  
Brief Pain Inventory Cutoffs 
Classifying pain into severity categories according to cutpoints on a 0-10 numeric rating 
scale is of extensive use in research and clinical practice. Cutpoints are used to drive 
treatment decisions, develop practice guidelines, and determine effectiveness of 
interventions. Where the cutoff point is set for severe pain also affects descriptive 
epidemiology, including etiological reports on longitudinal cancer pain, as well as point 
prevalence estimates in populations. When a patient reaches a level of pain considered 
severe, the event is often considered a “treatment failure” because successful pain 
management should have prevented the patient from first reaching severe pain. It is important 
to note that because severity cutpoints are used in decision making and indicate treatment 
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failure, there is debate over the classification of severe pain; in practice even a score of 5 may 
be considered severe, and thus a trigger for palliative intervention. 
In their 1995 study, Cleeland and colleagues explored the utility of dividing pain into 
three categories based on cutoffs on the BPI NRS measure: mild pain was defined as a score 
of 1-4, moderate pain as 5-6, and severe pain as 7-10.11 These pain severity cutoffs were used 
to establish a basis for later work on clinically meaningful changes in pain that could indicate 
therapeutic effectiveness. Farrar and colleagues have conducted several studies to quantify 
clinically meaningful changes on 0-10 NRS measures. In their 2003 study of the such a 
measure using receiver operating characteristic methods, “the best cut-off points were 
determined to be: 33% for the percent pain intensity difference; > or =2 for the raw pain 
intensity difference on a 0-10 numeric rating scale; > or =2 (i.e., moderate or better) for pain 
relief; > or =33% for the percent maximum total pain relief; and > or =2 (good or better) for 
global medication performance.”43 The aim of using cutoffs on a NRS to define severe pain 
is to initiate palliative intervention when it is needed. The present study addresses the need 
cited for further exploration and definition of pain severity cutpoints.9-12 By exploring the 
effects of different severe pain cutoffs on population-level estimates of risk of severe pain, 
the present study will help to either justify or suggest changes to the cutoff points most 
commonly used in clinical practice today.  
Pain associated with disease or therapeutic interventions 
Disease-related pain 
Cancer pain associated with the disease per se, and not with treatments (discussed below) 
can result from conditions caused by the tumor or cancerous cells including the following: 
blocked blood vessels causing poor circulation, bone fracture from metastasis to bone, 
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infection, inflammation, psychological or emotional problems, or nerve pain due to pressure 
exerted by a tumor.44  In breast cancer patients with metastases to bone, common cancer pain 
presentations include spine metastasis that may impinge on nerve roots and produce radicular 
pain.18 In addition, metastasis to the base of the skull may produce headache, pain associated 
with head movement, and pain in the face, shoulder, and neck.18 Disease processes alone 
have the potential to cause severe and/or persistent pain through the mechanisms described or 
through additional mechanisms such as immobility or infection, especially as severity 
increases and the cancer metastasizes beyond its primary site.  
Specific treatment recommendations 
Standard clinical interventions for breast cancer depend on disease severity upon 
presentation (as indicated by stage at diagnosis) and presence versus absence of metastases. 
Treatment strategies usually involve a combination and/or succession of combinations of 
surgery, radiation, chemotherapy, or hormonal treatment (including tamoxifen). Treatment 
strategies as presented are recommendations of the National Cancer Institute (NCI), based on 
synthesis of information gained from past clinical trials; it is important to note that clinical 
trials are also currently underway to compare different recommended strategies; the NCI 
guidelines reflect present knowledge, which is constantly being built upon.  
For treatment purposes, breast cancers fall into the following main categories: (A) ductal 
carcinoma in situ, (B) lobular carcinoma in situ, (C) stages I, II, IIIA, and operable IIIC 
breast cancer, and (D) stage IIIB, inoperable IIIC, IV, recurrent, and metastatic breast cancer. 
For ductal carcinoma in situ (a non-invasive, precancerous condition that may progress to a 
different, invasive form), the NCI recommends the following three strategies: (a) breast-
conserving surgery and radiation therapy, with or without tamoxifen, (b) total mastectomy 
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with or without tamoxifen, and (c) breast-conserving surgery without radiation therapy. For 
lobular carcinoma in situ, the following strategy is recommended: (a) observation after 
diagnostic biopsy, (b) tamoxifen to decrease the incidence of subsequent breast cancers, and 
(c) bilateral prophylactic total mastectomy, without axillary node dissection. For the other 
categories of breast cancer described above (Stage I, II, IIIA, and operable IIIC breast cancer, 
as well as stage IIIB, inoperable IIIC, IV, recurrent, and metastatic breast cancer) the most 
common form of treatment is what is called a “multimodality approach”, in which a 
combination of palliative treatments, surgery with adjuvant chemotherapy, radiation, and 
hormonal therapies may all be given at once, or tried in pairs, multiples, or different orders. 
The effectiveness of the various orders of treatment and choices of treatment are being 
evaluated in various clinical trials, but at this time the combinations and sequences of these 
therapies are determined by the treating physician based on information and disease status 
throughout the course of treatment. The therapeutic interventions described above are largely 
for curative intent, although interventions with palliative intent can be integrated into these 
strategies at all points on the continuum of care, as illustrated in the conceptual model shown 
in Figure 1.  
Treatment interventions and pain 
Each type of therapeutic intervention may be examined with regard to its potential acute 
or chronic pain-related side effects. Surgery, radiation, chemotherapy, and hormonal therapy 
are each commonly used to treat breast cancers. The goal of surgery is to excise cancerous 
cells, in an aim to remove them from the body. Post-operative pain related to surgery is 
normally categorized as acute rather than chronic, and may involve swelling, soreness, or 
disruption of normal functioning; for example, post-operative pain following surgery on the 
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thorax may involve difficulty breathing. Radiation is considered a local, rather than systemic 
treatment, in which high-energy beams are aimed at cancer cells with the goal of damaging 
their DNA in the cancerous cells, such that they may fail to reproduce and ultimately die. The 
side effects of radiation therapy may build up over time, and may include pain,45 but are 
generally considered more treatable and tractable than those adverse effects associated with 
chemotherapy. Chemotherapy is a systemic treatment aimed at destroying or slowing cancer 
cell growth. Side effects can have a severe negative impact on quality of life, sometimes 
causing anemia, anorexia, fatigue, nausea and vomiting, esophagitis, neutropenia, 
myelosuppression, and thrombocytopenia. These conditions can translate to weakening of the 
immune system, anorexia, bleeding, irritation, or inflammation. Some chemotherapies (e.g. 
vincristine) cause pain by direct toxicity to nerves; peripheral neuropathy is an important 
painful chemotherapy sequalea. Chronic pain may be experienced when patients are 
immobile, or when they try to eat or conduct normal daily activities (source: NCI). Pain 
associated with chemotherapy may be severe and debilitating, and the association between 
chemotherapy and pain is strong and well-established. However, it is important to 
acknowledge also that as it succeeds in shrinking tumors and alleviating disease-related 
symptoms including pain, chemotherapy may also have palliative effects.46  
Hormonal therapy for women has historically consisted of tamoxifen and other anti-
estrogen agents, and is associated with side effects similar to the symptoms of menopause, 
including hot flashes, irregular menstrual periods and vaginal discharge or bleeding. 
Hormonal therapies have the potential to reduce pain, but quality of life issues are of greater 
interest than pain when evaluating the effects of hormonal treatment. New classes of 
hormonal therapies called anti-aromatase agents are emerging as an important class of 
 19 
19
hormonal agents to treat breast cancer; thus far, pain has not emerged as a major side effect 
of these therapies. It is important to note that if hormonal or other therapies create sleep 
disturbances, patients’ resilience/resistance to pain may be impaired by sleep deprivation. 
Therapeutic interventions for cancer pain 
Cancer pain can be alleviated when any of the interventions described above to treat the 
disease are successful. In addition, radiation, chemotherapy, surgery (as in creation of nerve 
blocks to prevent pain), or pharmacologic agents may each be administered solely for 
palliative purposes. Analgesics used to treat cancer pain fall into three main categories: (1) 
non-steroidal anti-inflammatory agents (NSAIDs) or acetaminophen, (2) opioids, and (3) 
adjuvant analgesics, which may treat concurrent pain-exacerbating symptoms such as 
insomnia or vomiting, enhance the analgesic efficacy of opioids, or provide analgesia for 
specific types of pain. Adjuvant analgesics include antidepressants, anticonvulsants, 
corticosteroids, laxatives, and antiemetics (among others). Drugs from the three families of 
analgesics are often given in combination.47 Cyclooxygenase-2 (COX-2) inhibitors, a class of 
NSAID was introduced in 1999, but COX-2 inhibitors are now less widely available in the 
U.S. following their market recall in 2004 related to risk of heart attack and stroke. In 
prescribing it may be useful to categorize pharmacologic analgesics based on their drug-
metabolizing enzymes (DMEs), and then use information about cytochrome p450 (CYP) 
genotypes to improve chances of successful pain treatment. In addition to pharmacological 
agents, non-pharmacological modalities are commonly used as adjuvants. The non-
pharmacological modality may be general (e.g. visual imagery) or pain-etiology specific (e.g. 
acupuncture, ice). 
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Figure 4.Analgesic ladder for treatment of cancer pain. World Health Organization 
(reproduced with permission).  
 
Figure 4 depicts a widely known modular approach to management of cancer pain, 
developed by the WHO, referred to as the “three-step 
analgesic ladder” (or “staircase”), from: Cancer pain 
relief and palliative care. Report of a WHO expert 
committee (WHO Technical Report Series, 804.1-75. 
1990. Geneva, World Health Organization). The first 
tier, for mild to moderate pain, consists of NSAIDs 
and acetaminophen with or without adjuvant 
interventions. As pain escalates or persists, treatment 
progresses to the second tier, in which an opioid, such as codeine, hydrocodone or low-dose 
morphine, is added to the NSAID with or without an adjuvant intervention.47 If pain persists 
beyond step 2, pain treatment progresses to the third tier where treatment consists of stronger 
opioids such as higher-dose morphine, hydromorphone, methadone, fentanyl, or oxycodone 
(all known as full opioid agonists).  The WHO analgesic ladder approach to managing cancer 
pain has been criticized for emphasizing by-the-clock rather than as-needed dosing and 
careful therapy individualized to each patient.47 Although the WHO analgesic ladder is 
widely known and used, validation studies of its efficacy (i.e., studies designed to gain 
information on reliability over time of the measure’s ability to consistently manage pain 
successfully) are limited,48,49 and pain researchers and practitioners continually debate the 
appropriateness of its structure and application. The WHO pain ladder is a treatment 
guideline that involves the tiered categorization of pain as mild, moderate, or severe. 
Although the WHO ladder does not demarcate specific cutoffs on a pain NRS, 
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implementation of guidelines that rely on such tiered categorizations rely also on the findings 
of studies that establish numeric cutpoints on numeric pain rating scales to distinguish mild, 
moderate, or severe pain on the scale.9 The application of the WHO ladder tool to NRSs for 
the purpose of treatment decisions is considered a modular pain management strategy. 
The WHO has also made recommendations that focus on forming a more effective policy 
of pain control throughout the world. These recommendations consider the shift toward 
symptom palliation and increasing survival than toward curing the cancer. Because changes 
in pain can be important signals of disease progression that call for adjustments in 
intervention, treatment strategies that use signs other than pain to evaluate disease 
progression are important in ensuring that pain treatment does not decrease treatment 
effectiveness. 
ECOG performance status and disease progression have been found to be two important 
indicators of cancer severity.50-53 For the present study, ECOG performance status is 
considered as a baseline covariate in Manuscript 1, and a time-dependent covariate in 
Manuscript 2.  
Racial disparities in cancer and cancer pain 
In past research, racial/ethnic minority status has been found to be of consistent value in 
predicting worse outcomes; a review of the literature on disparities in breast cancer found 
that African-American women are at higher risk for breast cancer mortality than their white 
counterparts.54 With regards to disease severity and mortality, a recent study of survival in 
the Carolina Breast Cancer Study found that African-American women were genetically at 
higher risk than Caucasian women for a faster-progressing basal form of breast cancer.55 This 
finding could mean greater potential for pain risks due to faster disease progression among 
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African-American women with breast cancer. Across diseases and settings, white and 
socially privileged patients appear to receive far better pain management than ethnic and 
social minorities.8 One study concludes that ethnicity is a factor contributing to inadequate 
pain assessment and treatment, with patients of color reporting more pain than Caucasians.56 
This finding was corroborated by another study that found that African-American patients (a) 
reported more daily pain (34% as compared to 25% of white patients), (b) had greater odds 
of failing to receive any analgesic agent, and (c) were found to have inadequate pain 
management at higher rates than white patients in outpatient clinics.57 Such disparities have 
been further confirmed and discussed in other investigations, which have cited differences in 
treatment patterns, pain management strategies, and the use of hospice care as potential 
contributing factors.54,58,59 Further study is recommended on patient- and physician-level 
factors in pain disparities.56 
To improve both disease and pain outcomes, we must address the sources of the 
disparities that have been so consistently observed and documented in pain research. The 
sources of pain disparities by minority status are complex, simultaneously involving factors 
on all levels of health and health care. The present study aims to improve our understanding 
of risk factors for pain experienced over time, further examining race as a risk factor by 
investigating the hypothesis that pain over time is experienced differently between Caucasian 
and non-Caucasian patients with metastatic disease.  
Bisphosphonates and pain 
The data for the present study come from a bisphosphonate clinical trial. 
Bisphosphonates are a class of drugs that include clodronate, ibandronate, pamidronate, and 
zoledronate. They are commonly used as an adjuvant pain treatment using the WHO cancer 
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pain analgesic ladder. According to one review of the role of bisphosphonates in treatment of 
bone metastases, pamidronate is recommended in women with pain caused by osteolytic 
metastasis to relieve pain when used concurrently with systemic chemotherapy and/or 
hormonal therapy, since the authors found that pamidronate treatment was associated with a 
modest pain control benefit in clinical trials included in the review.60 The reviewers’ 
conclusions from a 2004 Cochrane review of bisphosphonates for relief of bone pain 
secondary to metastases state that: “There is evidence to support the effectiveness of 
bisphosphonates in providing some pain relief for bone metastases… [but] there is 
insufficient evidence to recommend bisphosphonates for immediate effect; as first line 
therapy; to define the most effective bisphosphonates or their relative effectiveness for 
different primary neoplasms. Bisphosphonates should be considered where analgesics and/or 
radiotherapy are inadequate for the management of painful bone metastases.” 61 Another 
2005 Cochrane review concluded that bisphosphonates reduce skeletal events and bone pain 
in advanced breast cancer where bone metastasis is present.62 It is useful in interpreting the 
findings of the present study to keep in mind that all of the patients under study (i.e., both 
treatment arms) were being treated with bisphosphonates and adjuvant standard therapy. 
Substantive differences in analgesic effects comparing specific bisphosphonates have not as 
yet been established, but the effect of bisphosphonate treatment on the present study sample 
is potential underestimation of pain. 
C. Literature search strategies 
Pain in cancer is a popular topic of scientific inquiry, leading to a particularly large body 
of existing and growing literature on the subject. The advantage of a vast body of relevant 
literature is that in undertaking a new study, one has available numerous multi-faceted and 
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varied sources of information virtually limitless in depth and scope. However, while in the 
case of a small existing body of research, one could feasibly read at least the abstracts of 
everything that had been published on the topic and then select the most relevant works from 
among that comprehensive set of initial search results; comprehensive review is more of a 
challenge with a large body of literature. A careful strategy must be implemented to select 
those works as candidates for closer examination.  
The reference seeking strategy was implemented at every stage of the research, up to the 
point of final acceptance of each resultant manuscript for publication. The strategy involved a 
combination of (a) database searching, (b) priority to syntheses and critical assessments that 
have resulted from systematic evidence reviews already conducted to date, (c) advice from 
cancer pain experts on identifying key studies, (d) previous relevant work that members of 
the committee and I have conducted in collaboration with other researchers, (e) Institute for 
Scientific Information (ISI) Web of Science citation links, (f) mining of existing reference 
lists, and (g) using the internet through Google Scholar searches or organization web pages 
(e.g., American Pain Society). All references must have been listed in PubMed or another 
UNC Health Sciences Library electronic database, or retrieved from government or society 
websites (in the case of reports) in order to be included in the present literature review. 
A search was conducted of the MEDLINE database through PubMed (1957 to present, 
U.S. National Library of Medicine). Medical Subject Heading (MeSH) terms were used 
when searching this database wherever possible. The first search was as follows: 
("Pain"[MeSH] OR "Pain, Intractable"[MeSH] OR "Pain Measurement"[MeSH]) AND 
"Neoplasms"[MeSH]). This search came up with 17,427 records. When these results are 
limited to English and Human studies, 12,936 records result. Table 1 shows how this set of 
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results served as the root for the concept of “cancer pain”, and then was combined using the 
Boolean operator “and” with other concepts of interest, such as longitudinal study and pain 
management (including treatment guidelines and algorithms) to narrow search results. Roots 
for key concepts are indicated in italics. 
Table 1. Pubmed literature search narrowing strategy 
 
Search # Goal Query Results
 CANCER PAIN   
#1 Cancer Pain 
Search ("Pain"[MeSH] OR "Pain, 
Intractable"[MeSH] OR "Pain 
Measurement"[MeSH]) AND 
"Neoplasms"[MeSH] 
17,427
#2 Root for Cancer Pain 
Search ("Pain"[MeSH] OR "Pain, 
Intractable"[MeSH] OR "Pain 
Measurement"[MeSH]) AND 
"Neoplasms"[MeSH] Limits: English, Humans 
12,936
 
 LONGITUDINAL   
#3 
"Longitudinal Studies" 
(MeSH) 
Search  
“longitudinal” Limits: English, Humans 
405,974
#4 
"Repeated measures" 
(Non-MeSH) 
Search  
"repeated measures" Limits: English, Humans 
6,511 
#5 Root for Longitudinal Search #3 OR #4 411,152
#6 
Cancer Pain - 
longitudinal 
Search #2 AND #5 1,327 
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The search narrowing strategy then involved reviewing the titles and abstracts among sets 
of references retrieved through PubMed for relevance and potential contribution to the 
present study. Those works deemed through this qualitative process to be of greatest 
relevance and timeliness were selected for inclusion in the critical review of the literature.  
D. Critical review of literature 
Critical assessment of the literature relies in part upon evidence grading systems such as 
that described by Sackett and colleagues to rank methodological rigor.63  In evaluating the 
literature, I employed the method used by Jadad and colleagues in their 1995 study exploring 
the evidence for the WHO analgesic ladder.49 This method is described in the Ontario Cancer 
Treatment Practice Guidelines,64,65 and is modified from Sackett (1989)63 and Cook (1992).66 
It is important to note that evidence grading systems are limited for assessing quality of 
observational studies. Critical assessment has relied also upon the inclusion and exclusion 
criteria used in existing systematic evidence reviews, as well as expert opinion. My ability to 
qualitatively assess the relevance of different works is informed by my past research 
experience and tools for evaluating methodology and study design. Publications on which I 
have collaborated as an author include (a) an NCI-funded study of patient decision making in 
advanced-stage cancer,15 (b) a study of patient characteristics relating to expectations of 
benefit from phase I trials,16 (c) how conceptions of risk among patients with advanced 
cancer play into their treatment choices,67 (d) an economic study comparing two 
bisphosphonate treatments as part of palliative care in outpatient settings in the U.S.,68 and 
(e) the subsequent adaptation of this economic model to the Canadian palliative care 
setting.69   
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Syntheses of large sets of articles published on cancer pain have been conducted in the 
form of evidence-based reports; these large-scale reviews offer some distinct advantages. 
First, these reports are compiled by initially casting a wide net in gathering virtually all 
relevant peer-reviewed literature published on the topic within a given timeframe, ensuring a 
comprehensive collection of literature from which the reviews are drawn. Next, by applying 
methodological criteria to assess the design and relevance of the studies gathered, greater 
weight in the synthesis is given to those studies of higher methodological rigor and scientific 
value. Lastly, through their synthesis of the most relevant background issues (studies of 
prevalence, measurement and interpretation, and pain-related effects of treatments and 
analgesics), such reports often provide a considered assessment of the present state of 
knowledge, identifying where gaps in current knowledge exist. Table 2 shows the list of key 
publications selected for evidence extraction. Figures 5-17 are evidence extractions for the 
most recent of these works. The evidence extraction follows the template used for AHRQ 
evidence reports, and focuses on study-specific methods, findings, and limitations for each 
study. 
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Table 2. Literature chosen for evidence extraction/review.  
 
Article 
# 
Title and First Author, if listed 
Agency (if report) 
Citation (if article) 
Year Figure #
1 
Bisphosphonates for breast cancer (Review).
Pavlakis N  
Cochrane Reviews 2006 5 
2 
Ethnic Differences in Pain Among 
Outpatients with Terminal and End-Stage 
Chronic Illness. Rabow MW, Dibble SL. 
Pain Medicine; 6:235-241 2005 6 
3 
American pain society recommendations for 
improving the quality of acute and cancer 
pain management. Gordon D. 
Arch Intern Med. 2005 Jul 
25;165(14):1574-80. 
2005 7 
4 
Categorizing the severity of cancer pain: 
further exploration of the establishment of 
cutpoints. Paul SM. 
Pain 2005; 113:37-44 2005 8 
5 Occurrence of cancer pain. McGuire DB. 
J Natl Cancer Inst Monogr: 
51-56 
2004 9 
6 
Bisphosphonates for the relief of pain 
secondary to bone metastases. Wong R. 
Cochrane Reviews 2004 10 
7 
A clinical decision and economic analysis 
model of cancer pain management. 
Abernethy AP. 
Am J Manag Care; 9:651-
664 
2003 11 
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Article 
# 
Title and First Author, if listed 
Agency (if report) 
Citation (if article) 
Year Figure #
8 
The Unequal Burden of Pain: Confronting 
Racial and Ethnic Disparities in Pain.  
Green CR 
Pain Medicine; 4:277-294 2003 12 
9 
Management of Cancer Symptoms: Pain, 
Depression, and Fatigue.  
Carr D. 
AHRQ 2002 13 
10 
Management of cancer pain.  Evidence 
Report/Technology Assessment No. 35. 
Goudas L. 
AHRQ 2001 14 
11 
Implementing Guidelines for Cancer Pain 
Management: Results of a Randomized 
Controlled Clinical Trial. DuPen S. 
J Clin Oncol. Jan 
1999;17(1):361-370. 
1999 15 
12* 
The management of chronic pain in patients 
with breast cancer. The Steering Committee 
on Clinical Practice Guidelines for the Care 
and Treatment of Breast Cancer.  
Canadian Society of 
Palliative Care Physicians. 
Canadian Association of 
Radiation Oncologists 
1998 A 
13 
The WHO analgesic ladder for cancer pain 
management. Stepping up the quality of its 
evaluation. Jadad A. 
JAMA. Dec 20 
1995;274(23):1870-1873. 
1995 16 
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Article 
# 
Title and First Author, if listed 
Agency (if report) 
Citation (if article) 
Year Figure #
14 
When is cancer pain mild, moderate or 
severe? Grading pain intensity by its 
interference with function. Serlin RC. 
Pain 1995; 61:277-284 1995 17 
15* 
Acute Pain Management: Operative or 
Medical Procedures and Trauma Clinical 
Practice Guideline No. 1. Jacox A. 
AHRQ (AHCPR at time of 
publication) 
1992 A 
A Indicates a reference not included in the review because it is an outdated guideline. 
Using survival analysis techniques, Shekelle and colleagues estimate that clinical practice 
guidelines become outdated after about 6 years. To ensure the timeliness of information in 
this critical literature review, only works of particular relevance that are older than 7 years as 
of 2006 are included in the evidence extraction phase. 
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Figure 5. Evidence extraction: Pavlakis N, et al. 2005. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Bisphosphonates 
for breast cancer. 
 
Pavlakis, N., R. 
Shmidt et al. 
 
Cochrane 
Database Syst 
Rev (3) : CD 
003474 
2005 
Assessment of effects of 
bisphosphonates on skeletal 
events, bone pain, quality of 
life and survival in women 
w/ early and advanced 
breast cancer. 
 
Study Reviewed 21 
Randomized Controlled 
Trials Selected by two 
independent reviewers. 
Meta-Analyses were 
based on the fixed-
effects model (Mantel-
Haenszel). 
Statistically 
significant effects of 
several 
bisphosphonates, 
were found (both oral 
and iv) in women 
with advanced breast 
cancer and evident 
bone metastases. 7 
studies showed 
improvement in bone 
pain in these women.  
3 studies showed 
Ibandronate (oral & 
iv) as improving 
global quality of life. 
 
Good results in 
reduction of skeletal 
event, and bone pain for 
advanced breast cancer 
+ bone metastases. No 
significant evidence 
w/o bone metastases 
even for advanced 
breast cancer. No 
results on optimal 
timing of initiation of 
therapy and treatment 
duration. 
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Figure 6. Evidence extraction: Rabow MW and Dibble SL, 2005. 
 
Title, Citation, and Authors Year Design Methods Findings Conclusions and Limitations 
The unequal burden of 
pain: disparities and 
differences(continuation) 
 
Ethnic differences among 
outpatients with terminal 
and end-stage chronic 
illness 
 
Rabow MW and Dibble SL 
2005 
To explore ethnic and 
country of origin 
differences in pain 
among outpatients with 
terminal and end-stage 
chronic illness. 
 
Cohort study within a 
year-long trial of 
palliative care 
consultation. 
 
Setting: Outpatient 
general medicine 
practice in an academic 
medical center. 
 
90 patients with 
advanced congestive 
heart failure, chronic 
obstructive pulmonary 
disease, or cancer, and 
with a prognosis 
between 1 and 5 years. 
 
Outcome measures. 
Patients’ report of 
pain using the Brief 
Pain Inventory and 
analgesic 
medications 
prescribed by 
primary care 
physicians. 
Differences in pain 
report and 
treatment were 
assessed at study 
entry, at 6 and 12 
months. 
The overall 
burden of pain 
was high. White 
patients reported 
less pain than 
others (in least, 
average and 
current pain). No 
significant 
differences were 
found between 
Asian, Black, and 
Latinos patients. 
No differences 
between US born 
patients and 
others. 
No differences in 
pain in regard to 
country of origin, or 
minority ethnicities, 
but difference 
between white and 
non-white. Patients 
of all ethnicities are 
inadequately treated 
for their pain, and 
further study is 
needed to determine 
the relative patient 
and physician 
contributions to the 
finding of unequal 
symptom burden 
and inadequate 
treatment effort. 
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Figure 7. Evidence extraction: Gordon D, et al. 2005. 
 
Title, Citation, and 
Authors Year Design Methods Findings 
Conclusions and 
Limitations 
American Pain 
Society 
Recommendations 
for Improving the 
Quality of Acute 
and Cancer Pain 
Management. 
 
Debra B. Gordon 
et al. – APS 
Quality of Care 
Taskforce. 
 
Archives of 
Internal Medicine 
/ Vol 165 
 
2005 
1995 APS Quality 
Improvement Guidelines for 
the Treatment of Acute Pain 
and Cancer Pain were 
revised. 
 
Study Review Based on 51 
articles from Medline & 
Cumulative Index to 
Nursing & Allied Health 
Databases, from 1994 
through may 2004. 
Reviews by 11 
multidisciplinary 
members of APS with 
expertise in Quality 
Improvement or 
Measurement. 
 
5 experts from 
organizations that 
focus on health care 
quality reviewed final 
recommendations. 
 
3000 members of APS 
were invited to provide 
input. 
Assessment and 
communication are 
not sufficient to 
improve quality of 
pain management. 
 
Implementation and 
improvements in pain 
treatment that are 
timely, safe, evidence 
based and 
multimodal are 
needed. 
 
 
Updated and expanded 
Guidelines with new 
Quality Indicators and 
measures. 
 
Recommendations 
focus on Acute Pain 
and Cancer Pain, 
because of a lack of 
evidence & consensus 
about assessment and 
treatment of chronic 
non cancer pain. 
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Figure 8. Evidence extraction: Paul SM, et al. 2005. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Categorizing the 
severity of cancer 
pain: further 
exploration of the 
establishment of 
cutpoints. Pain; 
113:37-44 Paul 
SM, Zelman DC, 
Smith M, et al. 
2005 
Purposes: to determine the 
optimal cutpoints for mild, 
moderate, and severe pain 
based on patients' ratings of 
average and worst pain 
severity, using a larger 
range of potential cutpoints, 
and to determine if those 
cutpoints distinguished 
among the three pain 
severity groups on several 
outcome measures. 
 
Secondary analysis of 212 
oncology patients 
ANOVA and 
MANOVA to establish 
cutpoints, with F test 
statistic 
Results confirm a 
non-linear 
relationship btw. 
cancer pain severity 
and interference and 
also confirm that the 
boundary between a 
mild and a moderate 
level of cancer pain is 
at 4 on a 0-10 
numeric rating scale.  
 
However, results did 
not confirm Serlin 
severe cutpoint of 7. 
This study found ≥ 7 
to be severe. 
 
Present study was a 
homogenous pt. 
population, not 
multinational like 
Serlin. Serlin pts. Were 
recruited both inpatient 
and outpatient Settings.  
 
Concludes that there is 
a need for further 
exploration of pain 
cutoffs for severity. 
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Figure 9. Evidence extraction: McGuire DB, 2004. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Occurrence of 
Cancer Pain. 
 
Deborah B. 
McGuire 
 
Journal of the 
National Cancer 
Institute 
Monographs No. 
32 
 
2004 
Defines the limitations and 
inadequacies of pain related 
studies. 
Makes recommendations for 
design and methods of pain 
studies. 
 
43 studies were reviewed. 
 
 
Critical review; 
monograph 
Researchers have 
inadequately studied 
pain, using  small, 
heterogeneous 
samples, with 
undifferentiated 
causes in a cross 
sectional format, 
yielding little to no 
usable data. 
Studies need to focus 
on homogeneous 
classification, 
longitudinal approach 
across all phases of 
trajectory, 
homogeneous samples 
(population groups, 
types of cancer, types of 
pain).  
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Figure 10. Evidence extraction: Wong R and Wiffen PJ, 2002. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Bisphosphonates 
for the relief of 
pain secondary to 
bone metastases. 
The Cochrane 
Database of 
Systematic 
Reviews 2002, 
issue 2. Art. No: 
CD002068 
Wong R, Wiffen 
PJ 
 
 
2002 
To determine the 
effectiveness of 
bisphosphonates for the 
relief of pain from bone 
metastases. 
 
Review of Randomized 
trials where pain and/or 
analgesic consumption were 
outcome measures. 
30 studies used (21 blind, 4 
open, 5 active control). 
Total of 3682 patients. 
Proportions of patients 
with pain relief at 4, 8 
and 12 weeks were 
assessed. 
8 studies showed 
NNT at 4 weeks of 
11, and at 12 weeks 
of 7. 1 Study showed 
a small improvement 
in quality of life at 4 
weeks. 
There is evidence to 
support the 
effectiveness of 
bisphosphonates in 
providing some pain 
relief for bone 
metastases. Insufficient 
evidence to recommend 
as first line therapy. 
Bisphosphonates should 
be considered where 
pain persists through 
analgesic and /or 
radiotherapy. 
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Figure 11. Evidence extraction: Abernethy AP, et al. 2003. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
A clinical 
Decision and 
Economic 
Analysis Model of 
Cancer Pain 
Management. 
 
The American 
Journal of 
Managed Care, 
Vol. 9, No.10.  
 
Amy P. 
Abernethy 
Gregory P. 
Samsa, David B. 
Matchar 
 
2003 
Designing model that 
educates clinical decision 
makers and healthcare 
professionals about cancer 
pain and effectiveness of 
pain management strategies. 
 
Tailored cost-effectiveness 
analysis using an evidence 
based decision analytic 
model. 
Model compares: 
- Guideline-Based 
Care (GBC) 
- Oncology-Based 
Care (OBC) 
- Usual Care (UC) 
Model calculates 
likelihood of cancer 
pain in population, 
pain management 
effectiveness, and cost 
of pain management. 
After one month, 
percentage of patients 
with effective pain 
management and cost 
per type of care: 
GBC: 80%- $579 
OBC: 55%- $466 
UC: 30% - $315 
Guideline based Cancer 
Pain Management leads 
to improved pain 
control with modest 
increases in resource 
use. 
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Figure 12. Evidence extraction: Green CR, et al. 2003. 
 
Title, Citation, and 
Authors Year Design Methods Findings 
Conclusions and 
Limitations 
The unequal burden 
of pain: confronting 
racial and ethnic 
disparities in pain.  
Green DR et al.8 
 
2003 
To provide pertinent 
evidence regarding 
differences in pain 
perception, assessment 
and treatment for 
racial and ethnic 
minorities. 
Review article – 
Selective literature 
review performed by 
experts in pain. 
Racial and ethnic 
disparities in pain 
perception, 
assessment and 
treatment were found 
in all settings, and 
across all types of 
pain. The literature 
suggests that the 
sources of disparities 
are complex and 
involve patients, 
health care provider, 
and health care 
system. 
 
There is a need for a 
comprehensive pain 
research agenda with 
improved training for 
health care providers 
and educational 
interventions for 
patients. 
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Figure 13. Evidence extraction: Carr D, et al. 2002. 
 
Title, Citation, and 
Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Management of 
Cancer Symptoms: 
Pain, Depression, and 
Fatigue. Evidence 
Report/Technology 
Assessment No. 61 
AHRQ Publication 
No. 02-E032. 
Rockville, MD: 
Agency for Healthcare 
Research and Quality. 
Carr D, Goudas L, 
Lawrence D, et al. 
2002 
Evidence report on the 
topic of Management 
of Cancer Symptoms: 
Pain, Depression, and 
Fatigue was produced 
on request from the 
Office of Medical 
Applications Research, 
National Institutes of 
Health, and the 
National Cancer 
Institute for a 
Consensus 
Developmental 
Conference. The 
purpose was to review 
available evidence on 
cancer symptom 
management. 
English, 1966 -
September 2001 in 
mainly MEDLINE, 
CANCERLIT, 
Cochrane.   
 
> 200 English-
language articles. 
Specific inclusion 
criteria and methods 
of synthesis were 
developed for each of 
the topics.  Relevant 
data were abstracted 
and synthesized. 
 
Prevalence of cancer 
pain varied from 14 to 
100%, dependent on 
setting. More than 100 
scales used to assess 
pain. Randomized 
controlled trials (RCTs) 
establish that many 
current treatment 
modalities can 
individually reduce 
cancer pain. For 
specific problems such 
as postherpetic 
neuralgia and oral 
mucositis, there are 
sufficient trials upon 
which to base specific 
treatment 
recommendations 
 
Pain, depression, and 
fatigue are common 
problems among 
patients with cancer. 
Few high-quality 
RCTs to help guide 
treatment decisions.  
 
Additional studies are 
needed on prevalence 
and impact of these 
symptoms, and to 
define factors that 
correlate with these 
symptoms. 
 
Paucity of studies in 
children. 
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Figure 14. Evidence extraction: Goudas L, 2001. 
 
Title, Citation, and 
Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Management of 
cancer pain.  
Evidence 
Report/Technology 
Assessment No. 35  
AHRQ Publication 
No. 02-E002.  
Rockville, MD:  
Agency for 
Healthcare Research 
and Quality. Goudas 
L Carr D, Bloch R, et 
al. 
2001 
 
Report summarizes 
published evidence 
on the prevalence 
of cancer-related 
pain and the 
efficacy of drug 
and nondrug 
therapies for its 
treatment. 
 
English, human – mainly 
Medline, CancerLit, and 
the Cochrane Controlled 
Trials Registry (1966 to 
December 1998).   
Searched approximately 
19,000 titles and identified 
22 epidemiologic surveys, 
188 randomized controlled 
trials, and 100 
nonrandomized studies of 
treatments of cancer-related 
pain. 
 
Meta-analysis was 
performed when there were 
sufficient data to address a 
specific question.   
 
Cancer pain adds 
substantially to the 
already considerable 
national disease 
burden of cancer, 
particularly in 
minorities, women, 
and the elderly.  
Survey data for the 
most part do not 
track pain and other 
symptoms 
longitudinally across 
time.  
 
Epidemiological data 
indicate cancer pain 
relief may be 
inadequate. 
Need for developmentally 
appropriate and culturally 
sensitive pain assessment 
instruments that are 
reliable and easy to 
administer. The growth in 
sophistication of quality-
of-life assessment and 
advances in the field of 
chronic pain treatment 
that model relationships 
between pain, disability, 
and impairment offer a 
valuable opportunity to 
understand these 
interactions in the context 
of cancer pain 
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Figure 15. Evidence extraction: DuPen SL, et al. 1999. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
Implementing 
Guidelines for 
Cancer Pain 
Management: 
Results of a 
Randomized 
Controlled 
Clinical Trial. 
DuPen SL et al. 
Journal of Clinical 
Oncology, 17 (1): 
361-37071 
1999 
Clinical guidelines for 
cancer pain mgmt. were 
implemented and evaluated 
in the community setting for 
whether they improved care. 
 
Prospective randomized 
longitudinal controlled 
study.  
 
81 cancer pts. aged 37 to 76 
yrs. 
Relied on Cleeland 
pain treatment 
algorithm and AHCPR 
guidelines. 3-month 
study with periodic 
assessment of 
outcomes: BPI, Pain 
Treatment 
Acceptability Scale, 
Side effects, and 
FACT. 
Patients Randomized 
to algorithm group 
achieved statistically 
significant reduction 
in usual pain 
intensity. Concurrent 
chemotherapy and 
patient adherence 
were significant 
mediators of worst 
pain. No significant 
difference in quality 
of life or other 
symptoms between 
groups. 
 
 
Study supports use of 
algorithmic decision 
making in cancer pain 
mgmt. Comprehensive 
pain assessment and 
evidence-based 
processes enhance usual 
pain outcomes. 
 
Small sample size; 
worst pain may be 
constant or 
breakthrough 
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Figure 16. Evidence extraction: Jadad AR and Browman GP, 1995. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
The WHO 
Analgesic Ladder 
for Cancer Pain 
Management. 
Stepping Up the 
Quality of Its 
Evaluation. 
 
Jadad AR and 
Browman GP 
 
JAMA, Vol 274, 
No. 23. 
 
1995 
Systematic review of studies 
evaluating the effectiveness 
of the World Health 
Organization analgesic 
ladder as an intervention for 
cancer pain management. 
 
studies from various sources 
(MEDLINE 1982 to 1995, 
textbooks, reference lists) 
8 studies purporting to 
evaluate the 
effectiveness of the 
WHO ladder  were 
included in the review. 
69% to 100% of 
patients achieved 
adequate analgesia. 
Studies did not 
provide information 
on pain assessment, 
were retrospective, 
had high withdrawal 
rates, or short follow 
up periods etc. No 
other conclusions 
could be reached. 
Studies provide some 
valuable information on 
the course of cancer 
pain  and its treatment. 
However the evidence 
they provide is 
insufficient to estimate 
confidently the 
effectiveness of the 
WHO analgesic ladder 
for cancer pain 
treatment. 
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Figure 17. Evidence extraction: Serlin RC, et al. 1995. 
 
Title, Citation, 
and Authors Year Design Methods Findings 
Conclusions and 
Limitations 
When is cancer 
pain mild, 
moderate or 
severe? Grading 
pain severity by 
its interference 
with function. 
Pain; 61:277-284 
Serlin RC, 
Mendoza TR, 
Nakamura Y, et 
al. 
 
1995 
Purpose was to determine at 
what points we can best 
distinguish “mild” from 
“moderate” from “severe” 
pain on the BPI. 
 
N = 1897 pts. w metastatic 
cancer and pain. 4 samples 
in US, France, China, and 
Philippines.   
ANOVA and 
MANOVA analyses 
with F test statistic 
Found optimal 
cutpoints that form 3 
distinct levels of pain 
severity on 0-10 
NRS. 1-4: mild, 5-6: 
moderate, 7-10: 
severe. Also found 
non-linear 
relationship between 
the BPI severity and 
interference scales. 
The analysis established 
useful severity 
cutpoints using a 
diverse sample. The 3-
tiered metric is 
especially relevant to 
the WHO analgesic 
ladder. 
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In compiling, evaluating, interpreting, and synthesizing results from many relevant 
epidemiological studies, especially those reporting results of cancer pain clinical trials, the 
Agency for Healthcare Research and Quality (AHRQ) has created two evidence-based 
reports (summarized in Figures 13 and 14 above) of particular use in establishing the present 
state of knowledge about cancer pain. The first of these two reports was published in 2001, 
entitled Management of Cancer Pain.47 One of the main objectives was to summarize 
published evidence on the prevalence of pain related to cancer; cancer-related pain was 
defined as pain caused by cancer, by cancer treatment such as surgery, radiation, or 
chemotherapy, or by the side effects of treatment. The authors found that cancer’s impact on 
public health is due to its considerable prevalence in the world and its association with 
devastating morbidity and mortality,72-74 and that pain is a key dimension of the degradation 
of quality of life associated with this disease.1,2 The report reviewed observational studies on 
the epidemiology of cancer pain, randomized controlled trials, and selected nonrandomized 
studies. Their search strategy was unrestricted by age, gender, ethnicity, or type of cancer, 
and excluded studies of acute postoperative pain. The method used to ascertain studies for 
review in the 2001 report was to identify English language human studies by searching 
Medline, CancerLit, and the Cochrane Controlled Trials Registry, published from 1966 to 
December 1998. These search results were supplemented by bibliographies and other 
sources, yielding approximately 19,000 titles. The authors then narrowed this list using a 
multidimensional evidence grading scale that evaluated validity, quality, and relevance.  
Ultimately, the 2001 report summarized 24 epidemiological surveys of cancer 
pain7,30,57,75-96 and abstracted results from 188 randomized controlled trials of cancer pain 
treatment into evidence tables. Each trial was assessed according to its methodological 
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quality and applicability. Meta-analysis was performed when there were sufficient data to 
address a specific question. The report also examined data from 100 nonrandomized studies. 
The median number of patients enrolled in the randomized trials of primary analgesics 
(NSAIDs, opioids, and adjuvants) was found to be 70 or fewer. Information about the 
location, nature, and mechanism of pain before and after treatment was minimal for all 
interventions examined. Heterogeneous reporting of outcomes, nonuniformity of pain 
measurements, and incomplete reporting of relevant data precluded all but three meta-
analyses. The report concludes that randomized controlled trials have established many 
current treatment modalities effective in individually reducing cancer pain. However, these 
trials constitute only a hundredth of the published literature on cancer pain, enroll only 1 in 
10,000 patients at risk for cancer pain in developed countries, are often heterogeneous, and 
are often of poor methodological quality, leaving several questions unanswered that the 
report originally set out to investigate, such as: “what are the epidemiological characteristics 
of cancer-related pain, including pain caused by cancer, by procedures used to treat cancer, 
and by the side effects of cancer treatment?”, and “What is the relative efficacy of current 
analgesics for cancer pain?”.47 Studies of risk factors suggest that age, gender, tumor type, 
genetics, psychosocial context, and culture affected pain and analgesic efficacy. This 
particular report concludes that more research, especially in the form of higher-quality 
clinical trials, will be needed to advance progress in cancer pain relief. Other studies of risk 
factors for pain have found that among patients with breast cancer, younger patients are at 
higher risk for post-treatment pain.45,97 Minority patients have been found consistently to be 
at greater risk of worse pain outcomes and of undertreated cancer pain specifically.8,24,25,56  
Recent studies (in addition to the evidence-based reviews discussed) have cited the need for 
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future studies to identify specific risk factors and investigate those risk factors identified to 
date.6,98  
In 2002 the AHRQ released a followup to its 2001 report entitled Management of Cancer 
Symptoms: Pain, Depression, and Fatigue5. The 2002 report identified and summarized the 
findings of 29 epidemiological studies, including the 24 studies reviewed in the first report 
plus five additional studies99-103 identified between 1998 and 2001. Several studies reported 
on the prevalence and/or incidence of cancer-related pain. These were nationwide or 
multicenter surveys including as many as 35,000 patients, and hospital or clinic-based 
surveys including a few hundred or fewer patients. More than half of the studies were 
conducted in the United States. The majority of the remaining studies were from Europe. No 
single survey identified a pain prevalence rate below 14% of the patients surveyed. Disease 
severity was found to be associated with more pain, and analgesics were found to be 
sometimes (but not always) successful in alleviating pain. Other than these two evident 
themes, there were no other clear associations, consistent across studies, between the 
prevalence or incidence of pain and specific patient factors, disease characteristics, the 
setting in which care is provided (e.g., primary care or specialized oncology or pain treatment 
clinics), or specific treatments directed towards the underlying disease. The report makes 
several other conclusions; first, they note that findings from observational and survey studies 
indicate that the majority of patients with cancer experience pain at some point during their 
treatment, and that cancer pain impairs both patients’ quality of life and functional status. 
The report states that the further along disease has progressed, the greater the likelihood of 
pain and severe pain. It is important to note that the timeline for progression varies by patient 
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and tumor type. Thus, disease progression is preferable to time for use as an indicator of 
potentially increasing pain.   
The authors of the same 2002 report5 identified evidence indicating that undertreated pain 
adds substantially to the disease burden imposed by cancer, and that despite advances in 
treatment, the disease continues to cause great suffering both among those who die and 
among those who survive. Pain is often not eliminated, even when standard analgesic therapy 
practice is implemented according to the WHO ladder method for treating cancer pain. The 
current literature does not yet provide a comprehensive description of the patient’s 
experience of pain over the course of treatment or continuum of care. The report cites a need 
for tumor-specific studies of longitudinal pain trajectories, with consideration of how various 
treatments available might affect patients’ experience of pain during their treatment.  
The 2004 monograph by McGuire6 summarized in Figure 9 is particularly critical of 
existing cancer pain studies in terms of epidemiological and methodological quality. The 
author concludes from the review that there is a need for tumor-specific information on 
patients’ experiences of pain over time. 
Study of disparities in pain outcomes by racial and ethnic minority status has evolved 
within the fields of research on both pain in general as well as cancer pain specifically. A 
2003 review by Green and colleagues (Figure 12) summarizes findings of studies to date on 
pain disparities (across diseases and settings), focusing on differences in quality of care 
between non-minority and minority patients. Several areas of the issue are examined. In the 
area of experimental pain research, Campbell and colleagues observed that non-Caucasians 
appeared to have lower pain thresholds and tolerance than Caucasians when tested for 
electrical, heat, pressure and cold pressor pain.104 African-Americans in that study reported 
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greater use of passive pain coping strategies and more hypervigilance. However, controlling 
for these factors still did not eliminate the differences in pain responses by race.104 In the area 
of communication, better patient-physician communication was reported in racial/ethnic 
concordant patient-physician pairs, along with higher patient involvement in medical 
decisions. The authors state that pain assessment is inadequate as soon as pain is reported as 
severe, and that minorities are consistently undertreated, with ethnicity and gender 
influencing physician management. On the system level, findings are reported that suggest 
disparities. For example, insufficient quantities of opioid analgesic were found in stock in 
pharmacies associated with higher minority population areas in New York City. From their 
comprehensive review, the authors conclude that white and socially privileged patients 
receive far better pain management than ethnic and social minorities.8 
Rabow and Dibble (2005) sought to examine not only the influence of ethnic and 
geographical factors on specific disease-related pain, but also which deficiencies in end-of-
life care are involved in the inadequacy of pain treatment. The findings summarized in Figure 
6 indicate that ethnicity is a factor contributing to inadequate pain assessment and treatment, 
with patients of color reporting more pain than white Caucasians. The authors attribute their 
findings to a previously well-documented and established pattern of both physicians 
inattention to their patients’ pain and physicians’ resistance to the advice of specialist 
consultants.56 
In a 2003 evaluation by Abernethy and colleagues105 of a pain treatment decision analytic 
model (Figure 11), the authors compared three pain management strategies using an 
adaptable spreadsheet model with inputs from published U.S. population demographics, 
cancer registry data, high-quality studies of cancer pain management, standard 
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reimbursement schedules, and expert opinion. The three strategies compared were (1) 
guideline-based care, (2) oncology-based care, and (3) usual care. Outcomes calculated 
included the likelihood of cancer pain in a healthcare population, how effectively that pain is 
managed, and average monthly cost of treatment. This study concluded that cancer pain 
management based on guideline-based care led to improved pain control, with modest 
increases in resource use.  
The 1999 study by Du Pen and colleagues (Figure 15) is of particular importance in 
synthesizing information about guideline effectiveness.71 Patients were randomized to 
receive either (1) standard-practice pain and symptom management therapies used by 
community oncologists, or (2) pain management care according to an algorithm derived from 
the AHCPR (now AHRQ) guidelines discussed above.5 Patients randomized to the algorithm 
group achieved statistically significant reductions in usual pain intensity. Concurrent 
chemotherapy and patient adherence were found to be significant mediators of worst pain. 
No significant differences in quality of life or other symptoms were observed between 
groups. The Du Pen study supports the use of algorithmic decision making in accordance 
with current guidelines for cancer pain management The authors conclude that 
comprehensive pain assessment and evidence-based processes enhance usual pain 
outcomes.71 
A few studies have further developed the BPI measure by classifying pain into severity 
categories according to cutpoints on a 0-10 numeric rating scale. This classification is of 
extensive use in research and clinical practice. Cutpoints are used to drive treatment 
decisions, develop practice guidelines, and determine effectiveness of interventions. Where 
the cutoff point is set for severe pain also affects descriptive epidemiology, including 
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etiological reports on longitudinal cancer pain, as well as prevalence estimates at a given 
time point.9-12 The Serlin study (Figure 17), conducted among metastatic cancer patients, 
found optimal cutpoints that form 3 distinct levels of pain severity on 0-10 NRS. 1-4: mild, 
5-6: moderate, 7-10: severe. Serlin and colleagues also found non-linear relationship between 
the BPI severity and interference scales. The findings of a 2005 study by Paul and 
colleagues10 in outpatient oncology patients with metastases confirmed Serlin and 
colleagues’ finding of a non-linear relationship between cancer pain severity and 
interference. However, the Paul study (see Figure 8) found a slight difference regarding the 
severity cutpoint of 7. While the Serlin classification would categorize a score of 7 or above 
as severe, in the Paul study a score of exactly 7 would still fall into the moderate category, 
while anything above a 7 would be classified as severe. The Paul study did, however, 
confirm Serlin’s findings that the boundary between a mild and a moderate level of cancer 
pain is at 4 on a 0-10 numeric rating scale.10  
The 1995 review by Jadad and Browman49 (Figure 16) is key in shedding light on the 
usefulness and effectiveness of the WHO analgesic ladder for guiding cancer pain 
management. perform a systematic review of studies evaluating the effectiveness of the 
WHO analgesic ladder as an intervention for cancer pain management. The authors 
conducted a systematic critical review of studies that evaluated patients with cancer pain 
treated according to the WHO analgesic ladder. The study summarized eight case-series 
studies selected from among the following sources: MEDLINE from 1982 to 1995, hand 
search of textbooks and meeting proceedings, reference lists, and direct contact with authors. 
Jadad and Browman found that the studies suffered from several methodological limitations, 
and that analgesia was adequate in 69% to 100% of patients analyzed in the studies. They 
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conclude that it would be inappropriate to judge the performance of clinicians, programs, and 
institutions or to design policies based on evidence from the WHO ladder, because that 
evidence is insufficient to estimate confidently its effectiveness.49 
E. Synopsis 
In summary, longitudinal risks of pain, adequacy of analgesic treatment, racial/ethnic 
differences in the experience or burden of pain, determination of severity cutpoints on NRS 
pain measures, and the need for tumor-specific information are some of the problems in need 
of further study in the field of cancer pain research. Assessment and communication are not 
enough to effectively treat pain; evidence-based practices must be implemented in the 
treatment of pain.106 This means that research should inform clinical practice in order to 
prevent worse pain outcomes over time among patients with cancer. 
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III. STATEMENT OF SPECIFIC AIMS 
 
CHAPTER III 
 
STATEMENT OF SPECIFIC AIMS 
 
A. Study questions/specific aims 
 
The over-reaching goal of this project was to better understand risks and risk factors for 
pain severity and interference outcomes over the course of disease among patients with 
metastatic breast cancer. Manuscript 1 addresses Aims 1 and 2 below, and Manuscript 2 
addresses Aims 2, 3, and 4. We hope that this research will underscore the need for 
improvement in pain management strategies, and will provide tools to effect improvements 
in these strategies through better prediction of pain outcomes over time. 
AIM 1: To provide descriptive epidemiologic information about pain hazards over time 
among patients with metastatic breast cancer, exploring the effect of using different intensity 
cutpoints on the Brief Pain Inventory (BPI) severity and interference 0-10 subscales with 
regard to baseline clinical and demographic covariates as risk factors.  
Research question: What are the hazards of reaching different pain severity and interference 
thresholds over 51 weeks, and what baseline clinical and demographic factors are associated 
with occurrence of these outcomes? 
AIM 2: To explore the relationship between the pain severity and interference BPI 
subscales with regard to sets of clinical and demographic covariates as predictors. 
Research question: Given that the relationship between the severity and interference 
subscales of the BPI is nonlinear, how do clinical and demographic predictors compare in 
their associations with hazards over time for pain severity and interference outcomes?
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AIM 3: To estimate the effects of both baseline and time-dependent clinical and 
demographic characteristics on time to first reaching a pain severity or interference score of 7 
or above on the 0-10 BPI severity and interference scales. 
Research question: How do baseline and time-dependent risk factors predict the outcomes of 
reaching a 7 or above on the BPI severity and interference scales? 
AIM 4: To investigate the hypothesis that, as compared with their Caucasian 
counterparts, non-Caucasian patients would have worse longitudinal outcomes with regard to 
(a) pain severity, and (b) pain interference in daily functions.   
Research question: Within our sample of longitudinal data collected in a clinical trial among 
patients with metastatic breast cancer, will our findings confirm existing findings of 
racial/ethnic disparities in the burden of pain? Also, with regard to hazards for these pain 
outcomes, how does the race variable fit in with other baseline and time-dependent clinical 
and demographic factors in a predictive model? 
B. Hypotheses 
In assessing risk of pain among different groups, we expected that those with lesser 
disease severity and better performance status at baseline (these lesser severity categories are: 
patients who are classified as “active” performance status at baseline, patients who have not 
had a previous skeletal complication [defined as experiencing one or more of the following: 
pathologic fractures, spinal cord compression with vertebral compression fracture, the need 
for surgery to treat or prevent pathologic fractures or spinal cord compression, or the need for 
radiation to bone107], patients with less time between bone metastasis and randomization, and 
patients undergoing hormonal therapy alone versus hormonal therapy adjunct to 
chemotherapy) would have lower hazards of experiencing severe pain earlier in the course of 
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treatment, lower hazards of experiencing pain severity and interference in the highest 
intensity categories (7 or above), and less severe experience of pain over time, as compared 
with their counterparts. This result was expected because as severity increases, so also do two 
potentially pain-causing factors: disease progression and the implementation of more 
aggressive multimodal treatment strategies. We expected that within a given 80-day interval, 
reductions over time in ECOG performance status would be concomitant with worse pain 
outcomes, as would having experienced any of the following since the last study visit: 
hospital admission, surgery, chemotherapy, or radiation. The temporality of these events 
within intervals, and their relationship with the timing of pain precludes conclusions about 
causality. 
With regard to non-clinical covariates, we hypothesized that higher age would be 
associated with better longitudinal pain outcomes, and that membership in economically 
advantageous demographic categories at baseline: full-time employment, North American 
geographic region, college education, and most importantly, that Caucasian race would be 
associated with lower risk over time for pain severity and interference outcomes, as 
compared with their counterparts.   
C. Rationale 
The present study was designed to use longitudinally-collected pain data to address key 
gaps identified in current pain research. Through investigating our hypotheses and research 
questions in fulfillment of the specific aims described, our findings will help provide 
descriptive epidemiological information on pain hazards over the course of treatment among 
breast cancer patients, will justify or suggest changes to the cutoff points most commonly 
used in clinical practice today, and will explore the relationship between pain severity and 
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interference with daily functions. The tumor type under analysis for the present study, 
metastatic breast cancer, is common in relation to other tumor types, may exist in 
longstanding chronic forms, and is associated with high morbidity, mortality, and potential 
for pain, whether the pain is associated with disease and/or with treatment. These findings are 
also expected to aid those who treat breast cancer patients in identifying which patient 
characteristics and events are associated with greater risk for worse pain severity and 
interference outcomes. This knowledge can help clinicians target pain management 
strategies, tailor them to patient’s risk factors, and better advise patients and patients’ 
families on disease status, as well as on options for both cancer treatment and pain control. 
The long-term goal of this work is to aid in future clinical practice recommendations for 
treatment of pain in metastatic breast cancer.  
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IV. METHODS 
 
CHAPTER IV 
 
METHODS 
 
A. Overview of methods 
The present study was a retrospective cohort study that describes the longitudinal 
epidemiology of pain, assessed using the Brief Pain Inventory (BPI) among 1124 patients 
with metastatic breast cancer. We conducted a secondary data analysis of existing data from 
a clinical trial (Novartis protocol 4244603010) that assessed patient outcomes over at least 51 
weeks. The “core phase” of the trial followed patients to 357 days, and an “extension phase” 
continued to follow patients beyond the core phase, such that patients who were receiving 
benefit from being in the trial would not be discontinued from the trial at the end of the core 
phase. Further details about the trial population are given below in the section entitled 
Subject identification/source population. 
For Manuscript 1, we conducted proportional hazards analyses for reaching different 
thresholds of pain on the Brief Pain Inventory (BPI) severity and interference scales over 
time, comparing which sets of clinical and demographic baseline predictors affect hazards of 
reaching different thresholds of pain as defined by cutpoints on the 0 – 10 severity and 
interference scales. Patients reaching the intensity cutpoints of 3, 4, 5, 6, and 7 or above on 
each scale are the outcomes of interest in predictive modeling to analyze each cutpoint 
separately, then all cutpoints together, exploring interactions between covariates and 
cutpoints. Time-to-event was treated as continuous in these analyses. Sensitivity analyses 
address (a) how deaths are counted, and (b) handling of missing data.
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For Manuscript 2, we estimated the effects of both baseline and time-dependent clinical 
and demographic characteristics on hazards for first reaching a pain severity or interference 
score of 7 or above on the 0-10 BPI severity and interference scales. We modeled the 
relationship between the two pain outcomes and sets of potential predictors using piecewise 
exponential models under an assumption of interval-censored time. Sensitivity analyses 
address (a) how deaths are counted, and (b) handling of missing data. 
B. Study design 
1. Subject identification/source population 
The present retrospective cohort study was a secondary analysis of existing data from a 
clinical trial (Novartis protocol 4244603010). Informed consent was obtained from each 
patient in the original trial, and the multicenter trial was carried out under approval from each 
institution’s ethical review board, in accordance with applicable laws in each country and the 
Declaration of Helsinki. The secondary analysis in the present study was conducted under 
approval from the University of North Carolina at Chapel Hill Institutional Review Board. 
The trial assessed patient outcomes over at least 51 weeks using the Brief Pain Inventory 
(BPI)108 to measure pain among 1,648 patients with metastatic breast cancer or multiple 
myeloma. Saad et al.109 provide a full report of the primary analyses of the double-blind, 
multicenter clinical trial, the purpose of which was to compare two bisphosphonate drugs, 
intravenous zoledronic acid [4 or 8 mg] versus intravenous pamidronate disodium [90 mg], 
as an adjunct to standard therapies, in the treatment of multiple myeloma and breast cancer 
patients with cancer-related bone lesions. No placebo arm was used. The intent-to-treat (ITT) 
study population consisted of men and women with stage III multiple myeloma (n = 510) or 
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stage IV breast cancer with ≥ 1 lytic or mixed bone metastasis (n = 1130). For the purpose of 
the present analysis, we limited the sample to women with breast cancer (n = 1124).  
a. Trial inclusion/exclusion criteria 
Patients were included in the trial if they had a histologically confirmed diagnosis of 
breast cancer with at least 1 bone metastasis confirmed by conventional radiographs of bone 
(plain film); were ambulatory; were aged at least 18 years; and had an ECOG performance 
status of less than 3 (see the Predictors section for more information about this variable). 
Patients were required to be receiving antineoplastic therapy at the time of randomization and 
to be in good clinical condition. Patients receiving hormonal therapy for breast cancer had to 
be on first- or second-line hormonal therapy for metastatic disease. They could not be 
receiving greater than second-line hormonal therapy for metastatic disease, except in 
combination with chemotherapy. Patients were excluded from the trial if they were pregnant; 
had undergone treatment with bisphosphonates at any time during the 12 months prior to visit 
1 (unless limited to a single dose administered at least 14 days prior to visit 1); had breast 
cancer with lymphangitic lung metastases; had clinically symptomatic brain metastases; had 
been treated with other investigational drugs within 30 days prior to randomization; had a 
history of noncompliance to medical regimens or potentially unreliable behavior (e.g., 
alcoholism, psychosis, drug addiction); or had heart disease meeting grade III or IV of the 
New York State Heart Association functional classification. 
b. Trial stratification, geography, and timeframe 
 The sample was stratified at enrollment into two categories: (1) patients with breast 
cancer undergoing chemotherapy or breast cancer patients undergoing both chemotherapy 
and hormonal therapy, versus (2) patients with breast cancer undergoing first-line or second-
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line hormonal therapy without chemotherapy. These stratification categories were used as 
covariates in the present study. The clinical trial was conducted at 207 centers in the 
following countries (grouping identified in parentheses): Canada and the United States 
(North America); Argentina, Brazil, Chile, Peru, and Uruguay (South America); Austria, 
Belgium, the Czech Republic, France, Germany, Ireland, Italy, the Netherlands, Poland, 
Spain, Sweden, Switzerland, and the United Kingdom (Europe); and Australia, Israel, New 
Zealand, and South Africa (other). The first patient was recruited on October 16, 1998, and 
the last assessment was completed on the last patient on January 12, 2001.  
2. Measurement, assessment, and validity 
a. Outcomes: pain severity and interference 
Patients completed the Brief Pain Inventory questionnaire (see Appendix B) according to 
the trial data assessment schedule shown in Figure 18.  
Figure 18. Trial data assessment schedule (BPI and ECOG measurements). 
 
Months  0    3    6    9    12  
Days -14 0 21 42 63 84 105 126 147 168 189 210 231 252 273 294 315 336 357
Weeks -2 0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 45 48 51
Visits 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
ECOG  x    x    x    x     x 
BPI  x x x  x  x  x  x  x  x  x x 
 
 
Patients completed the Brief Pain Inventory questionnaire at baseline, months 1 and 2, 
and every other month thereafter up to months 12 and 13 (Weeks 50 and 51). The BPI was 
administered in person before the patient was interviewed by the physician or received study 
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medication. The Brief Pain Inventory (BPI) measure consists of several parts, but this study 
uses only the pain severity and interference items. Severity was measured as: average pain, 
pain right now, worst pain, and least pain, all four of which are answered on a 0-10 scale, 
with 0 = “no pain” and 10 = “worst pain imaginable”. The "worst pain" or the arithmetic 
mean of the 4 severity items can be used as measures of pain severity.  For the present study, 
at the advisement of the BPI instrument’s creators, we use the arithmetic mean of the 4 
severity items rather than the “worst pain” score alone. The BPI includes a 7-item pain 
Interference scale, which consists of the same 0-10 response scale to the question: “describe 
how, during the last 7 days, pain has interfered with your: 1) general activity, 2) mood, 3) 
walking ability, 4) normal work (includes both work outside the home and housework), 5) 
relations with other people, 6) sleep, and 7) enjoyment of life. The arithmetic mean of the 7 
interference items was used to measure pain interference. 
In general, numeric rating scales for pain severity such as the BPI have been 
demonstrated to be valid and sensitive to change.110 According to the American Pain Society 
Clinical Practice Guideline for the Management of Cancer Pain in Adults and Children,18 
NRS measures are among the most common, valid, and reliable measures used to assess 
cancer pain severity, and are preferred by patients over VAS measures. The BPI has been 
administered and assessed for validity in several languages including Spanish, French, 
Japanese, Chinese, Italian, Hindi, German, Greek, and Vietnamese.34-40  
In a key study of clinically meaningful change for the BPI, Farrar and colleagues43 
conducted a validation study in 134 cancer patients that concluded that the minimally 
important difference (MID) was a change or difference of 2 or more points in a generic 
numeric rating scale of pain intensity that (like the BPI) ranged from 0-10. The clinical 
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anchor for “important difference” in their study was the outcome of whether additional pain 
medication was needed 30 minutes after a first dose of pain medication was given (i.e., the 
successful treatment of pain). The authors zeroed in on the 2-point difference using the 
maximized sensitivity and specificity from the results of their receiver operating 
characteristic (ROC) curve analysis.  
b. Predictors: clinical and demographic variables 
In addition to the pain assessments, subjects were asked to provide demographic, clinical, 
and outcomes information through interviews, written questionnaires, and physical 
examinations, to complete the clinical case report form and other original clinical trial source 
documents in accordance with the study protocol. Analyses comparing treatment arms as 
predictors have already been conducted and are reported elsewhere.111 Comparisons between 
the treatment arms are not a part of the present study because the two comparative treatments 
were not found to affect pain in the report of the clinical trial results by Rosen et al. (2001). 
For the present analyses, we group all the patients together to compare them with regard 
to clinical and demographic characteristics. These characteristics included ECOG 
performance status [1 = active (ECOG status of 0 or 1), 0 = restricted (ECOG status of 2 or 
above)], age, education (1 = college degree, 0 = no college degree), employment status (1 = 
full-time, 0 = other), geographic region (North America, South America, Europe, or Other – 
defined previously per-country), antineoplastic therapy on study entry, analgesic therapy, 
previous skeletal complications (0 = no, 1 = yes), and dates of initial cancer diagnosis, initial 
metastasis, initial metastasis to bone, and disease progression. On the ECOG status data 
collection form, Karnofsky Performace Status (KPS) anchors are given as follows. ECOG 
status = 0 (KPS = 90-100); ECOG status = 1 (KPS = 70-80); ECOG status = 2 (KPS = 50-
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60); ECOG status = 3 (KPS = 30-40); and ECOG status = 4 (KPS = 10-20). Skeletal-related 
events (SREs) were defined in the trial as one or more of the following: pathologic fractures, 
spinal cord compression with vertebral compression fracture, the need for surgery to treat or 
prevent pathologic fractures or spinal cord compression, or the need for radiation to bone.107  
In several cases, we recoded baseline covariates as dichotomous in order to facilitate 
modeling techniques. Caucasian race, college education, full-time employment, age, and 
North American geographic region were dichotomized as such for this reason. We coded the 
full-time employment and college education variables (each of these variables had about 16% 
missing data at baseline) as three-level categorical variables, with the categories as “yes”, 
“no”, or “missing”, with “yes” as the referent so that the effect of lower educational 
attainment or no employment could be assessed. This technique prevents these observations 
from being dropped from the models. Age was normally distributed, and dichotomized for 
Manuscript 1 at its mean of 57.9 (SD ±12.7). The lower age category was 24-57, and the 
higher age category was 58-95. The age variable was continuous in decades for exploratory 
analyses in Manuscript 1 and for Manuscript 2. 
Time-dependent characteristics included in the present study were performance status 
over time (also measured by ECOG performance status with the same dichotomous 
categorization described above), surgery since the last study visit, chemotherapy treatment 
since the last study visit, and radiation treatment since the last study visit. The trial visit 
schedule shown in Figure 18 displays when ECOG performance status data were collected 
throughout the trial. 
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C. Methods 
1. Data preparation 
a. Coding 
For the purposes of these analyses, we recoded several variables. Race, education, 
employment, and geographic region were dichotomized; Table 3 describes the coding 
scheme for each of the variables used in the analysis.  
Table 3. Variable coding/recoding scheme  
 
Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
SBJ1N Subject number num -    
VIS1N Visit Number num - Inclusion/Exclusion by VIS1N: 
Keep records where 2 LE VIS1N 
LT 20 or 97 LE VIS1N LT 99 
DAYSRAND Days from 
randomization 
Imputation 1 
num - = LSTDATE - V2DATE If 
maximum VIS1N for a patient is 
LE 19 
LSTDATE Last date patient 
observed 
DATE11 -  
V2DATE Date of 
randomization 
DATE11 -  
PAINDTE Date of BPI 
assessment 
DATE11 -  
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
BPITIME BPI Days since  
Rand  
num - = PAINDTE - V2DATE if 2 LE 
VIS1N LT 20 or 97 LE VIS1N 
LT 99 
      Note: If BPITIME is negative, 
set equal to 0. 
AGE1N Age in years num - -   
1 = 'Caucasian' 
2 = 'Black' 
3 = 'Oriental' 
RCE1C Race num - 
4 = 'Other'; 
CAUC   Caucasian race  num 0 = not cauc.
1 = caucasian
if RCE1C = . then cauc = .; (not 
applicable because no data are 
missing for race) 
else if RCE1C = 1 then cauc = 1;
else if RCE1C in (2,3,4) then 
cauc = 0; 
COU1A Country char - -   
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
GEOG Geographic Region char NA = North 
America 
=NA If COU1A = USA or CDN 
     SA = South 
America 
= SA If COU1A = BR, PE, RA, 
RCH or U 
     EU = 
European 
Union 
= EU If COU1A = A, B, CH, 
CZ, D, E, F, GB, I, IRL, NL, PL, 
or S 
     O = Other = O If COU1A = AUS, IL, NZ, 
or ZA 
GEOGNA num 0 = Not North 
America 
  
Dichotomous 
geographical region
  1 = North 
America 
if GEOG = 'NA' then geogna = 1;
else if GEOG ne 'NA' then 
geogna = 0;  
PREVSRE2 Previous SRE num 0 = None 
1 = Previous SRE 
STRAT_E Strata for Efficacy 
analysis 
num 1='Multiple myeloma' 
2='Breast cancer with chemo' 
3='Breast cancer with hormonal' 
CHEMO num 
  
Chemotherapy at 
baseline   
if strat_e = 2 then chemo = 1; 
else if strat_e = 3 then chemo = 0; 
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
1 = Adverse event(s) (also specify on the 
Adverse Events form) 
2 = Abnormal laboratory value(s) 
3 = Abnormal test procedure result(s) 
4 = Unsatisfactory therapeutic effect 
5 = Subject's condition no longer requires 
study drug 
6 = Protocol violation 
7 = Subject withdrew consent 
8 = Lost to follow up 
9 = Administrative problems 
P_REASON Study completion 
form – primary 
reason for 
premature 
discontinuation 
num 
10 = Death (please complete Serious Adverse 
Events form and record adverse events leading 
to death on the Adverse Events form) 
 
DATEDIED Date of death DATE11    Date of death 
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
ECOG Performance 
Status (Raw) 
 
num 
  
  
   
ECOG 
  
  
  
     
     
0 = Fully active 
1 = Restricted 
2= Ambulatory 
3 = Limited self-
care 
4 = Disabled 
5 = Dead 
= ECOG 
at each visit 
 
 
 
 
 
BECOGA num 0 = Restricted 
  
Active ECOG 
baseline Y/N   1 = Active 
if baseline ECOG 
(interim variable 
base_ecog = ECOG at 
first visit) in (0,1) then 
becoga = 1; else if 
base_ecog = . then 
becoga = .; else if 
base_ecog in (2,3,4) then 
becoga = 0; 
SURG_ Surgery since last 
visit 
num 0 = No 
1 = Yes 
 
RAD_ Radiation since last 
visit 
num 0 = No 
1 = Yes 
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
CHEM_ Chemotherapy since 
last visit 
num 0 = No 
1 = Yes 
 
ADMIT Hospital admission 
since last visit 
num 0 = No 
1 = Yes 
  
WPAINL7D Worst pain num    - 
LPAINL7D Least pain num    - 
APAINL7D Average pain num    - 
PAINNOW Pain now num     
BPIC BPI Severity 
Composite Score 
num  = Average of WPAINL7D, 
LPAINL7D, APAINL7D, 
PAINNOW if none of these 4 = .
GENACT Interference in 
general activities 
num  - 
MOOD Interference in 
mood 
num   -
WALK Interference in 
walking ability 
num   
- 
WORK Interference in 
normal work 
num   
- 
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Variable 
name 
Label Type Code Source / derivation 
(if applicable) 
RELATION Interference in 
relations with other 
people 
num   
- 
SLEEP Interference in sleep num   -
ENJOY Interference in 
enjoyment of life 
num   
- 
INTERFERE BPI Interference 
composite score 
num  = average of GENACT, MOOD, 
WALK, WORK, RELATION, 
SLEEP, ENJOY (if at least 4 of 
these are nonmissing - if 4 or 
more are missing, Interfere = .) 
Note: LT = less than. GT = greater than. LE = less than or equal to. GE = greater than or 
equal to. NE = not equal to. Rand = randomization. Num = numeric. Char = character. Single 
dot “.” indicates missing value in SAS. 
 
b. Exploratory analysis 
We examined each categorical predictor variable for its frequency distribution and extent 
of missing data, and each continuous predictor and continuous outcome variable for its 
normality distribution, skew, kurtosis, and outliers, in order to select the appropriate 
statistical tests. Exploratory analyses assessed how the baseline characteristics and outcomes 
differed by race at the time of randomization. 
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c. Bias, confounding, and effect measure modification 
Self-selection and diagnostic bias for participation in clinical trials should always be 
acknowledged as a threat to external validity when extrapolating findings, since those 
who participate in the trial may not represent the population to which one wishes to 
generalize. The large trial population of 1,124 patients may be considered a strength of 
the present study, assuming minimal impact of potential bias due to the sampling 
methods on this sample’s representativeness of women with metastatic breast cancer. 
Early research on how clinical trial participants differ from non-participants suggests that 
trial participants have less mortality than non-participants.112 In their 2004 study of 
cancer clinical trial participation, Murthy and colleagues found that younger and minority 
patients were less likely than their counterparts to participate in cancer clinical trials.113 
However, the distribution of race in this study (recorded as “Black” for 5.7% of the 
sample) appears close to the distribution of race among prevalent first malignant breast 
cancer cases in 2002 in the U.S. (Black = 7.4% of total cases) estimated by Surveillance, 
Epidemiology and End Results (SEER).114 With regards to age, women aged 57 years or 
less composed approximately half the trial population, while 20% of prevalent breast 
cancer cases were aged 54 or lower in 2002 U.S. estimates (27-year limited-duration 
prevalence, first malignant cancer only).114 Thus, both the age and race distributions in 
the present study seem to roughly approximate the populations to which we would 
generalize the findings, although the influence of potential bias with regard to traits 
affecting pain outcomes cannot be ruled out entirely.  
Because this was a cohort study, information bias would be of concern if the outcome 
of perceived pain were misclassified with respect to any of the covariates. Patients may 
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underreport or overreport the pain they experience. Although underestimation of pain is 
more a problem in retrospective studies involving spontaneous patient reports,30 it is still 
possible that in the present study, patients may underreport pain (there is more evidence 
for underreporting, rather than overreporting, being a likely problem). Based on cultural 
views, some patients may believe that pain is a spiritual or religious test of their faith, or 
believe that it is wrong to take or become addicted to opioids. These patients may 
therefore refuse to report their pain or accept palliative treatment.31 When interpreting the 
results of the present study, we acknowledge that, due to potential and probable 
underreporting,30,31,115,116 our estimates may be biased downward toward lower amounts 
of pain than patients actually experience. Misreporting of pain is a problem that could 
vary with respect to the covariates, but without having a “true” score to compare with the 
reported score for any patients in the study, the magnitude and/or direction of this 
potential bias cannot be known. Clinicians and researchers must rely on patient report of 
pain, since no neurophysiological or laboratory test can measure pain.117 However, it is 
possible to measure and estimate the extent of misreporting, and to educate patients such 
that they would be more likely to report the truth in the goal of receiving the most 
appropriate treatments. Potential bias from differential item functioning in the present 
study could lead to either under- or over-estimation of effects with regard to their true 
values. 
Because bisphosphonates have been found to reduce skeletal events and bone pain in 
advanced breast cancer where bone metastasis is present,62 it is useful in interpreting the 
findings of the present study to keep in mind that all of the patients under study (i.e., both 
treatment arms) were being treated with bisphosphonates and adjuvant standard therapy. The 
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effect of the entire study sample undergoing bisphosphonate treatment in the present study 
would be that pain may be underestimated in this sample as compared with patients 
undergoing standard therapy alone. 
Predictive modeling methods do not assess the effect of a specific exposure or 
treatment upon the outcome of interest. Traditional epidemiologic methods for assessing 
confounding under the overarching goal of assessing an exposure – outcome relationship 
do not apply because the goal of predictive modeling is to identify those factors that 
account for the most variance in the model being fit to describe the outcome, and further, 
to build the most parsimonious predictive model possible.118,119 Instead of using a 
directed acyclic graph (DAG) with identification of unblocked backdoor paths, for the 
present study we sought to diagram possible theoretical associations between the set of 
variables being studied and the outcomes. Figure 19 is a schema that represents a 
preliminary exploratory analyses of possible associations among the covariates and the 
outcomes. Indeed, most all of the covariates could feasibly be associated with the others, 
and most covariates could feasibly be directly associated with pain outcomes. 
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Figure 19. Explanatory covariates; relationships with each other and with the 
outcomes. 
 
Unlike confounding, effect measure modification may still be assessed in predictive 
models. The covariates were assessed for potential effect measure modification through 
testing the inclusion of interaction terms in the modeling processes, using likelihood ratio 
tests to compare models with and without interaction terms. Where effect measure 
modification was found to be present, stratified results are reported. 
d. Power calculation 
To calculate the respective sample sizes that would be needed to detect a statistically 
significant change in the BPI intensity scale, a simple change-from-baseline approach was 
used to compute the mean and standard deviation of change scores; the change-from baseline 
method was used only for the purpose of power calculation. Change scores were computed 
only for those who have a BPI score at both visit 10 (24 weeks post-randomization) and at 
baseline. Clinical meaningfulness of change scores is not considered in the sample size 
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calculations, which are geared instead toward statistically significant changes on the scale. 
The simplified sample size calculation method involving a calculation of change scores is the 
current standard for longitudinal studies, and is deemed acceptable but not ideal, in 
consideration of current software limitations that do not yet fully accommodate longitudinal 
data structures (Personal communication, Gary Koch, March 2005). The power calculation is 
thus geared toward the hypothetical estimation of a statistically significant difference in 
change scores between the exposure groups in each type of cancer. In terms of precision, the 
95% confidence intervals (CIs) around point estimates would be too imprecise if they 
included the next integer (e.g., the 95% CI around a baseline estimate of 7.0 should not 
include 8.0). In this calculation, we use as the exposure the covariate of chemotherapy 
treatment versus hormonal therapy alone. 
An alpha of 0.05 was used in the sample size calculations, in accordance with current 
conventions. A beta of 99% is desirable when using clinical trials data, however, power to 
detect statistically significant differences in change scores was the main outcome of the 
sample size calculation, since sample sizes are already fixed. Based on preliminary analyses 
of the clinical trial data, the expected mean BPI score at baseline should be similar for both 
groups for each anchor measurement at baseline, and should be above 3.0 (a mean derived 
from a population of cancer patients which was not constrained to those being treated for 
pain specifically), with an expected standard deviation of BPI scores at baseline of ± 2.17 
points.  
Parameters for these sample size calculations were as follows: 
- Two-tailed alpha of 0.05 for both 2-group comparisons. The basis for this 
significance criterion is the acceptance in accordance with convention of a 5% 
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probability of rejecting the null hypotheses (that BPI change scores did not differ 
between each of the two groups). 
- Power = the outcome of interest for the sample size calculations, since sample sizes 
are fixed in this secondary data analysis design. 
- SD of BPI change scores = ± 2.22 for breast, ± 2.11 for prostate. Numbers of patients 
in each exposure category are shown below. 
- Correlation between levels (over repeated assessments) of BPI scores = 0.57 (based 
on unpublished analyses of longitudinal BPI data) 
- Sample size estimates assume no dropout 
- The sample size formula used was for independent samples t-tests. The effect sizes 
entered into the formula were entered and varied according the benchmarks for effect 
size described below. As stated in nQuery (version 3.0),120 the effect size is an index 
of the separation expected between the observed means in the two groups. 
Table 4. nQuery analysis: chemotherapy as exposure 
 
Exposure groups n(%): 
Breast cancer with chemotherapy          525       (46.71)     
Breast cancer with hormonal treatment          599       (53.29)      
     
Change scores: 
N                          789      Sum Weights               789 
Mean                -0.57     Sum Observations     -452.58 
Std Deviation       2.22      Variance              4.95 
 
Cohen’s benchmarks for effect size121 were used for this sensitivity analysis of sample 
sizes needed. Effect sizes of 0.2, 0.5, and 0.8 may be characterized as small, medium, and 
large, respectively. Above 0.8 may be considered a very large effect size, and is shown below 
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because the expected difference in means of 2 points would correspond with a minimally 
important difference (2-point expected difference in means).  
Table 5. Power calculation: sample sizes needed to detect differences in means 
 
Expected difference in 
means 
Unadjusted ES 
(= Mean diff / 
SD of 2.22) 
Power (%)120 
0.44 0.20 91 
1.11 0.50 99 
1.78 0.80 99 
2.00 (MID) 0.90 99 
Note: Unadjusted ES assumes no within-group correlation of change scores. 
For each effect size based on mean change scores, the sample sizes shown in Table 4 
would be needed to test this range, in accordance with the parameters shown in Table 5 (ES = 
effect size, SD = standard deviation, MID = minimally important difference).  
2. Statistical analysis 
We conducted the analyses using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) 
and SAS-callable SUDAAN Release 9.0 (Research Triangle Institute, Research Triangle 
Park, NC, USA). All analyses were conducted on the ITT sample, which included all female 
breast cancer patients who had been randomized in the trial. We calculated descriptive 
statistics and assessed extent of missing data for the predictor and outcome variables under 
study. These analyses were performed under two possible assumptions about the data: that 
time in the model was continuous versus categorical (also called “interval-censored”). The 
analyses for Manuscript 1 (MS1) assessed the relationship of baseline predictors with time to 
reach pain cutpoints 3, 4, 5, 6, or 7 on the 0-10 severity and interference scales, under a 
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model with a continuous time assumption. The analyses for Manuscript 2 (MS2) assessed the 
relationship of baseline and time-dependent covariates on the outcome of reaching a 7 or 
above on the severity or interference scales, under a model with categorical time assumption. 
a. Baseline predictors of hazards for severity and interference scales: analyses of 
multiple cutpoints (MS1)  
Time-to-event was calculated as the number of days from randomization until the patient 
reported reaching a given severity cutpoint (3, 4, 5, 6, or 7) on the BPI. For each cutpoint, 
those who never reached that cutpoint as of trial completion (51 weeks, or 357 days, post-
randomization) or dropped out of the study were classified as censored. For censored 
patients, the event indicator variable was set to 0, and time at risk was the time from their 
randomization date to trial completion or dropout.  
We used visual examination of Kaplan-Meier (KM) curves along with the log-rank test 
statistic to assess the candidacy of each covariate for stepwise univariate modeling. 
Covariates for which the KM curves did not cross and the log-rank test was significant at a 
criterion of α = 0.05 were considered best candidates as potential explanatory variables for 
inclusion in the Cox proportional hazards models. Continuous covariates were dichotomized 
at the mean if normally distributed, or at the median if non-normally distributed, for the 
purposes of the KM curve analysis and to be used as dichotomous predictors. Age was 
normally distributed, and dichotomized for the multivariate analyses at its mean of 57.9  
(SD ±12.7). This resulted in age categories of 24-57 and 58-95 years. Days from bone 
metastasis to randomization was non-normally distributed, and dichotomized at its median of 
104 days (interquartile range = 36 to 475 days).  
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Time-to-event model building techniques were conducted with the goal of creating 
parsimonious predictive models to determine the covariate-adjusted hazards of reaching each 
cutpoint over time. These techniques relied on the stepwise procedure with model entry 
specified at 0.25, and staying criteria specified at 0.15. The univariate Cox proportional 
hazards models are expressed as follows: 
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To analyze the time until first reaching each cutpoint explored (3, 4, 5, 6, and 7 on the 0-
10 scale) simultaneously with the same explanatory covariates, we fit multivariate Cox 
proportional hazards models using PROC SURVIVAL in SUDAAN, which implements a 
Taylor series variance estimation to account for within-subjects correlation between multiple 
possible outcomes. The explanatory variables used as baseline predictors were ECOG 
performance status, age, race, college education, full-time employment, and previous skeletal 
related event. We chose this set of explanatory variables for the multivariate model because 
these factors had emerged as most consistently influential across the univariate analyses. In 
the multivariate model, each patient had several potential outcomes: time to 1st reaching the 
score of each cutpoint (3, 4, 5, 6, and 7) or higher on the 0-10 scales. To model these 
outcomes simultaneously, we fit the Cox proportional hazard model as follows:  
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where j = 3, 4, 5, 6 or 7 for the different pain score cutpoints. This equation applies to any 
patient i. We assume proportional hazards across different outcomes reflected by a 
constant jα . jkβ can be the same for different outcomes.  
In univariate and multivariate models, the exponentiated individual parameters, keβ , are 
the hazards. In comparing hazards with each other, hazard ratio (HR) values greater than 1.0 
imply a significantly higher hazard of reaching a given pain endpoint relative to the reference 
group, if the confidence interval excludes the null value at a significance criterion of α = 
0.05. We used only the baseline assessment of all the clinical and demographic covariates 
described. Therefore, each variable in this set of p covariates was considered time-
independent in the models.   
b. Hazards model for time to first occurrence of a 7 or above, categorical time 
assumption, incorporation of time-dependent covariates (MS2) 
For both the clinical and statistical interest of cutpoint 7 on the BPI, we chose to model 
the hazards for time to first occurrence of a 7 or above on each scale. The trial data 
assessment schedule involved visits scheduled every 21 days, with BPI assessments every 2 
visits and ECOG assessments every 4 visits. The pain severity questions were asked over the 
timeframe of the past seven days (with the exception of “describe your pain right now”) and 
the pain interference questions were asked over the timeframe of the past 24 hours. This 
means that gaps in information as long as 5 weeks exist in the severity data, and even longer 
gaps exist in the interference data. Given these gaps in information, the present study 
involved interval-censored data because a patient could have experienced an event between 
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two assessments but the exact date of the event is unknown. Interval-censored data may be 
analyzed under an assumption of categorical rather than continuous time at risk for hazards 
models. We handled this assumption using a piecewise exponential model (using PROC 
GENMOD) with categorized time in Poisson regression. As adapted from Stokes, Davis and 
Koch, Categorical Data Analysis using the SAS System (2000), the piecewise exponential 
likelihood for the present models, with continuous covariates, is as follows: 
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where yik is equal to 1 if the event occurred, or 0 if the event did not occur for the ith 
person during the kth interval, Nik is the total person-time of exposure (in days), mi is the 
maximum number of intervals for subject i, and λik is the hazard parameter. The piecewise 
exponential model assumes that there are conditionally independent exponential distributions 
with hazard parameters λik for the respective time periods.122 The properties of this method 
enable us to obtain effect estimates from Poisson regression computations using the 
assumption of the piecewise exponential model, regardless of whether we make the 
conditional arguments necessary to assume a Poisson distribution. Stokes and colleagues 
(2002) discuss these specific properties further.122  
For the categorical data analysis, intervals were assigned as every 80 days following 
randomization, with a total of 5 intervals. Intervals were numbered 0 through 4, with the last 
interval beginning 320 days following randomization, and ending at 400 days (57 weeks) 
following randomization. Interval 0, also called the “first interval” was the referent and was 
80 days in length. Although the choice of interval length and number of intervals can be 
completely arbitrary for the piecewise exponential model to still be valid,33 we chose the 80-
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day interval length based on the distribution of events in the intervals; model convergence 
requires a minimum number of events in any given interval.  
For any interval in which a patient remained in the study but did not reach the outcome, 
time at risk was set at 80 days. A patient’s last interval was the interval in which she (a) 
reached the outcome of a 7 or above, (b) dropped out before the 400-day mark, or (c) died 
before the 400-day mark. For those who reached the outcome, in their last interval an event 
indicator variable was set to 1, and time at risk was defined as the time from the beginning of 
the interval to the date of the report of a 7 or above. For patients who dropped out early or 
died, time at risk in the last interval was equal to the number of days from the beginning of 
the last interval to the date of dropout or death. If a patient never reached the outcome in any 
interval, that observation was censored, such that the event indicator variable was set to 0 for 
all intervals, and time at risk within each interval was assigned as 80 (or, in the cases of 
dropout or death, the time at risk in the last interval would be the number of days from the 
beginning of their last interval to the date of dropout or death).  
To account for within-subjects correlation of multiple outcome assessments over time, we 
used generalized estimating equation (GEE) methods to adjust the standard errors and 
confidence intervals around the estimated model parameters. We assessed model fit by 
evaluating the significance at a criterion of α = 0.05 of the Residual χ2 score statistic for 
contribution of covariates and all possible time-by-covariate interaction terms not included in 
the model.  
c. Exploring the severity-interference relationship (MS1 and MS2) 
These data presented an opportunity to explore the relationship between the BPI intensity 
composite score and the BPI interference composite score. Both scales are rated numerically 
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on a 0-10 scale, with 10 indicating greatest severity or interference. To explore the 
relationship of these two subscales, we explored the similarities and differences in how sets 
of explanatory covariates affected pain severity versus interference outcomes. 
d. Sensitivity analyses  
Handling deaths in the analysis (MS1 and MS2) 
 
An overarching issue that affected all the survival analyses was that in the analyses, death 
may be dealt with either by: 1) censoring, or 2) treating death as an event of the worst 
possible outcome (severe pain).123 We conducted a sensitivity analysis to address this issue. 
For those individuals who died, instead of censoring their observation, we assigned time to 
reach severity of 7 or higher at the time of death as if death were comparable to a BPI score 
of 10, and the time of death was the last time for pain assessment. The dropout date was 
effectively either the last day of enrollment in the trial, or the last day the BPI was 
administered, whichever was the later of the two. We compared the model results using this 
technique with those results from conventional censoring.  
Counting days from randomization to event (continuous time assumption) (MS1 and 
MS2). 
The analysis methods required that we make certain assumptions about handling the 
event indicator and time at risk variables, given missing data scenarios present in the data. 
There were four possible such scenarios, for which we implemented the following coding for 
event indicator and time-to-event variables:  
- (Scenario A) if a patient reached a BPI measurement of [3,4,5,6, or 7] (hereafter 
referred to as “the outcome”) then the dichotomous event indicator variable was set 
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equal to 1 and time at risk was set equal to the number of days from randomization to 
the date of the first occurrence of the outcome.  
- (Scenario B) If the patient had complete BPI data but never reached the outcome, 
then the dichotomous event indicator variable was set equal to 0 and time at risk was 
set equal to total number of days the patient was in the study (leading to these 
observations being censored in the survival analysis).  
- (Scenario C) If a patient did not have any BPI data then the patient was not included 
in the survival analysis.  
- (Scenario D) If the patient had some BPI data but never reached the outcome, then the 
dichotomous event indicator variable was set equal to 0. The observation was 
censored as in Scenario B, but total time at risk was set equal to either the total 
number of days the patient was in the study (assumption D.i), or to the number of 
days from randomization to the date of the preceding non-missing BPI measurement 
(assumption D.ii).  We conducted a sensitivity analysis to assess the impact of 
different missing data handling methods, using these two variations of Scenario D 
(D.i and D.ii).  
Another missing data handling technique used was to code the full-time employment and 
college education variables (each of these variables had about 16% missing data at baseline) 
as three-level categorical variables, with the categories as “yes”, “no”, or “missing”, with 
“yes” as the referent so that the effect of lower educational attainment or no employment 
could be assessed. This technique prevents these observations from being dropped from the 
models. 
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3. Quality assurance/quality control 
a. Outcome scoring 
The BPI scoring rules were quality-control checked by hand for correct calculation, as 
well as to make sure that all reverse-scored items were properly reversed. Three people 
separately carried out quality control (QC) checks on subsets of randomly chosen 
observations, with each subset representing a scoring situation with possible error potential, 
and several observations in each subset.  
b. Recoding 
For variables that were recoded (for example, a multi-level categorical variable such as 
ECOG status being dichotomized to active versus inactive for the present analyses), the 
recoding was verified using SAS to cross-tabulate the new and old variables, including 
display of missing values, using the following code: “PROC FREQ; tables [original variable] 
* [new variable] / missing”. I examined each cross-tabulation to make sure that there were no 
errors created in the recoding process, and had a second person verify the cross-tabulations. 
c. Data restructuring 
For the survival analyses conducted under the continuous time assumption, it was 
necessary to convert the original dataset from multiple observations/records per patient (each 
visit constituting a separate observation within a given subject’s multiple records), to a 
structure with only one record per patient, with multiple assessments over time reflected as 
separate variables within the single record. Event indicator and time-to-event/time-at-risk 
variables were created using the data restructuring methods described in Allison (1995)124 
and in Stokes, Davis, and Koch (2000).122 We checked the accuracy of each restructuring by 
comparing before and after printouts at each phase, cross-checked by a separate programmer 
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who examined the records as well as the data restructuring code in SAS. In addition, we 
implemented these same QC procedures to check the creation and coding of indicator 
variables and time-at-risk variables. The same QC and accuracy checking procedures were 
implemented when data had to be restructured (e.g., one observation per cutpoint per patient 
or one observation per interval per patient) for the survival analyses. 
d. Primary data (clinical trial) 
For clinical and demographic data, the pharmaceutical sponsor used a Contract Research 
Organization (CRO) to conduct data quality checks and queries as follows: Data items from 
the data collection forms (case report forms, or CRFs) were entered into the study database 
(Clintrial version 3) at the CRO, using double data entry with verification upon second entry. 
Text items (e.g. typed comments) were entered once and checked manually against the CRFs. 
Subsequently, the information entered into the database was systematically checked by Data 
Management staff, using error messages printed from validation programs and database 
listings. Obvious data entry errors were corrected by CRO personnel. Other errors or 
omissions were entered on Data Query Forms, which were returned to the investigational site 
for resolution based on source documentation.  A copy of the signed Data Query Form was 
kept with the CRFs, and once the original was received at the CRO, the resolutions were 
entered into the database. QC audits of all key safety and efficacy data in the database were 
made when the last query from an individual patient was returned.
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V. RESULTS 
 
 
CHAPTER V 
 
RESULTS 
A. Manuscript 1: Pain Severity and Interference Hazards, with Exploration of BPI 
Cutpoints, Among Women with Metastatic Breast Cancer 
 
ABSTRACT 
Background. Knowledge about risk factors for cancer pain over the course of disease in 
specific tumor types is limited. This study assesses pain hazards over time among patients 
with metastatic breast cancer. We identify risk factors for worse pain outcomes over time and 
explore the effect of using different intensity cutpoints on the Brief Pain Inventory (BPI) 
severity and interference with daily living 0-10 subscales, as related to baseline clinical and 
demographic characteristics. 
Methods. We conducted proportional hazards analyses of existing data from a clinical 
trial that assessed patient outcomes observed at 11 visits over 51 weeks using the BPI to 
measure pain among 1124 patients with metastatic breast cancer. Univariate (per-cutpoint) 
and multivariate (cutpoints 3, 4, 5, 6, and 7) models were used to estimate hazards for time to 
reach each outcome on the BPI severity and interference scales. The sets of clinical and 
demographic baseline explanatory variables were then compared among the models.  
Results. In multivariate analyses of the severity scale, compared with Caucasian race, 
non-Caucasian race was associated with 2.29 times the hazard of reaching severity cutpoint 7 
versus 1.38 for cutpoint 3, all other covariates held constant. For the interference scale, 
compared with active baseline Eastern Cooperative Oncology Group (ECOG) status, 
restricted baseline ECOG status was associated with 2.97 times the hazard of reaching 
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interference cutpoint 7 versus 2.00 for cutpoint 3, all other covariates held constant. Other 
baseline factors associated with higher hazard of reaching higher scores on the severity scale 
were: restricted baseline ECOG performance status, previous skeletal related event (SRE), 
and not employed full-time (hazard ratios [HRs] = 1.70, 1.23, and 1.33, respectively). 
College education and age dichotomized at 57 years did not appear to have independent 
influence on the severity scale. Other predictive factors on the interference scale were: non-
Caucasian race, previous SRE, age ≤ 57 years, and not employed full-time (HRs = 1.40, 1.20, 
1.39 and 1.45, respectively). College education did not appear to affect pain on the 
interference scale. 
Conclusions. Our findings that non-Caucasian race, younger age, and restricted baseline 
performance status are important predictors of pain over time are consistent with previous 
cross-sectional risk factor studies and with clinical practice. ECOG performance status and 
race are of key prognostic importance. In confirming these characteristics as predictors of 
pain hazards over time in women with metastatic breast cancer, our findings inform 
individualized prognoses for pain outcomes according to baseline patient attributes. Early 
intervention and more aggressive pain management strategies can be tailored to these 
personalized prognoses over the course of treatment, to delay first occurrence of higher pain 
scores among those at greatest risk for severe pain and pain interference in daily activities. 
1. Introduction 
Epidemiologic inquiry into the course of cancer-related pain has potential to enhance 
understanding of pain risk factors, measurement and classifications of pain intensity, and 
means to improve pain management. Cancer pain prevalence estimates have varied widely, 
ranging from 14% to 100%. Chronic or recurrent pain affects about 30% of all patients with 
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cancer, and about 60 to 90% of patients with advanced cancer.1,2 There is a need to study 
patients’ experiences of pain over the course of disease using longitudinally-collected, tumor-
specific data, as well as to evaluate the effect of risk factors on pain over the course of cancer 
treatment. The Agency for Healthcare Research and Quality (AHRQ) evidence-based reports 
focusing on cancer pain published in 2001 and 2002 cite the need for more comprehensive 
description of the patient’s experience of pain over the course of treatment or continuum of 
care.  
The AHRQ synthesis of studies of influences on cancer pain suggest that age, gender, 
tumor type, genetics, psychosocial context, and cultural factors (e.g., societal norms) affect 
both the experience of pain, and analgesic efficacy. Specific studies of risk factors for pain 
have found that among patients with breast cancer, younger patients are at higher risk for 
post-treatment pain.3,4 Minority patients have been found consistently to be at greater risk of 
not only mortality from disease as compared with Caucasian patients,5,6 but also worse pain 
outcomes, and specifically undertreated cancer pain.7-10  A recent study of survival in the 
Carolina Breast Cancer Study found that African-American women were genetically at 
higher risk than Caucasian women for a faster-progressing form of breast cancer.5 This 
finding could mean greater potential for pain risks due to faster disease progression among 
African-American women with breast cancer. Studies (in addition to the evidence-based 
reviews discussed) have cited the need for future study to identify specific risk factors and 
further investigate those factors identified to date.11,12  
Pain outcomes research and clinical practice often depend on classifying pain into 
severity categories according to cutpoints on a 0-10 numeric rating scale.13,14  Cutpoints are 
used to drive treatment decisions, develop practice guidelines, and determine effectiveness of 
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interventions. The World Health Organization (WHO) pain ladder is a treatment guideline 
that involves the tiered categorization of pain as mild, moderate, or severe; such tiered 
categorizations rely on specific numeric cutpoints on numeric pain rating scales as guides to 
clinicians to help distinguish levels of pain intensity on the scale.13 Where the cutoff point is 
set for severe pain also informs descriptive epidemiology, including etiological reports on 
longitudinal cancer pain, as well as prevalence estimates at a given time point. In 1991, 
Serlin and colleagues report a study in metastatic cancer patients, using analysis of variance 
methods to anchor the BPI severity scale using the BPI interference scale. They found 
optimal cutpoints that formed 3 distinct levels of pain severity on 0-10 numeric rating scale 
(NRS): 1-4: mild, 5-6: moderate, 7-10: severe,15 and discuss a non-linear relationship 
between the BPI severity and interference scales. Paul and colleagues14 also derived 
cutpoints using other patient-reported outcomes measures to anchor the BPI severity scale. 
Instead of the 7 cutpoint to designate severe pain, they found that the 7 cutpoint signified 
moderate pain, and the 8 cutpoint designated severe pain.14 To date, all efforts to categorize 
pain intensity categories have compared cutpoints with each other and with external anchors 
or measures indicative of disease states.13-16  In order to optimize the use of pain scales in 
research and practice, further investigation is needed to compare and categorize BPI 
cutpoints.  
This study assesses pain hazards over time among women with metastatic breast cancer, 
identifying sets of clinical and demographic explanatory variables predictive of greater 
hazards for pain intensity over 51 weeks. We compare these sets of predictors in univariate 
and multivariate models using different intensity cutpoints 3 through 7 on the BPI severity 
and interference 0-10 subscales. In addition, we compare all models to explore the 
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relationship between the pain severity and interference BPI subscales. Our goal was to 
provide information to inform clinical practice, especially with regards to how the BPI is 
used to assess, categorize, and treat severe pain in metastatic breast cancer. 
2. Methods 
For the entire sample of women with metastatic breast cancer, we conducted Cox 
proportional hazards analyses for reaching different thresholds of pain on the BPI severity 
and interference scales over time, comparing which sets of clinical and demographic baseline 
predictors affect time to first reaching different thresholds of pain as defined by cutpoints on 
the 0 – 10 severity and interference scales. Reaching the intensity cutpoints of 3, 4, 5, 6, and 
7 or above on each scale were the outcomes of interest in predictive modeling to analyze 
each cutpoint separately, then all cutpoints together, exploring interactions between 
covariates and cutpoints. We chose this range of cutpoints since the values of 0, 1, 2, as well 
as 8, 9, and 10 on the 0-10 scales are consistently indicative of only the best or worst 
outcomes; the values of 3-7 on the BPI scales warrant closer attention in analyses, as this 
range of values is used to establish categories of pain such as mild, moderate, or severe. The 
results of the clinical trial treatment comparisons are reported elsewhere;17 comparisons 
between the treatment arms were not a part of the present study. 
a. Patients and procedures 
This study was a secondary analysis of existing data from a clinical trial (Novartis 
protocol 4244603010). Informed consent was obtained from each patient in the original trial, 
and the multicenter trial was carried out under approval from each institution’s ethical review 
board, in accordance with applicable laws in each country and the Declaration of Helsinki. 
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The present study was conducted under approval from the University of North Carolina at 
Chapel Hill Institutional Review Board.  
The original clinical trial assessed patient outcomes over 51 weeks using the BPI18 to 
measure pain among 1124 patients with metastatic breast cancer. Saad et al.19 provide a full 
report of the primary analyses of the double-blind, multicenter clinical trial, the purpose of 
which was to compare two bisphosphonate drugs, intravenous zoledronic acid [4 or 8 mg] 
versus intravenous pamidronate disodium [90 mg], as an adjunct to standard therapies, in the 
treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions. 
No placebo arm was used. The original intent-to-treat study population consisted of men and 
women with stage III multiple myeloma (n = 510) or stage IV breast cancer with at least 1 
lytic or mixed bone metastasis (n = 1130). For the purpose of the present analysis, we 
excluded 6 men, limiting the sample to women with breast cancer (n = 1124). The trial was 
conducted at 207 centers in the following countries (grouping identified in parentheses): 
Canada and the United States (North America); Argentina, Brazil, Chile, Peru, and Uruguay 
(South America); Austria, Belgium, the Czech Republic, France, Germany, Ireland, Italy, the 
Netherlands, Poland, Spain, Sweden, Switzerland, and the United Kingdom (Europe); and 
Australia, Israel, New Zealand, and South Africa (other). The first patient was recruited on 
October 16, 1998, and the last assessment was completed on the last patient on January 12, 
2001. 
b. Assessment of outcomes: pain severity and interference 
Patients completed the Brief Pain Inventory questionnaire at baseline, months 1 and 2, 
and every other month thereafter up to Week 51. The BPI was administered in person prior to 
the patient being interviewed by the physician or receiving study medication. The BPI 
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measure consists of several parts, but this study used only the pain severity and interference 
items. Severity is measured as: average pain, pain right now, worst pain, and least pain, all 
four of which are answered on a 0-10 scale, with 0 = “no pain” and 10 = “worst pain 
imaginable”. The severity composite score was calculated as the arithmetic mean of the 4 
severity items when none of the 4 were missing. The BPI includes a 7-item pain Interference 
scale, which consists of the same 0-10 response scale to the question: “describe how, during 
the last 7 days, pain has interfered with your: 1) general activity, 2) mood, 3) walking ability, 
4) normal work (includes both work outside the home and housework), 5) relations with 
other people, 6) sleep, and 7) enjoyment of life. The arithmetic mean of the 7 interference 
items was used to measure pain interference. This mean was calculated only when at least 4 
of the 7 individual items were not missing at a given assessment. 
In general, numeric rating scales (NRS) for pain severity such as the BPI have been 
demonstrated to be valid and sensitive to change.20 According to the American Pain Society 
Clinical Practice Guideline for the Management of Cancer Pain in Adults and Children,21 
NRS measures are among the most common, valid, and reliable measures used to assess 
cancer pain severity, and are preferred by patients over visual analogue scale (VAS) 
measures. The BPI has been administered and assessed for validity in several languages 
including Spanish, French, Japanese, Chinese, Italian, Hindi, German, Greek, and 
Vietnamese.22-28  
c. Assessment of predictors: clinical and demographic covariates 
In addition to the pain assessments, subjects were asked to provide demographic, clinical, 
and other outcomes information through interviews, written questionnaires, physical 
examinations, and completion of the clinical case report form and other original clinical trial 
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source documents in accordance with the study protocol. For our analyses, we grouped all the 
patients together, comparing how pain hazards differed in relation to baseline clinical and 
demographic characteristics. These characteristics include performance status (measured by 
Eastern Cooperative Oncology Group [ECOG] performance status [1 = active (ECOG status 
of 0 or 1), 0 = restricted (ECOG status of 2 or more)]), age, education (1 = college degree, 0 
= no college degree), employment status (1 = full-time, 0 = other), geographic region (North 
America, South America, Europe, or Other, all defined in the previous section), 
antineoplastic therapy on study entry (chemotherapy plus hormonal therapy vs. hormonal 
therapy only), previous skeletal-related event, or SRE (0 = no, 1 = yes), and time from 
documented initial bone metastasis to randomization. SRE refers to a set of complications 
defined in the trial as experiencing one or more of the following: pathologic fractures, spinal 
cord compression with vertebral compression fracture, the need for surgery to treat or prevent 
pathologic fractures or spinal cord compression, or the need for radiation to bone.29 
d. Statistical analysis 
We conducted the analyses using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA) 
and SAS-callable SUDAAN Release 9.0 (Research Triangle Institute, Research Triangle 
Park, NC, USA). Analyses were conducted on the intent-to-treat sample, which included all 
female breast cancer patients who had participated in the trial.  
We examined descriptive data on demographic characteristics and clinical variables at the 
time of study enrollment. We assessed the extent of missing data for the pain outcome 
variables at each study visit at every relevant study visit. Some patients were missing pain 
outcome data at every visit. The present analyses excluded these patients (n = 73 completely 
missing for severity, leaving an analysis sample of n = 1051 for the severity scale, and n = 77 
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completely missing for interference, leaving an analysis sample of n = 1047 for the 
interference scale). We used Cox proportional hazards models to assess the relationship of 
baseline predictors with time to reach pain cutpoints 3, 4, 5, 6, or 7 on the 0-10 severity and 
interference scales. We examined these cutpoints separately in the univariate analyses, and 
simultaneously in the multivariate analyses.  
Time-to-event was calculated as the number of days from trial enrollment until the 
patient reported reaching a given severity cutpoint (3, 4, 5, 6, or 7) on the BPI. For each 
cutpoint, those who never reached that cutpoint as of trial completion (51 weeks, or 357 days, 
post-randomization) or dropped out of the study were classified as censored. For censored 
patients, the event indicator variable was set to 0, and time at risk was the time from their 
enrollment date to trial completion or dropout.  
We used visual examination of Kaplan-Meier (KM) curves along with the log-rank test 
statistic to assess the candidacy of each covariate for stepwise univariate modeling. 
Covariates for which the KM curves did not cross and the log-rank test was significant at a 
criterion of α = 0.05 were considered best candidates as potential explanatory variables for 
inclusion in the Cox proportional hazards models. Continuous covariates were dichotomized 
at the mean if normally distributed, or at the median if non-normally distributed, for the 
purposes of the KM curve analysis and to be used as dichotomous predictors. Age was 
distributed normally, and dichotomized for the multivariate analyses at its mean of 57.9 (SD 
±12.7). The lower age category was 24-57, resulting in age categories of 24-57 and 58-95 
years. Days from bone metastasis to randomization was non-normally distributed, and 
dichotomized at its median of 104 days (interquartile range = 36 to 475 days).  
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Time-to-event model building techniques were conducted with the goal of creating 
parsimonious predictive models to determine the covariate-adjusted hazards of reaching each 
cutpoint over time. These techniques relied on the stepwise procedure with model entry 
specified at 0.25, and staying criteria specified at 0.15. The univariate Cox proportional 
hazards models are expressed as follows:   
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To analyze the time until first reaching each cutpoint explored (3, 4, 5, 6, and 7 on the 0-
10 scale) simultaneously with the same explanatory covariates, we fit multivariate Cox 
proportional hazards models using PROC SURVIVAL in SUDAAN, which implements a 
Taylor series variance estimation to account for within-subjects correlation between multiple 
possible outcomes. The explanatory variables used as baseline predictors were ECOG 
performance status, age, race, college education, full-time employment, and previous skeletal 
related event. We chose this set of explanatory variables for the multivariate model because 
these factors had emerged as most consistently influential across the univariate analyses. In 
the multivariate model, each patient had several potential outcomes: time to first reaching the 
score of each cutpoint (3, 4, 5, 6, and 7) or higher on the 0-10 scales. To model these 
outcomes simultaneously, we fit the Cox proportional hazard model with p covariates as 
follows:  
1
0( ) ( )
p
j jk jk
k
X
jh t h t e
α β
=
+∑= where j = 3, 4, 5, 6 or 7 for the different pain 
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score cutpoints. This equation applies to any patient i. We assume proportional hazards 
across different outcomes reflected by a constant jα . jkβ can be the same for different 
outcomes. We used only the baseline assessment of all the clinical and demographic 
covariates described. Therefore, each covariate was considered time-independent in the 
models.  
These data presented an opportunity to explore the relationship between the BPI intensity 
composite score and the BPI interference composite score. Both scales are rated numerically 
on a 0-10 scale, with 10 indicating greatest severity or interference. To explore the 
relationship of these two subscales, we explored the similarities and differences in how sets 
of explanatory covariates affected pain severity versus interference outcomes, using the same 
analyses described above to estimate hazards for pain on each of the two scales. 
e. Sensitivity analyses 
Censoring deaths versus assigning worst pain score 
An overarching issue that affected all the survival analyses was that in the analyses, death 
may be dealt with either by: 1) censoring, or 2) treating death as an event of the worst 
possible outcome (severe pain).30 We conducted a sensitivity analysis to address this issue. 
For those individuals who died, instead of censoring their observation, we assigned time to 
reach severity of 7 or higher at the time of death as if death were comparable to a BPI score 
of 10, and the time of death was the last time for pain assessment. The dropout date was 
effectively either the last day of enrollment in the trial, or the last day the BPI was 
administered, whichever was the later of the two. We compared the model results using this 
technique with those results from conventional censoring.  
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Missing data methods  
The continuous time assumption for survival analysis required assumptions about 
handling the event indicator and time at risk variables, when pain data were partially missing. 
In these cases, we implemented the following coding for event indicator and time-to-event 
variables: if the patient had some BPI data but never reached the outcome, then the 
dichotomous event indicator variable was set equal to 0. The observation was censored, and 
total time at risk was set equal to either the total number of days the patient was in the study 
(Assumption A), or to the number of days from trial enrollment to the date of the preceding 
non-missing BPI measurement (Assumption B).  We conducted a sensitivity analysis to 
compare results under Assumption A versus Assumption B.  
Another missing data handling technique used was to code the full-time employment and 
college education variables (each of these variables had about 16% missing data at baseline) 
as three-level categorical variables, with the categories as “yes”, “no”, or “missing”, with 
“yes” as the referent so that the effect of lower educational attainment or no employment 
could be assessed. This technique prevents these individuals from being dropped from the 
models. 
3. Results 
We assessed the risk of pain severity and interference outcomes among 1,124 women 
with metastatic breast cancer, whose baseline characteristics are presented in Table 1. The 
two variables for which more than 1% of patients had missing observations at baseline were 
education and employment status, which were each missing for approximately 16% of the 
sample. Only 14% of patients reported being employed full-time at the time of trial 
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enrollment. This is likely due to the fact that all patients in the trial had metastatic disease at 
enrollment.  
Of the 438 patients (39% of the original 1124 enrolled) who did not complete visit 19, 
132 patients (30%) discontinued the study due to adverse events. Twenty-six percent (n = 
113) died. For the entire trial population, approximately 52% of adverse events experienced 
were bone pain, making it the most frequent type of adverse event. Implications of this fact 
with regards to the proportional hazards assumption are addressed in the sensitivity analysis. 
Table 2 shows the study population remaining at each scheduled BPI assessment (visits 2, 3, 
4, 6, 8, 10, 12, 14, 16, 18, and 19) and the proportion of participants completing the BPI 
severity and interference assessments. Of those women enrolled in the trial at any given visit, 
the proportion who had completed BPI assessments was consistently no less than 82%. Data 
were excluded for visits at which the BPI was not scheduled. Patients were excluded from the 
analyses if they had BPI scores missing at all assessments (73 patients were excluded from 
the original 1,124 due to missing severity data, and 77 were excluded due to missing 
interference data). Of the 438 patients (39% of the original 1124 enrolled) who did not 
complete visit 19, 132 patients (30%) discontinued the study due to adverse events, and 113 
patients (26%) discontinued due to death. Additional details regarding patient disposition for 
the overall clinical trial are reported by Rosen et al.17  
Figure 1 shows the Kaplan-Meier curves for time to first reach BPI severity cutpoints 3, 
4, 5, 6, and 7. These curves are based on all subjects with at least one BPI severity score (n = 
1051). The time until first reaching a given pain score increases as the pain score outcome 
increases; thus, over the observation period patients overall were more likely to reach a score 
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of 3 or above than to reach a score of 4 or above, and successively higher pain scores were 
less likely.  
Results of the univariate (per-cutpoint) Cox proportional hazards analyses, shown in 
Tables 3 and 4, corroborated assessments of the KM curves and log-rank tests in identifying 
restricted ECOG performance status and non-Caucasian race as most consistently predictive 
of worse pain outcomes across cutpoints for both severity and interference outcomes. 
Previous SRE was a predictor in each univariate model by cutpoint, except for 7 on the 
severity scale, and for all cutpoints except for 6 on the interference scale. Continuous age in 
decades was a predictor for only the 7 cutpoint on the severity scale, but was a predictor for 
all cutpoints on the interference scale. College education was a predictor only for the 6 
cutpoint on the severity scale. The number of days from bone metastasis to randomization 
(categorical coding, dichotomous at median = 104 days) was not found to be predictive in 
any univariate model, nor were geographic region or chemotherapy adjunct to hormonal 
therapy at baseline. ECOG performance status, experience of a previous SRE, race, age 
dichotomous at the mean of 57, education, and employment were included as predictors in 
the multivariate (all-cutpoint) proportional hazards models for pain severity and interference. 
Employment status was not found to be predictive in any univariate model, but was retained 
for the multivariate model because the log-rank test statistics were statistically significant at 
α = 0.05 for all cutpoints. As a demographic characteristic, employment status also has a 
priori value as a potential predictor in the multivariate models because employment at 
baseline signifies better health. 
For the multivariate model of pain severity outcomes, a proportional hazards model was 
fit to assess hazards simultaneously for time to first occurrence of a 3, 4, 5, 6, or 7 on each of 
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the 0-10 severity and interference scales, with employment status and college education as 3-
level categorical variables, and age dichotomous at 57 years or less versus > 57. Table 5 
displays the model parameters for the multivariate model for all cutpoints. Factors that were 
associated with higher hazard of reaching any of the 3-7 cutpoints on the severity scale were: 
restricted baseline ECOG status (HR = 1.70, 95% confidence interval [CI] =1.41 - 2.06), 
previous skeletal related event (SRE) (HR = 1.23, 95% CI =1.06 – 1.44), and not employed 
full-time (HR = 1.33, 95% CI =1.06 – 1.67). Age and college education did not appear to 
have a significant association with pain severity (HR = 1.12, 95% CI =0.97 – 1.31, and HR = 
1.18, 95% CI =0.99 – 1.41, respectively). Race was found to modify the effect of reaching 
any cutpoint 3-7; a race by cutpoint interaction term was found statistically significant (Wald 
F test p-value = 0.033) and included in the multivariate model. Hazard ratios comparing 
Caucasian race with non-Caucasian race for first occurrence of pain severity differed 
according to cutpoint. For example, compared with Caucasian race, non-Caucasian race was 
associated with 2.29 times the hazard of reaching severity cutpoint 7 versus 1.38 for cutpoint 
3, all other covariates held constant. This contrast may be calculated either using the HRs as 
follows: HRnon-Caucasian * HRCutpoint 7  = 1.38 * 1.66, or using the ß coefficients (not shown in 
tables) estimated from the model as follows: 
 
Non-caucasian Cutpoint 7 Non-caucasian * cutpoint 7 [ (1-0) + (1-1) + (1-0)]e β β β = [0.32 + 0.51]e = 2.29 
Other contrasts can be computed similarly. 
Table 6 displays the model parameters for the multivariate Cox proportional hazards 
model with time to first pain interference cutpoints as the correlated outcomes. Factors that 
were associated with higher hazard of reaching any cutpoint on the interference scale were: 
non-Caucasian race (HR = 1.40, 95% CI =1.13 – 1.74), previous SRE (HR = 1.20, 95% CI 
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=1.03 – 1.40), younger age (57 years or less) (HR = 1.39, 95% CI =1.19 – 1.62), and not 
employed full-time (HR = 1.45, 95% CI =1.15 – 1.83). The 95% CI for college education did 
not exclude the null value (HR = 1.08, 95% CI =0.91 – 1.28). For the interference outcome, 
baseline ECOG performance status was found to modify the effect of reaching any cutpoint 
3-7; the ECOG performance status by cutpoint interaction term was found statistically 
significant (Wald F test p-value =  0.004) and included in the multivariate model. For the 
interference scale, hazard ratios comparing restricted versus active Eastern Cooperative 
Oncology Group (ECOG) performance status for first occurrence of pain interference 
differed according to cutpoint. For example, compared with active baseline ECOG status, 
restricted baseline ECOG status was associated with 2.97 times the hazard of reaching 
interference cutpoint 7 versus 2.00 for cutpoint 3, all other covariates held constant (this and 
other contrasts in the presence of the interaction term may be calculated as described above 
for the severity outcome). 
The factors found to be predictive of greater hazards for both the severity and 
interference outcomes were non-Caucasian race, restricted baseline ECOG status, previous 
SRE, and not being employed full time. Younger age was predictive of higher hazards only 
in the interference scale. Hazards of reaching higher pain cutpoints differed by race on the 
severity scale, and by ECOG status on the interference scale. All of the findings were found 
to be robust in direction, magnitude, and statistical significance under sensitivity analyses 
varying handling of deaths and missing data. 
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Table 6. (MS1: Table 1). Baseline patient characteristics and missing data (N = 1124). 
 
Characteristic ValuesA
Number of patients 
with values missing at 
baseline (%)
Age in years, mean ± SD 57.5 ± 12.6 0 (0)
Female 1124 (100) 0 (0)
RaceB 0 (0)
Caucasian 991 (88)
Black 64 (6)
Oriental 17 (2)
Other 52 (5)
College education 281 (25) 186 (17)
Employed full-time 157 (14) 182 (16)
Geographic regionC 0 (0)
North America  773 (69)
Europe  217 (19)
South America  39 (3)
Other 95 (8)
Baseline ECOG performance status 4 (0.4)
Active (0 or 1), recoded as 1 952 (85)
Restricted (≥2), recoded as 0 168 (15)
Antineoplastic therapy (trial 
stratification variable) 
0 (0)
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Characteristic ValuesA
Number of patients 
with values missing at 
baseline (%)
Chemotherapy 525 (47)
Hormonal therapy 599 (53)
Experienced previous skeletal related 
event 
677 (60) 3 (0.3)
Time from first bone metastasis to 
randomization, days 
157 (14) 3 (0.3)
Mean ± SD 406 ± 744
Median 108  
AValues are expressed as number (percentage) unless otherwise indicated. 
BRace categories are reported as they were asked in the clinical trial case report form. 
Race variable was recoded to Caucasian/non-Caucasian for the present analyses. 
CVariable was recoded to North America/Other for present analyses. 
Some totals do not add up to 100% due to rounding. 
SD = Standard deviation 
ECOG = Eastern Cooperative Oncology Group 
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Table 7. (MS1: Table 2). Study population and Brief Pain Inventory (BPI) completion 
at each scheduled assessment 
 
 
 Completeness of BPI Composite Scores 
 
Visit 
 
Severity Score 
 
Interference Score 
 
Study Population A 
n (% of pts. 
in trial at visit i) B
(% of 
starting N)
n (% of pts. 
in trial at visit i) B
(% of 
starting N)
Visit 2 1124 (100) 1024 (91) (91) 1029 (92) (92)
Visit 3 1117 (99) 975 (87) (87) 972 (87) (86)
Visit 4 1073 (95) 950 (89) (85) 953 (89) (85)
Visit 6 1019 (91) 898 (88) (80) 906 (89) (81)
Visit 8 942 (84) 806 (86) (72) 807 (86) (72)
Visit 10 896 (80) 794 (89) (71) 798 (89) (71)
Visit 12 812 (72) 675 (83) (60) 675 (83) (60)
Visit 14 784 (70) 673 (86) (60) 681 (87) (61)
Visit 16 706 (63) 598 (85) (53) 599 (85) (53)
Visit 18 672 (60) 551 (82) (49) 549 (82) (49)
Visit 19 686 (61) 584 (85) (52) 583 (85) (52)
AIndicates the number (percent) of patients remaining in the study at each scheduled BPI 
assessment visit.  
BIndicates number of patients at each BPI assessment for whom BPI Composite Scores 
could be calculated. 
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Table 8. (MS1: Table 3). Hazard ratios for pain severity: per-cutpoint univariate Cox 
proportional hazards models, continuous time assumption.  
 
 
Model: 
Severity 
Cutpoint Parameter Estimate SE 
HR 
( keβ )
95% CI  
for HR 
Resid. χ2 test 
statistic (df), 
p-value 
Active baseline ECOG -0.39 0.10 0.68 0.56 - 0.82 
Previous SRE 0.15 0.07 1.16 1.01 - 1.35 3 
Caucasian race -0.26 0.11 0.77 0.63 - 0.95 
0.92 (6), 
0.988 
Active baseline ECOG -0.53 0.10 0.59 0.48 - 0.72 
Previous SRE 0.16 0.08 1.18 1.00 - 1.39 4 
Caucasian race -0.34 0.11 0.72 0.57 - 0.90 
1.18 (6), 
0.978 
Active baseline ECOG -0.50 0.12 0.60 0.48 - 0.77 
Previous SRE 0.20 0.10 1.22 1.01 - 1.48 5 
Caucasian race -0.52 0.13 0.59 0.46 - 0.76 
2.58 (6), 
0.860 
Active baseline ECOG -0.46 0.15 0.63 0.47 - 0.85 
College educationA 0.003 0.002 1.003 0.999 - 1.006 
Previous SRE 0.39 0.13 1.48 1.15 - 1.89 
6 
Caucasian race -0.68 0.15 0.50 0.38 - 0.68 
0.97 (5), 
0.965 
Active baseline ECOG -0.62 0.19 0.54 0.37 - 0.78 
Caucasian race -0.86 0.19 0.42 0.29 - 0.62 7 
Age in decades 0.11 0.06 1.12 0.99 - 1.26 
3.73 (6), 
0.713 
Note: ECOG = Eastern Cooperative Oncology Group performance status. SRE = 
Skeletal related event.  
AValues for this line are reported to three decimal places to avoid rounding to 0.00. 
 106 
Table 9. (MS1: Table 4). Hazard ratios for pain interference: per-cutpoint univariate 
Cox proportional hazards models, continuous time assumption) 
 
 
Model: 
Interference 
Cutpoint Parameter Estimate SE 
HR
( keβ )
95% CI  
for HR 
Resid χ2 test 
statistic (df), 
p-value 
Active baseline ECOG -0.47 0.10 0.62 0.51 - 0.76 
Caucasian race -0.20 0.11 0.82 0.66 - 1.02 
Previous SRE 0.16 0.08 1.18 1.01 - 1.37 
3 
Age in decades -0.05 0.03 0.95 0.90 - 1.01 
1.04 (5), 
0.959 
Active baseline ECOG -0.61 0.10 0.54 0.44 - 0.66 
Caucasian race -0.19 0.12 0.83 0.66 - 1.04 
Previous SRE 0.15 0.08 1.17 0.99 - 1.37 
4 
Age in decades -0.07 0.03 0.93 0.87 – 0.99 
1.76 (5), 
0.881 
Active baseline ECOG -0.76 0.11 0.47 0.38 - 0.58 
Caucasian race -0.25 0.13 0.78 0.61 - 1.00 
Previous SRE 0.14 0.09 1.15 0.96 - 1.37 
5 
Age in decades -0.08 0.03 0.92 0.86 - 0.98 
2.55 (5), 
0.769 
Active baseline ECOG -0.90 0.12 0.41 0.32 - 0.51 
Caucasian race -0.42 0.14 0.66 0.51 - 0.86 6 
Age in decades -0.10 0.04 0.90 0.84 - 0.97 
1.88 (6), 
0.931 
Active baseline ECOG -1.06 0.14 0.35 0.27 - 0.45 
Caucasian race -0.50 0.16 0.61 0.44 - 0.83 
Previous SRE 0.23 0.13 1.25 0.98 - 1.61 
7 
Age in decades -0.13 0.05 0.88 0.80 – 0.96 
1.73 (5), 
0.885 
Note: ECOG = Eastern Cooperative Oncology Group performance status. SRE = 
Skeletal related event.  
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Table 10  (MS1: Table 5). Multivariate model: effect of explanatory variables on 
hazards for reaching pain outcomes (BPI severity scale cutpoints 3, 4, 5, 6, or 7). 
 
 
Independent Variables 
and Effects 
Hazards Ratio Lower 95% Limit Upper 95% Limit 
Cutpoint    
7 0.10 0.09 0.12 
6 0.21 0.18 0.23 
5 0.38 0.35 0.41 
4 0.64 0.60 0.67 
3 1.00 - - 
Restricted ECOG 
performance status 
        1.70 1.41 2.06 
Previous skeletal 
related event 
        1.23 1.06 1.44 
Age 57 years or less         1.12 0.97 1.31 
    
Less than College education     1.18   0.99  1.41 
Education missing 1.05 0.55 1.97 
College education 1.00 - - 
Not Employed full-time 1.33 1.06 1.67 
Employment missing 1.43 0.72 2.86 
Employed full-time 1.00 - - 
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Independent Variables 
and Effects 
Hazards Ratio Lower 95% Limit Upper 95% Limit 
Cutpoint * Race interaction term   
7 * non-Caucasian 2.29 1.58 3.33 
6 * non-Caucasian 1.99 1.48 2.66 
5 * non-Caucasian 1.76 1.37 2.26 
4 * non-Caucasian 1.46 1.16 1.84 
3 * non-Caucasian 1.38 1.12 1.70 
ReferentA 1.00 - - 
Note: ECOG = Eastern Cooperative Oncology Group performance status. Referent 
categories are displayed only for variables with more than two levels.  
AThe referent categories for the interaction term were {3, 4, 5, 6, or 7} or Caucasian.
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Table 11 (MS1: Table 6). Multivariate model: effect of explanatory variables on 
hazards for reaching pain outcomes (BPI interference scale cutpoints 3, 4, 5, 6, or 7). 
 
Independent Variables and 
Effects 
Hazards Ratio Lower 95% Limit Upper 95% Limit 
Cutpoint    
7 0.22 0.19 0.25 
6 0.37 0.33 0.40 
5 0.54 0.51 0.58 
4 0.75 0.71 0.78 
3 1.00 - - 
Previous skeletal 
related event 
1.20               1.03     1.40 
Non-Caucasian race 1.40               1.13     1.74 
  
Age 57 years or less 1.39               1.19     1.62 
    
Less than College education 1.08  0.91  1.28 
Education missing 0.76     0.35 1.65 
College education 1.00 - - 
Not Employed full-time 1.45  1.15 1.83 
Employment missing 1.78  0.78 4.06 
Employed full-time 1.00     - - 
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Independent Variables and 
Effects 
Hazards Ratio Lower 95% Limit Upper 95% Limit 
Cutpoint * Restricted ECOG performance status interaction term  
7 * Restricted ECOG 2.96 2.28 3.85 
6 * Restricted ECOG 2.52 1.98 3.20 
5 * Restricted ECOG 2.51 2.01 3.13 
4 * Restricted ECOG 2.16 1.77 2.65 
3 * Restricted ECOG          2.00 1.66 2.42 
ReferentA          1.00 - - 
Note: ECOG = Eastern Cooperative Oncology Group performance status. Referent 
categories are displayed only for variables with more than two levels.  
AThe referent categories for the interaction term were {3, 4, 5, 6, or 7} or Unrestricted 
ECOG status. 
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Figure 20. (MS1: Figure 1). Time to first reach BPI severity cutpoints 3, 4, 5, 6, and 7, 
unstratified results for entire sample. 
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4. Discussion 
The present study set out to assess risks of reaching different pain severity and 
interference thresholds over 51 weeks among a sample of women with metastatic breast 
cancer, to investigate a set of baseline clinical and demographic factors as risk factors for 
first occurrence of reaching cutpoints 3, 4, 5, 6, and 7 on 0-10 numeric rating scales of the 
BPI, and to help understand the value of various cutpoints for categorization of pain severity. 
Our analyses identified the following baseline clinical and demographic factors to be 
associated with greater hazards of experiencing both pain severity and interference over the 
course of the observation period: non-Caucasian race, restricted/inactive baseline ECOG 
performance status, age 57 years or less, not employed full-time, and having experienced a 
previous skeletal related event (defined as any of the following events: pathologic fractures, 
spinal cord compression with vertebral compression fracture, the need for surgery to treat or 
prevent pathologic fractures or spinal cord compression, or the need for radiation to bone).  
Our findings that age and race were important predictors of pain severity and interference 
with daily living over time are consistent with other risk-factor studies and clinical practice 
guidelines,31 including reports that among patients with breast cancer, younger patients are at 
higher risk for post-treatment pain,3,4 and that minority patients have been found consistently 
to be at greater risk of worse pain outcomes and of undertreated cancer pain specifically.7-10 
Similarly, the ECOG performance status and employment variables represent levels of 
activity versus restriction/impairment at baseline, an important construct that has emerged in 
past research as a predictor for pain and other health-related quality of life outcomes.32,33 
Oncologist-assessed ECOG performance status has been shown to have important prognostic 
value in predicting, with distinct discrimination at each level of the ECOG scale, survival 
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outcomes among patients with non-small cell lung cancer.34 In confirming these 
characteristics as risk factors over time among patients with metastatic breast cancer, our 
findings inform individualized prognoses for pain outcomes according to baseline patient 
attributes. Using this information, earlier intervention and more aggressive pain management 
strategies can be tailored to these personalized prognoses with the goal of delaying the first 
occurrence of higher pain scores among those at greater risk for severe pain and pain 
interference in daily activities. 
On the severity scale, race affected time to occurrence of reaching each cutpoint such that 
non-Caucasians were found to have greater hazards than Caucasians for experiencing pain 
scores of 5, 6, or 7. Paul and colleagues stated that they could not determine in an all-
Caucasian sample whether cutpoints vary based on cultural or ethnic differences in how 
individuals interpret pain severity ratings.14 The findings of the present study do provide 
evidence that cutpoints vary according to racial/ethnic categories, but do not address 
specifically the question of whether ethnic differences affect interpretation of pain severity 
ratings. Potential differences in clinical reporting and treatment of pain affect pain outcomes 
over the course of cancer. If there are significant differences by race in pain outcomes as 
reported by the patients, these differences may be due to either inaccurate patient reporting, 
or differences in actual true levels of pain. Without clear evidence of the former, it seems 
more conservative to assume that these differences reflect actual disparities in patients’ 
experiences of pain, originating from sources external to the patient.  
Our exploration of the relationship between the severity and interference subscales of the 
BPI showed that baseline clinical and demographic risk factors were largely similar between 
the two scales in their associations with pain hazards over time. However, while race appears 
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to influence time to first event of reaching different severity cutpoints, baseline ECOG 
performance status influenced time to first occurrence of reaching different cutpoints on the 
interference scale. The two scales measure distinct underlying constructs; interpretations of 
results obtained with these BPI subscales should take into account two baseline traits as 
modifiers of the effects measured by these subscales of the BPI: race for the severity 
subscale, and performance status for the interference subscale. 
In the univariate analyses, the constellation of risk factors was relatively consistent over 
the range of cutpoints from 3 to 7 for both the severity and interference scales, with race a 
significant predictor in all individual cutpoint (univariate) models. The findings from the 
multivariate pain severity analysis indicate that non-Caucasian women were at greater hazard 
of reaching higher pain severity scores earlier than their Caucasian counterparts. The 
interaction term for this hazard was significant at values of 5 and higher on the BPI. Given 
the potential risks of undertreated pain, these findings should aid in future research to 
evaluate the role of cutpoints in making pain treatment decisions, aimed to delay or prevent 
worse outcomes among those patients at greatest risk over time.  
The large trial population of 1,124 patients may be considered a strength of the present 
study, assuming minimal impact of potential bias related to the trial sampling methods on 
this sample’s representativeness of women with metastatic breast cancer. Early research on 
how clinical trial participants differ from non-participants suggests that trial participants have 
less mortality than non-participants.35 In their 2004 study of cancer clinical trial participation, 
Murthy and colleagues found that younger and minority patients were less likely than their 
counterparts to participate in cancer clinical trials.36 However, the distribution of race in this 
study (recorded as “Black” for 5.7% of the sample) appears close to the distribution of race 
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among prevalent first malignant breast cancer cases in 2002 in the U.S. (Black = 7.4% of 
total cases) estimated by Surveillance, Epidemiology and End Results (SEER).37 With 
regards to age, women aged 57 years or less composed approximately half the trial 
population, while 20% of prevalent breast cancer cases were aged 54 or lower in 2002 U.S. 
estimates (27-year limited-duration prevalence, first malignant cancer only).37 Thus, both the 
age and race distributions in the present study seem to represent the populations to which we 
would generalize the findings, although the influence of potential bias with regard to traits 
affecting pain outcomes cannot be ruled out entirely.  
A strength of the clinical trial design was that pain was measured at multiple time points. 
Because bone pain was the most frequent type of adverse event experienced by patients in 
this trial, it is realistic to assume that pain would be related to early termination through 
dropout or death. If this were the case, the censoring distribution would not be independent 
of the outcome, and the proportional hazards assumption would not be met. However, when 
we conducted sensitivity analyses varying handling of deaths and missing data, our findings 
did not change markedly in direction, magnitude, or statistical significance.  
A limitation of this study is that although the dataset used contains pain information at 
multiple assessment times per patient, the pain severity questions were asked over the 
timeframe of the past seven days (with the exception of “describe your pain right now”) and 
the pain interference questions were asked over the timeframe of the past 24 hours. This 
means that gaps in information as long as 5 weeks exist in the severity data, and even longer 
gaps exist in the interference data. The impact of this limitation on the present study is that 
although we are able to assess pain hazards over time based on the information available, 
pain severity and/or interference may have increased or decreased during the gaps between 
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assessments, but these changes not captured. This analysis was also limited by the 
characteristics of the clinical trial, which was designed to answer research questions about 
the relative efficacy of two bisphosphonates. The clinical trial itself dictated specific 
inclusion/exclusion criteria, and which covariates were collected in this sample. Although all 
patients were given at least standard treatment, the present study lacks more detailed 
information on analgesic treatments as they varied with time. Such information is useful in 
understanding fluctuations and changes in pain severity and interference over time. 
Future research should collect and model the effects of risk factors upon longitudinal pain 
outcomes, aided by prospective design to incorporate constellations of clinical and non-
clinical factors known to affect pain. In addition to clinical information such as analgesic 
treatment and guideline adherence, non-clinical factors should be included as well, such as 
patient medication adherence, patient and physician barriers to effective analgesic treatment 
(the patient portion of which can be measured through the Patient Barriers Survey38), patient-
physician communication, psychological, and cultural factors.  
Our findings emphasize the need for early intervention and more aggressive pain 
management strategies tailored to individual patient characteristics, and implemented over 
the course of treatment. This strategy may differ from modular pain management using the 
analgesic ladder and the previously defined BPI severity cutpoints. Given that patients with 
metastatic breast cancer who were non-Caucasian, restricted in performance status, younger, 
or not employed at baseline were found to have higher hazards as compared with their 
counterparts for first reaching higher levels of pain sooner, our findings suggest that 
intervention strategies be targeted to prevent or delay first occurrence of higher-intensity pain 
among those at greater risk.  
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B. Manuscript 2: Factors associated with differential hazards for pain treatment 
failure among metastatic breast cancer patients  
ABSTRACT 
Background. A research need has been cited for tumor-specific epidemiologic study of 
baseline and time-dependent risk factors, especially with regards to racial disparities, for pain 
experienced over time among patients with cancer. Clinical trials may collect pain data at 
multiple time points, but often only single time point or percentage-change-from-baseline 
approaches are implemented. The present study utilized longitudinal data to (a) identify 
baseline and time-dependent risk factors for time to first occurrence of experiencing a 7 or 
above (treatment failure) on Brief Pain Inventory 0-10 severity and interference scales; (b) 
test the hypothesis that racial/ethnic classification would be an important predictor for worse 
pain outcomes; and (c) explore the relationship between pain severity and interference as 
measured by the subscales of the BPI. 
Methods. We conducted a secondary analysis of existing data from a clinical trial that 
assessed patient outcomes over at least 51 weeks using the Brief Pain Inventory (BPI) to 
measure pain among 1124 women with metastatic breast cancer. We fit models to data 
structured by 80-day intervals to predict hazards of reaching a score of 7 or greater on the 
(BPI) severity and interference scales over 400 days, assessing race as well as baseline and 
time-dependent covariates as predictors of pain outcomes.  
Results. Caucasian race and active Eastern Cooperative Oncology Group (ECOG) 
performance status were associated with decreases in log incidence density, and radiation 
treatment since the last study visit was associated with an increase in log incidence density 
for both outcomes. The estimated survival rate at the first interval was 0.92 for Caucasian 
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women versus 0.80 for non-Caucasian women for the severity outcome, and 0.80 for 
Caucasian women versus 0.70 for non-Caucasian women for the interference outcome. In 
subsequent intervals, these rates declined similarly for Caucasian and non-Caucasian women, 
but for both pain outcomes, the cumulative survival rate for Caucasians in the last interval 
was still higher than the rate for non-Caucasian women in the first interval.  
Discussion. Our findings support the hypothesis that non-Caucasian race is a risk factor 
for worse pain severity and interference, not only cross-sectionally, but also longitudinally 
among women with metastatic breast cancer. Our findings with regard to 
restriction/impairment as measured over time by performance status offer longitudinal 
evidence to confirm that performance status is an important predictor of pain and other 
health-related quality of life outcomes. Our findings should help to inform individual 
prognoses and pain management strategies according to patient attributes that are available 
for assessment over time. Future research should aim to assess pain comprehensively over 
time in tumor-specific cohorts, and to incorporate data collection designs that specifically 
target sources of racial disparities. 
1. Introduction 
Pain, often called the “fifth vital sign”, is of particular concern in cancer due to the 
malignant nature of neoplastic disease, the physiological mechanisms of cancer progression, 
and the pain-causing potential of cancer treatments and their side effects. It is estimated that 
chronic or recurrent pain affects about 30% of all patients with cancer, and about 60 to 90% 
of patients with advanced cancer.1,2 However, the burden of pain is consistently found to be 
greater among non-Caucasian versus Caucasian patients in cross-sectional research. Few 
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studies of cancer pain have examined whether patients’ experiences of pain over the course 
of disease differ by race.  
In addition to being at higher risk for breast cancer mortality,3 non-Caucasian patients 
with cancer have been found to report greater pain, and to be at risk for having their pain 
inadequately assessed,4 managed, and treated.5 In a 1998 study by the SAGE group,6 
African-American patients (a) reported more daily pain (34% as compared to 25% of white 
patients), (b) had greater odds of failing to receive any analgesic agent, and (c) were found to 
have inadequate pain management at higher rates than white patients in outpatient clinics.6 
Such disparities have been further confirmed and discussed in other investigations, which 
have cited differences in treatment patterns, pain management strategies, and the use of 
hospice care as potential contributing factors to racial differences.3,7,8 Sources of pain 
disparities by minority status are complex, simultaneously involving factors on all levels of 
health and health care. This study explores race as a risk factor by investigating the 
hypothesis that pain hazards over time will be higher among non-Caucasian patients with 
metastatic breast cancer, as compared with their Caucasian counterparts.  
Approaches to pain research have comprised observational, experimental, meta-analytic, 
and measurement/validation designs to explore cancer pain incidence and prevalence, risk 
factors for pain, the effectiveness of various analgesic interventions, and the construction and 
testing of algorithms for pain management strategies based on available evidence. Although 
there is wide consensus that pain is a key dimension of detriments in health-related quality of 
life, large-scale evidence reviews have identified gaps in research, citing a need for tumor-
specific studies of patients’ experiences of pain over time, with consideration of how various 
factors affect longitudinal experiences of pain during the course of treatment.9,10 A 2004 
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monograph on the methodology and future directions for epidemiologic research of cancer 
pain calls for studies that more clearly characterize the pain experience over the cancer 
trajectory.11 Most pain prevalence investigations have involved only cross-sectional data 
collected at one point in time.11 In clinical trials, pain data may be collected at multiple time 
points, but the trial statistical analyses are often limited to the use of one measurement at a 
single time point or percentage-change-from-baseline approaches12 (in which the analysis 
covers data collected at only two time points: the first and last pain assessments, no matter 
how many times pain was assessed during the trial). The approaches described do not 
optimize understanding that can be gained from using time-to-event methods for analyzing 
data collected at multiple visits.  
The study of longitudinal pain outcomes must take into account established and potential 
risk factors for pain that have been found in previous studies. Studies of risk factors for pain 
have found that among patients with breast cancer, younger patients are at higher risk for 
post-treatment pain.13,14 In addition, tumor type, genetics, psychosocial context, and culture 
have been found to affect pain and analgesic efficacy.15  
In their measure validation study of the Brief Pain Inventory (BPI),16 Serlin and 
colleagues used the BPI interference scale to anchor cutpoints on the BPI severity scale for 
pain intensity levels.17 They found optimal cutpoints that form 3 distinct levels of pain 
severity on 0-10 numeric rating scale (NRS). 1-4: mild, 5-6: moderate, 7-10: severe. Serlin 
and colleagues also found non-linear relationship between the BPI severity and interference 
scales. The findings of a 2005 study by Paul and colleagues18 in outpatient oncology patients 
with metastases confirmed the previous finding of a non-linear relationship between cancer 
pain severity and interference. These two outcome measures are often administered together 
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in clinical trials, and are of importance in describing pain as a patient-reported outcome. 
Further investigation of the relationship between the scales can help us gain a more complete 
understanding of the impact of cancer pain. 
In addition to its importance for measure validation studies, the cutpoint of 7 on the BPI 
is also of clinical interest. Designations of severity based on cutpoints have been used to 
establish clinically meaningful changes (used to measure therapeutic effectiveness), as well 
as in the creation of clinical practice guidelines and in the analyses for numerous cross-
sectional studies of pain intensity in different populations. A patient-reported pain score of 7 
or above is often a red flag to clinicians that a change in pain management is necessary,19 
because treatment to that point has failed to prevent severe pain. Thus, a pain score of 7 may 
be termed a treatment failure. 
The aims of this study were (a) to identify baseline and time-dependent factors associated 
with time to first occurrence of experiencing a 7 or above on scales measuring pain severity 
and pain interference with daily function; (b) to test the hypothesis that racial/ethnic 
classification would be an important predictor for worse pain outcomes; and (c) to explore 
the relationship between pain severity and interference as measured by the 0-10 scales of the 
BPI. 
2. Methods 
a. Patients and procedures 
Our study was conducted under approval from the University of North Carolina at Chapel 
Hill Institutional Review Board. We analyzed data from participants in a clinical trial 
(Novartis protocol 4244603010). Informed consent was obtained from each patient in the 
original trial, and the multicenter trial was carried out under approval from each institution’s 
 125 
ethical review board, in accordance with applicable laws in each country and the Declaration 
of Helsinki. The trial assessed patient outcomes over 51 weeks using the BPI16 to measure 
pain among 1124 patients with metastatic breast cancer. Saad et al.20 provide a full report of 
the primary analyses of the double-blind, multicenter clinical trial, the purpose of which was 
to compare two bisphosphonate drugs, intravenous zoledronic acid [4 or 8 mg] versus 
intravenous pamidronate disodium [90 mg], as an adjunct to standard therapies, in the 
treatment of multiple myeloma and breast cancer patients with cancer-related bone lesions. 
No placebo arm was used. The intent-to-treat study population consisted of men and women 
with stage III multiple myeloma (n = 510) or stage IV breast cancer with ≥ 1 lytic or mixed 
bone metastasis (n = 1130). For the purpose of the present analysis, we limited the sample to 
women with breast cancer (n = 1124). The sample was stratified at enrollment into two 
categories: (1) patients with breast cancer undergoing chemotherapy or breast cancer patients 
undergoing both chemotherapy and hormonal therapy, versus (2) patients with breast cancer 
undergoing first-line or second-line hormonal therapy without chemotherapy. These 
stratification categories were used as covariates in the present study. The clinical trial was 
conducted at 207 centers in the following countries (grouping identified in parentheses): 
Canada and the United States (North America); Argentina, Brazil, Chile, Peru, and Uruguay 
(South America); Austria, Belgium, the Czech Republic, France, Germany, Ireland, Italy, the 
Netherlands, Poland, Spain, Sweden, Switzerland, and the United Kingdom (Europe); and 
Australia, Israel, New Zealand, and South Africa (other). The first patient was recruited on 
October 16, 1998, and the last measure was completed on the last patient on January 12, 
2001. 
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b. Assessment of outcomes: pain severity and interference 
 
Patients completed the Brief Pain Inventory questionnaire at baseline, months 1 and 2, 
and every other month thereafter up to month 13 (Week 51). The BPI was administered in 
person before the patient was interviewed by the physician or received study medication. The 
Brief Pain Inventory (BPI) measure consists of several parts, but this study uses only the pain 
severity and interference items. Severity is measured as: average pain, pain right now, worst 
pain, and least pain, all four of which are answered on a 0-10 scale, with 0 = “no pain” and 
10 = “worst pain imaginable”. The "worst pain" or the arithmetic mean of the 4 severity 
items can be used as measures of pain severity.  For the present study, at the advisement of 
the BPI instrument’s creators, we use the arithmetic mean of the 4 severity items rather than 
the “worst pain” score alone. The BPI includes a 7-item pain Interference scale, which 
consists of the same 0-10 response scale to the question: “describe how, during the last 7 
days, pain has interfered with your: 1) general activity, 2) mood, 3) walking ability, 4) 
normal work (includes both work outside the home and housework), 5) relations with other 
people, 6) sleep, and 7) enjoyment of life. The arithmetic mean of the 7 interference items 
was used to measure pain interference. 
In general, numeric rating scales for pain severity such as the BPI have been 
demonstrated to be valid and sensitive to change.21 According to the American Pain Society 
Clinical Practice Guideline for the Management of Cancer Pain in Adults and Children,22 
NRS measures are among the most common, valid, and reliable measures used to assess 
cancer pain severity. The BPI is available and has been administered and assessed for 
validity in several languages including Spanish, French, Japanese, Chinese, Italian, Hindi, 
German, Greek, and Vietnamese.23-29  
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c. Assessment of predictors: clinical and demographic covariates 
 
In addition to the pain assessments, subjects were asked to provide demographic, clinical, 
and outcomes information through interviews, written questionnaires, and physical 
examinations, to complete the clinical case report form and other original clinical trial source 
documents in accordance with the study protocol. Comparisons between the treatment arms 
are not a part of the present study. Analyses comparing treatment arms have already been 
conducted and are reported elsewhere.30 The present study groups all the patients together for 
the analysis and assesses the predictive value of baseline and time-dependent covariates with 
respect to the pain outcomes.  
Baseline characteristics include age, education (1 = college degree, 0 = no college 
degree), employment status (1 = full-time, 0 = other), geographic region (North America, 
South America, Europe, or Other – defined per-country in the Patients and Procedures 
section), antineoplastic therapy on study entry (chemotherapy plus hormonal therapy vs. 
hormonal therapy only), previous skeletal complications (0 = no, 1 = yes), and time from 
initial bone metastasis to randomization.  Skeletal complications are referred to as skeletal-
related events (SREs) and were defined in the trial as experiencing one or more of the 
following: pathologic fractures, spinal cord compression with vertebral compression fracture, 
the need for surgery to treat or prevent pathologic fractures or spinal cord compression, or the 
need for radiation to bone.31 
The following time-dependent characteristics (i.e., status during a given interval) were 
included: active/restricted performance status (1 = active [ECOG status of 0 or 1], 0 = 
restricted [ECOG status of 2, 3, or 4]), hospital admission (including day admission, 
overnight admission, or other), surgery, chemotherapy treatment, and radiation treatment. 
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d. Statistical analysis 
 
We conducted the analyses using SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). 
Analyses were conducted on the intent-to-treat sample, which included all female breast 
cancer patients who had been randomized in the trial (n=1124). We calculated descriptive 
statistics for baseline and time-dependent demographic characteristics and clinical variables. 
We used Chi-square tests, T-tests, and Wilcoxon rank-sum tests to assess baseline differences 
by race for each predictor and outcome variable. We assessed extent of missing data of the 
outcome variables at each study visit when pain had been assessed in the trial. Some patients 
had missing pain outcome data at every visit. Our pain outcomes analyses exclude these 
patients (n = 73 completely missing for severity, leaving an analysis sample of n = 1051 for 
the severity scale, and n = 77 completely missing for interference, leaving an analysis sample 
of n = 1047 for the interference scale). We conducted exploratory analyses of the race 
variable using visual examination of Kaplan-Meier survival curves, with a continuous time 
assumption. For these analyses, failures were defined as first occurrence of reaching a 7 on 
the severity and interference scales. 
For both the clinical and statistical interest of cutpoint 7 on the BPI, we chose to model 
the hazards for time to first occurrence of a 7 or above on each scale. The trial data 
assessment schedule involved visits scheduled every 21 days, with BPI assessments every 2 
visits and ECOG assessments every 4 visits. The pain severity questions were asked over the 
timeframe of the past seven days (with the exception of “describe your pain right now”) and 
the pain interference questions were asked over the timeframe of the past 24 hours. This 
means that gaps in information as long as 5 weeks exist in the severity data, and even longer 
gaps exist in the interference data. Given these gaps in information, the present study 
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involved interval-censored data because a patient could have experienced an event between 
two assessments but the exact date of the event is unknown. Interval-censored data may be 
analyzed under an assumption of categorical rather than continuous time at risk for hazards 
models. We handled this assumption using a piecewise exponential model (using PROC 
GENMOD) with categorized time in Poisson regression. As adapted from Stokes, Davis and 
Koch, Categorical Data Analysis using the SAS System (2000), the piecewise exponential 
likelihood for the present models, with continuous covariates, is as follows: 
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where yik is equal to 1 if the event occurred, or 0 if the event did not occur for the ith 
person during the kth interval, Nik is the total person-time of exposure (in days), mi is the 
maximum number of intervals for subject i, and λik is the hazard parameter. The piecewise 
exponential model assumes that there are conditionally independent exponential distributions 
with hazard parameters λik for the respective time periods.32 The properties of this method 
enable us to obtain effect estimates from Poisson regression computations using the 
assumption of the piecewise exponential model, regardless of whether we make the 
conditional arguments necessary to assume a Poisson distribution. Stokes and colleagues 
(2002) discuss these specific properties further.32  
For the categorical data analysis, intervals were assigned as every 80 days following 
randomization, with a total of 5 intervals. Intervals were numbered 0 through 4, with the last 
interval beginning 320 days following randomization, and ending at 400 days (57 weeks) 
following randomization. Interval 0, also called the “first interval” was the referent and was 
80 days in length. Although the choice of interval length and number of intervals can be 
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completely arbitrary for the piecewise exponential model to still be valid,33 we chose the 80-
day interval length based on the distribution of events in the intervals; model convergence 
requires a minimum number of events in any given interval.  
For any interval in which a patient remained in the study but did not reach the outcome, 
time at risk was set at 80 days. A patient’s last interval was the interval in which she (a) 
reached the outcome of a 7 or above, (b) dropped out before the 400-day mark, or (c) died 
before the 400-day mark. For those who reached the outcome, in their last interval an event 
indicator variable was set to 1, and time at risk in the last interval was defined as the time 
from the beginning of the interval to the date of the report of a 7 or above. For patients who 
dropped out early or died, time at risk in the last interval was equal to the number of days 
from the beginning of the last interval to the date of dropout or death. If a patient never 
reached the outcome in any interval, that observation was censored, such that the event 
indicator variable was set to 0 for all intervals, and time at risk within each interval was 
assigned as 80 (or, in the cases of dropout or death, the time at risk in the last interval would 
be the number of days from the beginning of their last interval to the date of dropout or 
death).  
To account for within-subjects correlation of multiple outcome assessments over time, we 
used generalized estimating equation (GEE) methods to adjust the standard errors and 
confidence intervals around the estimated model parameters. We assessed model fit by 
evaluating the significance at a criterion of α = 0.05 of the Residual χ2 score statistic for 
contribution of covariates and all possible time-by-covariate interaction terms not included in 
the model.  
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These data presented an opportunity to explore the relationship between the BPI intensity 
composite score and the BPI interference composite score. Both are on the same numeric 
rating scale from 0-10, with 10 indicating greatest severity or interference. To explore the 
relationship of these two subscales, we explored the similarities and differences in how sets 
of explanatory covariates affected pain severity versus interference outcomes. 
e. Sensitivity analyses 
Censoring deaths versus assigning worst pain score 
 
An overarching issue that affected all the survival analyses was that in the analyses, we 
may account for deaths in two ways: 1) by censoring them, 2) by treating them as events 
(severe pain). We conducted a sensitivity analysis to address this issue. For those patients 
who discontinued due to death, instead of censoring their observation, we assigned time to 
reach severity of 7 or higher as if the patient had reported a BPI score of 10 for the first 
missing pain assessment in the string of missing pain assessments following their dropout 
(the dropout date was effectively either the last day of enrolment in the trial, or the last day 
the BPI was administered, whichever was greater of the two).  
Handling missing data  
 
The survival analysis techniques required that we make certain assumptions about how to 
code the event indicator and time at risk variables, given missing data scenarios present in the 
data. There were four possible such scenarios, for which we implemented the following 
coding for event indicator and time-to-event variables, prior to conversion to the interval-
structured data set:  
- (Scenario A) if a patient reached a BPI measurement of [3,4,5,6, or 7] (hereafter 
referred to as “the outcome”) then the dichotomous event indicator variable was set 
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equal to 1 and time at risk was set equal to the number of days from randomization to 
the date of the first occurrence of the outcome.  
- (Scenario B) If the patient had complete BPI data but never reached the outcome, 
then the dichotomous event indicator variable was set equal to 0 and time at risk was 
set equal to total number of days the patient was in the study (leading to these 
observations being censored in the survival analysis).  
- (Scenario C) If a patient did not have any BPI data then the patient was not included 
in the survival analysis.  
- (Scenario D) If the patient had some BPI data but never reached the outcome, then the 
dichotomous event indicator variable was set equal to 0. The observation was 
censored as in Scenario B, but total time at risk was set equal to either the total 
number of days the patient was in the study (assumption D.i), or to the number of 
days from randomization to the date of the preceding non-missing BPI measurement 
(assumption D.ii).  We conducted a sensitivity analysis to assess the impact of 
different missing data handling methods, using these two variations of Scenario D 
(D.i and D.ii).  
Another missing data handling technique used was to code the full-time employment and 
college education variables (each of these variables had about 16% missing data at baseline) 
as three-level categorical variables, with the categories as “yes”, “no”, or “missing”, with 
“no” as the referent category. This technique prevents these observations from being dropped 
from the models. 
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3. Results 
Table 1 presents a summary of baseline characteristics of the sample and missing data for 
each of the baseline covariates. The only variable for which more than 1% of patients had 
missing observations at baseline was the employment status variable, which was missing for 
16% of the sample. However, only 14% of patients reported being employed full-time at the 
time of randomization. This is likely due to the fact that all patients in the trial had metastatic 
disease at enrollment.  
The most frequent reasons for dropout were adverse events (30% of trial “completers” – 
those who completed a case report form at visit 19) and death (26% of noncompleters). For 
the entire trial population, approximately 52% of adverse events experienced were bone pain, 
making it the most frequent type of adverse event. The implications of this fact with regards 
to the proportional hazards assumption are addressed in the sensitivity analysis. Table 2 
shows the study population remaining at each scheduled BPI assessment visit (visits 2, 3, 4, 
6, 8, 10, 12, 14, 16, 18, and 19) and these patients’ rates of completion of the BPI severity 
and interference assessments. Of the 438 patients (39% of the original 1124 enrolled) who 
did not complete visit 19, 132 patients (30%) discontinued the study due to adverse events, 
and 113 patients (26%) discontinued due to death. Additional details regarding patient 
disposition for the overall clinical trial are reported by Rosen et al.30 Of those patients 
enrolled in the trial at any given visit, the proportion who had completed BPI assessments 
was consistently no less than 82%.  
Table 3 shows how the baseline characteristics and outcomes differed by race at the time 
of randomization. A majority (84%) of the total of non-Caucasian patients  
(n = 133) were from North American sites (n = 112). There were no baseline differences by 
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race in ECOG performance status, education, employment, experience of a previous SRE, or 
time from first bone metastasis to randomization. Caucasian patients had slightly higher 
mean age (57.9 ± SD12.7) compared to the mean for non-Caucasian patients (54.8 ± 
SD11.0). Non-Caucasian patients had higher baseline pain severity and interference scores 
than Caucasian patients. The median severity score was 0.63 points higher for non-
Caucasians and the mean interference score was 0.86 points higher for non-Caucasians as 
compared with Caucasians. 
Figures 1 and 2 display Kaplan-Meier survival curves that show differences by race in 
hazards of reaching a 7 or above for both the severity and interference scales. Evidence for 
statistical significance of these differences, using a criterion of α = 0.05, is confirmed by the 
log-rank test statistics of 20.9 (p < 0.0001) and 8.6 (p = 0.0033), respectively.  
The interval-censored nature of these data as a result of the trial visit schedule is 
supported by the graphic shown in Figure 3, which shows the distribution of BPI assessments 
around each scheduled trial visit. There appear to be more discrete intervals toward the 
beginning of the observation period, and more overlap in BPI assessment times later in the 
trial (e.g., a person whose BPI assessment took place on their 300th day post-randomization 
could have had that assessment labeled as having taken place at either visit 14 or visit 16).  
We fit models to data structured by intervals assigned at every 80 days, and truncated at 
the end of Interval 4 (321-400 days post-randomization). Tables 4 and 6 show the parameters 
resulting from these models for the pain severity and interference outcomes, respectively. For 
each model, the intercept (α) represents the log incidence density for all referent categories 
(including non-Caucasian race) at the referent (lowest) interval.32 The model parameter 
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coefficients reflect increases or decreases in incremental log incidence density. We used a 
significance criterion of α = 0.05 to evaluate the contribution of each variable to the models.  
The pain severity results in Table 4 show that Caucasian race and active ECOG status 
were associated with decreases in log incidence density, and radiation treatment since the last 
study visit was associated with an increase in log incidence density for pain severity of 7 or 
more. Also for the severity outcome, Table 5 displays, for the severity scale, the estimated 
failure rates (incidence densities) and concomitant cumulative “survival” rates  for non-
Caucasian and Caucasian patients at each interval (“survival” in quotes because it refers not 
to mortality but to the probability of reaching an interval without experiencing pain of 7 or 
above, denoting treatment failure. The estimated survival rate at the first interval was 0.92 
for Caucasian patients versus 0.80 for non-Caucasian patients. In subsequent intervals, these 
rates declined similarly for Caucasian and non-Caucasian patients, but the cumulative 
survival rate for Caucasians in the last interval (0.84) was still higher than the rate for non-
Caucasians in the first interval.  
Table 6 shows that for the pain interference outcome, Caucasian race, age in decades, and 
active ECOG performance status were associated with decreases in log incidence density. 
However, the GEE-adjusted confidence limits for the effect of age upon hazards for pain 
interference did not exclude the null value. Hospital admission since the last study visit, and 
radiation treatment since the last study visit were each associated with increases in log 
incidence density for pain interference of 7 or more. Table 7 contains the estimated failure 
rates (incidence densities) and concomitant cumulative survival rates for non-Caucasian and 
Caucasian women at each interval for the interference outcome. The estimated survival rate 
at the first interval was 0.80 for Caucasian women versus 0.70 for non-Caucasian women. As 
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with the severity outcome, in subsequent intervals, these rates declined similarly for 
Caucasian and non-Caucasian women, but the cumulative survival rate for Caucasians in the 
last interval (0.71) was still better than the rate for non-Caucasians in the first interval.  
All results were robust in direction, magnitude, and statistical significance with regard to 
the two sensitivity analyses varying assumptions in (a) counting of deaths and (b) handling of 
missing data. 
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Table 12. (MS2: Table 1). Baseline patient characteristics and missing data (N = 1124). 
 
 
Characteristic ValuesA
Number of patients with 
values missing at baseline
(%)
Age in years, mean ± SD 57.5 ± 12.6 0 (0)
Female 1124 (100) 0 (0)
Caucasian race 991 (88) 0 (0)
College education 281 (25) 186 (17)
Employed full-time 157 (14) 182 (16)
Geographic region B 0 (0)
North America  773 (69)
Europe  217 (19)
South America  39 (3)
Other 95 (8)
Baseline ECOG performance status 4 (0.4)
Active (0 or 1), recoded as 1 952 (85)
Restricted (≥2), recoded as 0 168 (15)
Antineoplastic therapy (trial 
stratification variable) 
0 (0)
Chemotherapy 525 (47)
Hormonal therapy 599 (53)
Experienced previous skeletal related 677 (60) 3 (0.3)
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Characteristic ValuesA
Number of patients with 
values missing at baseline
(%)
event 
Time from first bone metastasis to 
randomization, days 
157 (14) 3 (0.3)
Mean ± SD 406 ± 744
Median 108  
A Values are expressed as number (percentage) unless otherwise indicated. 
B Variable is dichotomized to North America / Other for present analyses. 
Some totals do not add up to 100% due to rounding. 
SD = Standard deviation 
ECOG = Eastern Cooperative Oncology Group 
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Table 13. (MS2: Table 2). Study population and Brief Pain Inventory (BPI) completion 
at each scheduled assessment 
 
 
 Completeness of BPI Composite Scores 
 
Visit 
 
Severity Score 
 
Interference Score 
 
Study Population A 
n (% of pts. 
in trial at visit i) B
(% of 
starting N)
n (% of pts. 
in trial at visit i) B
(% of 
starting N)
Visit 2 1124 (100) 1024 (91) (91) 1029 (92) (92)
Visit 3 1117 (99) 975 (87) (87) 972 (87) (86)
Visit 4 1073 (95) 950 (89) (85) 953 (89) (85)
Visit 6 1019 (91) 898 (88) (80) 906 (89) (81)
Visit 8 942 (84) 806 (86) (72) 807 (86) (72)
Visit 10 896 (80) 794 (89) (71) 798 (89) (71)
Visit 12 812 (72) 675 (83) (60) 675 (83) (60)
Visit 14 784 (70) 673 (86) (60) 681 (87) (61)
Visit 16 706 (63) 598 (85) (53) 599 (85) (53)
Visit 18 672 (60) 551 (82) (49) 549 (82) (49)
Visit 19 686 (61) 584 (85) (52) 583 (85) (52)
AIndicates the number (percent) of patients remaining in the study at each scheduled BPI 
assessment visit.  
BIndicates number of patients at each BPI assessment for whom BPI Composite Scores 
could be calculated. 
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Table 14 (MS2: Table 3). Baseline characteristics by raceA 
 
  
Race 
 
  
  
Caucasian
Non-
Caucasian 
Test 
statistic: 
baseline 
differences
P-
value
Categorical baseline variables  
Geographic Region  
European Union 212 (21) 5 (4) 
North America 661 (67) 112 (84) 
South America 38 (4) 1 (1) 
Other 80 (8) 15 (11) 
6.08 B 0.014
Baseline ECOG performance status   
Active (0 or 1) 85 (37) 111 (84) 
Restricted (2) 147 (63) 21 (16) 
0.10 B 0.756
College education   
Yes 247 (27) 34 (28) 
No 580 (62) 76 (62) 
0.14 B 0.705
         Missing 102 (11) 12 (11)  
Employed full-time   
Yes 138 (15) 19 (16) 
No 693 (75) 91 (75) 
0.06 B 0.811
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Race 
 
  
  
Caucasian
Non-
Caucasian 
Test 
statistic: 
baseline 
differences
P-
value
        Missing 98 (11) 12 (10)  
Previous skeletal related event   
Yes 599 (61) 78 (59) 
No 389 (39) 55 (41) 
0.19 B 0.661
Continuous variables   
Age in years, mean ± SD 57.9 ±12.7 54.8 ±11.0 -3.05 C 0.003
Time from first bone metastasis to 
randomization in days, median (IQ range) 
103
(36 - 473)
124 
(36 - 606) 
0.20 C 0.654
Continuous outcomes   
BPI Composite Score - Severity, median  
(25%-75% interquartile range) 
2.75
(1.25 - 4.50)
3.38 
(1.75 - 5.75) 
3.59 C 0.0003
BPI Composite Score - Interference, median
(25%-75% interquartile range) 
3.00
(0.57 – 5.42)
3.86 
(1.43 - 6.86) 
3.08 C 0.0020
A Values are expressed as number (percentage) unless otherwise indicated. 
B Mantel-Haenszel Chi-Square test 
C  T-statistic for normal distribution, Wilcoxon rank sum statistic for non-normal 
distribution. 
ECOG = Eastern Cooperative Oncology Group. 
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Table 15 (MS2: Table 4). Model parameters: baseline and time-dependent predictors 
for hazard of first reaching BPI severity score of 7 or above (categorical time 
assumption). 
 
Parameter Est. SE 
 
HR 
( keβ ) 
Wald 95%  
CLs  
for HR Z 
p > 
|Z| 
Intercept -6.075 0.549 0.00 0.00-0.01 -11.06 <.0001 
Caucasian -0.889 0.209 0.41 0.27-0.62 -4.26 <.0001 
College education (=1) -0.332 0.202 0.72 0.48-1.07 -1.65 0.10 
   Education variable missing (=2) 0.857 0.887 2.36 0.41-13.39 0.97 0.33 
   < College education (=0, ref.) . . . . . . 
Employed full-time (=1) -0.277 0.280 0.76 0.44-1.31 -0.99 0.32 
   Employment status missing (=2) -0.675 0.918 0.51 0.08-3.08 -0.74 0.46 
   Not employed full-time (=0, ref.) . . . . . . 
Previous skeletal related event 0.170 0.176 1.18 0.84-1.67 0.97 0.33 
Age in decades 0.086 0.066 1.09 0.96-1.24 1.31 0.19 
Admitted to hospitalA 0.103 0.231 1.11 0.71-1.74 0.45 0.65 
Active ECOG statusA -0.611 0.197 0.54 0.37-0.80 -3.11 0.002 
SurgeryA 0.172 0.376 1.19 0.57-2.48 0.46 0.65 
Radiation therapyA 1.155 0.220 3.17 2.06-4.89 5.24 <.0001 
ChemotherapyA 0.249 0.173 1.28 0.91-1.80 1.44 0.15 
Interval 1: 81-160 days -1.828 0.280 0.16 0.09-0.28 -6.53 <.0001 
Interval 2: 161-240 days -1.349 0.247 0.26 0.16-0.42 -5.46 <.0001 
 143 
Parameter Est. SE 
 
HR 
( keβ ) 
Wald 95%  
CLs  
for HR Z 
p > 
|Z| 
Interval 3: 241-320 days -1.339 0.272 0.26 0.15-0.45 -4.92 <.0001 
Interval 4: 321-400 days -1.439 0.343 0.24 0.12-0.46 -4.19 <.0001 
Interval 0 (referent): 0-80 days . . . . . . 
ATime-dependent covariates – recorded as since the last study visit. 
Note: SE = standard error. HR = hazard ratio. CLs = confidence limits. ECOG  
status = Eastern Cooperative Oncology Group performance status. Ref. = referent 
category. SEs and related values are adjusted using generalized estimating equation (GEE) 
methods. 
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Table 16. (MS2: Table 5). Model-based 400-day outcome probabilities by race: failure is 
first occurrence of pain score 7 or higher on the BPI severity scale. 
 
 
Characteristic   Interval 
Incidence Density 
(Estimated  
Failure Rate) 
Estimated  
Cumulative 
SurvivalA Rate 
Non-Caucasian 0 (0-80 days) 0.0028 0.7993 
Non-Caucasian 1 (81-160 days) 0.0004 0.7741 
Non-Caucasian 2 (161-240 days) 0.0007 0.7319 
Non-Caucasian 3 (241-320 days) 0.0007 0.6920 
Non-Caucasian 4 (321-400 days) 0.0007 0.6543 
Caucasian 0 (0-80 days) 0.0011 0.9158 
Caucasian 1 (81-160 days) 0.0002 0.9013 
Caucasian 2 (161-240 days) 0.0003 0.8799 
Caucasian 3 (241-320 days) 0.0003 0.8590 
Caucasian 4 (321-400 days) 0.0003 0.8386 
Note: referent is based on coefficients multiplied by population proportions (for 
categorical variables) or population mean (for age).  
ASurvival does not indicate mortality, but rather reaching a given interval without having 
reached a pain score of 7. 
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Table 17. (MS2: Table 6). Model parameters: baseline and time-dependent predictors 
for hazard of first reaching BPI interference score of 7 or above (categorical time 
assumption).  
 
Parameter Est. SE 
 
HR 
( keβ ) 
Wald 95%  
CLs  
for HR Z 
p > 
|Z| 
Intercept -3.772 0.436 0.02 0.01-0.05 -8.65 <.0001 
Caucasian -0.514 0.190 0.60 0.41-0.87 -2.71 0.007 
College education (=1) -0.193 0.158 0.82 0.61-1.12 -1.23 0.220 
   Education variable missing (=2) 0.308 0.536 1.36 0.48-3.89 0.58 0.565 
   < College education (=0, ref.) . . . . . . 
Employed full-time (=1) -0.333 0.209 0.72 0.48-1.08 -1.60 0.111 
   Employment status missing (=2) -0.257 0.565 0.77 0.26-2.34 -0.45 0.650 
   Not employed full-time (=0, ref.) . . . . . . 
Previous skeletal related event 0.239 0.137 1.27 0.97-1.66 1.74 0.082 
Age in decades -0.162 0.054 0.85 0.76-0.95 -2.98 0.003 
Admitted to hospitalA 0.622 0.166 1.86 1.34-2.58 3.74 0.000 
Active ECOG statusA -1.112 0.148 0.33 0.25-0.44 -7.49 <.0001 
SurgeryA -0.251 0.296 0.78 0.44-1.39 -0.85 0.395 
Radiation therapyA A 0.983 0.187 2.67 1.85-3.86 5.25 <.0001 
ChemotherapyA 0.025 0.141 1.02 0.78-1.35 0.17 0.862 
Interval 1: 81-160 days -2.067 0.216 0.13 0.08-0.19 -9.56 <.0001 
Interval 2: 161-240 days -2.182 0.250 0.11 0.07-0.18 -8.74 <.0001 
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Parameter Est. SE 
 
HR 
( keβ ) 
Wald 95%  
CLs  
for HR Z 
p > 
|Z| 
Interval 3: 241-320 days -1.682 0.217 0.19 0.12-0.28 -7.74 <.0001 
Interval 4: 321-400 days -1.747 0.273 0.17 0.10-0.30 -6.41 <.0001 
Interval 0 (referent): 0-80 days . . . . . . 
ATime-dependent covariates – recorded as since the last study visit. 
Note: SE = standard error. HR = hazard ratio. CLs = confidence limits. ECOG status = 
Eastern Cooperative Oncology Group performance status. SEs and related values are 
adjusted using generalized estimating equation (GEE) methods. 
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Table 18. (MS2: Table 7). Model-based 400-day outcome probabilities by race: failure is 
first occurrence of pain score 7 or higher on the BPI interference scale. 
 
Characteristic   Interval 
Incidence Density 
(Estimated  
Failure Rate) 
Estimated  
Cumulative 
SurvivalA Rate 
Non-Caucasian 0 (0-80 days) 0.0046 0.6921 
Non-Caucasian 1 (81-160 days) 0.0006 0.6597 
Non-Caucasian 2 (161-240 days) 0.0005 0.6338 
Non-Caucasian 3 (241-320 days) 0.0009 0.5898 
Non-Caucasian 4 (321-400 days) 0.0008 0.5532 
Caucasian 0 (0-80 days) 0.0028 0.7993 
Caucasian 1 (81-160 days) 0.0003 0.7803 
Caucasian 2 (161-240 days) 0.0003 0.7618 
Caucasian 3 (241-320 days) 0.0005 0.7319 
Caucasian 4 (321-400 days) 0.0003 0.7145 
Note: referent is based on coefficients multiplied by population proportions (for 
categorical variables) or population mean (for age).  
ASurvival does not indicate mortality, but rather reaching a given interval without having 
reached a pain score of 7. 
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Figure 21. (MS2: Figure 1). Survival distribution function (continuous time 
assumption) for first occurrence of 7 on pain severity scale, by race. 
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Figure 22. (MS2: Figure 2). Survival distribution function for first occurrence of 7 or 
above on pain interference scale, by race. 
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Figure 23. (MS2: Figure 3). Distribution of visit windows around scheduled BPI visit 
dates 
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4. Discussion 
 
The 2001 AHRQ evidence review entitled Management of Cancer Pain states that 
“investigations of cancer pain and its control should seek to evaluate the influence of gender, 
race, age, psychosocial context, ethnicity, and culture on the experience and report of pain.”10 
The present study aimed to assess differences in time to first reaching a pain severity or 
interference score of 7 or above on the 0-10 BPI scales among women with metastatic breast 
cancer, using hazards models that account for interval-censored data collected at multiple 
assessments per patient as part of a clinical trial. Our secondary analyses of these 
longitudinal data estimated the associations of a set of baseline and time-dependent clinical 
and demographic characteristics with hazards for these two pain outcomes, compared the two 
scales for similarity in the sets of predictors found to be associated with higher or lower 
hazards over the course of 400 days post-randomization, and investigated the hypothesis that, 
as compared with their Caucasian counterparts, non-Caucasian women would have higher 
hazards of pain severity and pain interference in daily functions. In the present study, 
survival rates refer not to mortality rates, but instead to rates, derived from hazard rates, of 
patients’ survivorship over time in not reaching a 7 on a given outcome scale. When a patient 
reaches a 7, this event may be considered a “treatment failure” because successful pain 
management should have prevented the patient from reaching pain at or near the levels of 
highest intensity that she can imagine. It is important to note that although the 7 cutoff is 
used for these analyses, there is debate over the classification of severe pain; in practice even 
a score of 5 may be considered severe, and thus a indication for palliative intervention. 
For the pain severity outcome, Caucasian race and active ECOG performance status were 
associated with decreases in log incidence density, and radiation treatment since the last 
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study visit was associated with a concomitant increase in log incidence density for the 
severity outcome. For the pain interference outcome, Caucasian race, higher age in decades, 
and active ECOG performance status were associated with decreases in log incidence density 
for the outcome. Hospital admission since the last study visit, and radiation treatment since 
the last study visit were each associated with greater pain interference in a given interval.  
For both pain severity and interference, non-Caucasian women started the study with 
worse scores; the probability of making it through any given interval without experiencing a 
7 or more on either scale was lower for non-Caucasian women. Although the rates of change 
in incidence density over time are comparable by race, the Interval 1 survival rate for non-
Caucasian race was still lower than the Interval 4 survival rate for Caucasian race. These 
findings support the hypothesis that non-Caucasian race is associated with worse pain 
severity and interference outcomes, not only cross-sectionally, but also longitudinally among 
women with metastatic breast cancer. 
Neither surgery nor chemotherapy was found to be associated with higher pain hazards in 
a given interval, but radiation therapy had the highest association with greater pain intensity, 
as compared with all of the other covariates assessed. These findings are consistent with the 
concepts that (a) therapeutic benefits from chemotherapy and surgery may outweigh 
temporary pain associated with these interventions, and (b) a patient’s report of severe pain 
would cue the treating physician to initiate a round of radiation therapy. Within a given 
interval, it is more likely that pain precedes and even causes radiation therapy.  
Hospital admission since the last visit was found to be associated with reaching a 7 for 
the pain interference outcome, but not for the pain severity outcome. Hospital admission may 
have a greater impact on patients’ perceived levels of pain interference in their daily 
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activities than on patients’ perceived levels of pain severity. We may attribute this finding to 
the fact that once admitted to a hospital, patients may get more analgesic treatment and pain 
management than they would outside the hospital, but their daily activities would be 
disrupted by the admission. A limitation of the data used for the present analyses is 
ambiguity about temporality of events within intervals. This limitation precludes causal 
inferences with regard to the time-dependent variables. 
Another weakness of the present study is that although the dataset used contains pain 
information at multiple assessment times per patient, some gaps in the data exist. Gaps of at 
least one week in information exist in the BPI scores, and all pain events of interest are not 
captured; a patient could have experienced an event between two assessments but the exact 
date of the event is unknown. Ideally, pain would be assessed at shorter intervals to gather 
more complete information - multiple assessments per day, for every day of observation 
would be ideal. If a pain assessment instrument asks about the last 7 days, to gain complete 
information over time, the measure should be administered every 7 days. The impact of this 
limitation on the present study is that although we are able to assess pain hazards over time 
based on the information available, pain may have increased or decreased during the gaps 
between assessments. The piecewise exponential model helps accommodate these gaps, but 
more complete pain information without gaps would be desirable. 
This analysis was limited also by the characteristics of the clinical trial, which was 
designed to answer research questions about the relative efficacy of the two bisphosphonates. 
Limitations were imposed by the exclusion criteria and the covariates that were collected in 
the clinical trial. Future research should collect and model simultaneously the longitudinal 
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effects of these and other psychological, sociocultural, health care-level, and clinical 
characteristics known to affect pain.  
One strength of the present study is that it improves upon previous simple change-from-
baseline analyses, offering more information about pain intensity outcomes over the course 
of treatment. Change-from-baseline methods ignore considerable amounts of data collected 
during the trial, and are at best sub-adequate when used to compare health-related quality of 
life (HRQoL) outcomes among treatment groups in clinical trials. The present study utilizes 
BPI data collected at multiple assessment times over 400 days.  
Another strength is the robustness of the piecewise exponential model with 80-day 
intervals in modeling pain severity and interference outcomes. The two main difficulties in 
the analysis of data from repeated measures studies are 1) complication of the analysis by the 
dependence among repeated observations made on the same experimental unit (the patient in 
this case), and 2) imbalanced or partially incomplete data.32 The present study addresses 
these two challenges by 1) using GEE methods to account for the interdependence of 
multiple observations for each patient, and testing assumptions about handling of missing 
data due to death or early discontinuation. 
Future analyses of these data should comprise multivariate analyses that accommodate 
interval-censored data and include both baseline and other time-dependent covariates. Such 
analyses would provide more comprehensive information about predictors for the multiple 
outcomes on both the pain severity and interference subscales of the BPI. In addition, future 
analyses should account for multiple failures over time (e.g., a patient reaching severe pain, 
then experiencing a decrease in pain, then reaching severe pain again during the course of 
treatment).  
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Data collection in clinical trials can be improved for the purpose of epidemiologic study; 
given the marginal efforts and expenses in relation to the trial itself, it is of great 
informational benefit to incorporate into trial designs prospective, comprehensive 
assessments of pain in longitudinal tumor-specific cohorts, and to specifically target sources 
of racial disparities in this endeavor. 
Our findings that race was an important predictor of pain over time are consistent with 
other risk factor studies and clinical practice guidelines,34 including reports and extensive 
reviews that conclude that minority patients have been found consistently to be at greater risk 
of having undertreated pain and worse pain outcomes.4,5,35,36 Our findings with regard to 
restriction/impairment as measured over time by ECOG performance status offer longitudinal 
evidence to confirm that performance status is an important predictor of pain and other 
health-related quality of life outcomes.37,38 In confirming these characteristics as risk factors 
over time among women with metastatic breast cancer, our findings should help to inform 
individual prognoses and pain management strategies according to patient attributes that are 
available for assessment over time. Early intervention and more aggressive pain management 
strategies should be implemented to prevent worse outcomes among those at highest risk 
over the course of treatment for severe pain and high levels of pain interference in daily 
activities. 
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VI. CONCLUSIONS 
 
 
CHAPTER VI 
 
CONCLUSIONS 
 
A. Recapitulation of overall study aims, findings and degree to which the goals of 
the doctoral research have been met 
 
1. Overall study aims 
The over-reaching goal of this project was to better understand risks and risk factors for 
pain severity and interference outcomes over the course of disease among patients with 
metastatic breast cancer. Manuscript 1 addresses Aims 1 and 2 below, and Manuscript 2 
addresses Aims 2, 3, and 4. We hope that this research underscores the need for improvement 
in pain management strategies, and provides tools to effect improvements in these strategies 
through better prediction of pain outcomes over time. 
AIM 1: To provide descriptive epidemiologic information about pain hazards over time 
among patients with metastatic breast cancer, exploring the effect of using different intensity 
cutpoints on the Brief Pain Inventory (BPI) severity and interference 0-10 subscales with 
regard to baseline clinical and demographic covariates as risk factors.  
Research question: What are the hazards of reaching different pain severity and interference 
thresholds over 51 weeks, and what baseline clinical and demographic factors are associated 
with occurrence of these outcomes?
 AIM 2: To explore the relationship between the pain severity and interference BPI 
subscales with regard to sets of clinical and demographic covariates as predictors. 
Research question: Given that the relationship between the severity and interference 
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subscales of the BPI is nonlinear, how do clinical and demographic predictors compare in 
their associations with hazards over time for pain severity and interference outcomes? 
AIM 3: To estimate the effects of both baseline and time-dependent clinical and 
demographic characteristics on time to first reaching a pain severity or interference score of 7 
or above on the 0-10 BPI severity and interference scales. 
Research question: How do baseline and time-dependent risk factors predict the outcomes of 
reaching a 7 or above on the BPI severity and interference scales? 
AIM 4: To investigate the hypothesis that, as compared with their Caucasian 
counterparts, non-Caucasian patients would have worse longitudinal outcomes with regard to 
(a) pain severity, and (b) pain interference in daily functions.   
Research question: Within our sample of longitudinal data collected in a clinical trial among 
patients with metastatic breast cancer, will our findings confirm existing findings of 
racial/ethnic disparities in the burden of pain? Also, with regard to hazards for these pain 
outcomes, how does the race variable fit in with other baseline and time-dependent clinical 
and demographic factors in a predictive model? 
2. Findings 
Our findings from the analyses conducted for Manuscript 1 that non-Caucasian race, 
younger age, and impaired performance status are important predictors of pain over time are 
consistent with previous cross-sectional risk factor studies and with clinical practice 
guidelines. In confirming these characteristics as predictors of pain hazards over time in 
metastatic breast cancer, our findings inform individualized prognoses for pain outcomes 
according to baseline patient attributes. Early intervention and more aggressive pain 
management strategies can be tailored to these personalized prognoses over the course of 
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treatment to delay first occurrence of higher pain scores among those at greater risk for 
severe pain and pain interference in daily activities. The findings from the multivariate pain 
severity analysis indicate that non-Caucasian women are at greater hazard of reaching higher 
pain severity scores earlier than their Caucasian counterparts. The interaction term for this 
hazard is significant at values of 5 and higher on the BPI. Given the potential risks of 
undertreated pain, our findings should aid in future research to evaluate the role of cutpoints 
in making pain treatment decisions, aimed to delay or prevent worse outcomes among those 
patients at greatest risk over time.  
Our findings from the analyses conducted for Manuscript 2 support the hypothesis that 
non-Caucasian race is a risk factor for worse pain severity and interference, not only cross-
sectionally, but also longitudinally among women with metastatic breast cancer. Our findings 
with regard to restriction/impairment as measured over time by ECOG status offer 
longitudinal evidence to confirm that performance status is an important predictor of pain 
and other health-related quality of life (HRQoL) outcomes, as well as mortality/survival. In 
confirming the prognostic value for pain outcomes of ECOG status and race, our findings 
should help to inform individual prognoses and pain management strategies according to 
patient attributes that are available for assessment over time. Future research should aim to 
assess pain comprehensively over time in tumor-specific cohorts, and to incorporate data 
collection designs that specifically target sources of racial disparities. 
I hope that this research will underscore the need for improvement in pain management 
strategies, and will provide tools to effect improvements in these strategies through better 
prediction of pain risks over time. 
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3. Meeting the goals of the doctoral research 
To fulfill the goals of the doctoral research, the dissertation must be of appropriate scope 
and substantial rigor, as judged by the committee. I have taken the role of lead investigator 
on the design, analysis, consultation, and writing for two manuscripts that are suitable for 
submission. My work has benefited from verbal and written input by the Chair and 
committee members, as well as through regular consultation with the UNC Biometric 
Consulting Laboratory. At the dissertation interim committee meeting, all members present 
reached consensus that the scope of the research was appropriate. 
The proposal defense, preparation, submission for publication, and defense of this 
dissertation addresses the following specific goals enumerated in the Epidemiology 
Academic Policies Manual:  
“The defense of the dissertation proposal documents the ability to justify research 
concepts and methodology related to healthcare epidemiology and ensures that the 
dissertation falls within the framework of healthcare epidemiology.” 
 
The proposal defense involved presentation and justification of the concepts of 
importance in studying longitudinal pain outcomes in tumor-specific populations. Through 
ongoing consultation with the committee, I refined the scope of the dissertation such that I 
have used the data to explore concepts of pain measurement that are of importance and 
interest in the field currently. The committee found that the proposed work fell within the 
framework of healthcare epidemiology, and helped me refine the scope to be appropriate for 
the doctoral research.  
“The successful completion of defense of the dissertation further demonstrates 
research skills and the ability to integrate core concepts of healthcare epidemiology 
into research endeavors.” 
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The defense of the dissertation should be deemed by the committee to demonstrate my 
research skills and ability to integrate into my research endeavors core analytic, 
organizational, methodological, and theoretical concepts that I have learned in the 
Epidemiology program. 
“Publications, in peer-reviews journals, arising from the dissertation provide 
further evidence, of an outcome nature, of achieving the learning objectives.” 
 
As previously stated, I have taken the role of lead investigator on the design, analysis, 
consultation, and writing for two manuscripts that are suitable for submission. 
B. Strengths 
One strength of the clinical trial design was that pain was measured at multiple time 
points. Because bone pain was the most frequent type of adverse event experienced by 
patients in this trial, it is realistic to assume that pain would be related to early termination 
through dropout or death. If this were the case, the censoring distribution would not be 
independent of the outcome, and the proportional hazards assumption would not be met. 
However, when we conducted sensitivity analyses varying handling of deaths and missing 
data, our findings did not change markedly in direction, magnitude, or statistical significance.  
The large trial population of 1,124 patients may be considered a strength of the present 
study, assuming minimal impact of potential bias related to the sampling method on this 
sample’s representativeness of women with metastatic breast cancer. In their 2004 study of 
cancer clinical trial participation, Murthy and colleagues found that younger and minority 
patients were less likely than their counterparts to participate in cancer clinical trials.113 
However, the distribution of race in this study (recorded as “Black” for 5.7% of the sample) 
appears close to the distribution of race among prevalent first malignant breast cancer cases 
in 2002 in the U.S. (Black = 7.4% of total cases) estimated by Surveillance, Epidemiology 
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and End Results (SEER).114 With regards to age, women aged 57 years or less composed 
approximately half the trial population, while 20% of prevalent breast cancer cases were aged 
54 or lower in 2002 U.S. estimates (27-year limited-duration prevalence, first malignant 
cancer only).114 Thus, both the age and race distributions in the present study seem to 
represent the populations to which we would generalize the findings, although the influence 
of potential bias with regard to traits affecting pain outcomes cannot be ruled out entirely. 
According to the eligibility criteria that originally defined the patient population for the trial, 
the findings from the present study should be generalizeable to adult female patients with 
metastatic breast cancer who did not have severe cardiovascular disease, and were not 
pregnant.   
Another strength of the present study is that because the trial was conducted in 
accordance with applicable regulations, quality control procedures were conducted on the 
data to be used. For clinical and demographic data, the pharmaceutical sponsor used a 
Contract Research Organization (CRO) to conduct data quality checks and queries as 
follows: Data items from the data collection forms (case report forms, or CRFs) were entered 
into the study database (Clintrial version 3) at the CRO, using double data entry with 
verification upon second entry. Text items (e.g. typed comments) were entered once and 
checked manually against the CRFs. Subsequently, the information entered into the database 
was systematically checked by Data Management staff, using error messages printed from 
validation programs and database listings. Obvious data entry errors were corrected by CRO 
personnel. Other errors or omissions were entered on Data Query Forms, which were 
returned to the investigational site for resolution based on source documentation.  A copy of 
the signed Data Query Form was kept with the CRFs, and once the original was received at 
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the CRO, the resolutions were entered into the database. QC audits of all key safety and 
efficacy data in the database were made when the last query from an individual patient was 
returned. 
Another strength of the present study is that all of the findings were robust in direction, 
magnitude, and statistical significance with regard to the sensitivity analyses varying 
assumptions about counting of deaths and missing data. 
 In quantifying pain over the course of treatment for metastatic breast cancer, the 
present study is original in filling the need for epidemiologic study of tumor-specific 
longitudinal pain outcomes. It is hoped that our findings will further understanding of the 
definition and extent of pain and its measurement. By focusing on the experience of pain 
over time from the patient’s perspective, investigating cutpoints, and using analytic 
techniques that use all the data collected over the course of time among a sample of 1,124 
patients, the present research should be useful to clinicians in understanding the 
consequences of inadequate pain management. This study should also provide valuable 
information to those who are designing oncology clinical trials, as well as those designing 
measures of PROs and patient-physician communication. 
C. Limitations 
One important source of error that applies to the BPI in this study (and affects the 
measurement of both severity and interference outcomes) is missing data. Dropout due to 
death or due to declines in HRQoL is expected to lead to non-random missing data 
patterns. The impact of using missing data imputation methods, as well as assumptions 
that must be made when using different models given non-random missing patterns are 
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investigated and addressed through the analysis procedures, in collaboration with both the 
statistician and the methodologist. 
Another methodological limitation is that although the dataset used contains pain 
information at multiple assessment times per patient, some gaps in the data exist. The trial 
data assessment schedule involved visits scheduled every 21 days, with BPI assessments 
every 2 weeks and ECOG assessments every 4 weeks. All pain questions were asked over the 
timeframe of the past seven days (with the exception of “describe your pain right now”. This 
means that gaps of at least one week in information exist in the BPI scores, and that a given 
patient could have reached a 7 on the severity or interference scale between recorded 
assessments. Thus, the present study involves interval censored data because a patient could 
have experienced an event between two assessments but the exact date of the event is 
unknown. Ideally, pain would be assessed at shorter intervals to gather more complete 
information - multiple assessments per day, for every day of observation would be ideal. If a 
pain assessment instrument asks about the last 7 days, to gain complete information over 
time, the measure should be administered every 7 days. The impact of this limitation on the 
present study is that although we are able to assess pain hazards over time based on the 
information available, pain may have increased or decreased during the gaps between 
assessments. The piecewise exponential model helps accommodate these gaps, but more 
complete information would be desirable. 
This analysis was limited by the characteristics of the clinical trial, which was designed 
to answer research questions about the relative efficacy of two bisphosphonates. Limitations 
were imposed by the exclusion criteria and the covariates that were collected in the clinical 
trial. Future research should collect and model the effects of factors that are not in these 
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datasets but that are known to affect pain, such as adherence, patient and physician barriers to 
effective analgesic treatment (the patient portion of which can be measured through the 
Patient Barriers Survey116), and other predictors of cancer pain outcomes. 
A source of error is possible data transcription, management, and transmission 
problems omnipresent whenever paper-based case report forms are used in clinical trials. 
This limitation is addressed through the QC procedures described. 
Another source of error is patients underreporting or overreporting the pain they 
experience. Although underestimation of pain is more a problem in retrospective studies 
involving spontaneous patient reports,30 it is still possible that in the present study, 
patients may underreport pain (there is more evidence for underreporting, rather than 
overreporting, being a likely problem). Based on cultural views, some patients may 
believe that pain is a spiritual or religious test of their faith, or believe that it is wrong to 
take or become addicted to opioids. These patients may therefore refuse to report their 
pain or accept palliative treatment.31 When interpreting the results of the present study, 
we acknowledge that, due to potential and probable underreporting,30,31,115,116 our 
estimates may be biased downward toward lower amounts of pain than patients actually 
experience. However, pain is a subjective construct, and clinicians and researchers must 
rely on patient report of pain; no neurophysiological or laboratory test can measure 
pain.117 Addressing the limitation of underreporting at the source (i.e., at the time of the 
data collection) may require behavioral intervention strategies with the goal of 
encouraging patients to more accurately report their pain. Such interventions are beyond 
the scope of the present study, but are of life-and-death importance because pain is a 
prime indicator of disease severity that drives cancer treatment decisions. Patient 
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education to improve accuracy of self-reported pain may involve an ethical dilemma of 
asking people to possibly act in discordance with their religious or cultural beliefs, but in 
the name of improving disease outcomes and survival.  
D. Future directions 
Future analyses of these data could comprise multivariate analyses that accommodate 
interval-censored data and include both baseline and other time-dependent covariates. Such 
analyses would provide more comprehensive information about predictors for the multiple 
outcomes on both the pain severity and interference subscales of the BPI. In addition, future 
analyses should account for multiple failures over time (e.g., a patient reaching severe pain, 
then experiencing a decrease in pain, then reaching severe pain again during the course of 
treatment).  
Given our findings with regards to disparities in potential risks of non-Caucasians 
reaching pain cutpoints 5 through 7 earlier than Caucasians, we recommend questioning the 
modular approach to pain management with NRS severity categories 1-4, 5-6, 7-10. The 
findings from the present study should aid in future research to evaluate, based on outcomes, 
the role of cutpoints in treatment algorithms. 
The present study involves the study of patients with breast cancer. However, Novartis 
granted permission for me to carry out longitudinal analyses of pain in both the breast cancer 
sample described in the present study as well as in a sample of prostate cancer patients in a 
similarly constructed clinical trial (Novartis protocol number 42446-03-039: “A randomized, 
double-blind, placebo-controlled, multicenter, comparative, safety and efficacy study of 
intravenous zoledronate [4 and 8 mg] in prostate cancer patients with metastatic bone lesions 
receiving antineoplastic therapy”, concluded in 2001). Applying the analytic approaches used 
 169 
in the present study to the sample of prostate cancer patients would provide tumor-specific 
information on patients’ experiences of pain associated with another type of cancer. This 
information could help clinicians, bioethicists, psychologists, sociologists, and others to 
better measure, understand, and manage pain among prostate cancer patients.  
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Appendix B, continued (pg 2 of 2) 
 
Copyright 1991 Charles S. Cleeland, Ph.D. 
Pain Research Group 
Used by permission. 
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D. Permission: BPI Data Analysis – M.D. Anderson Cancer Center 
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